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Research data management 
The data provided and analyzed in the chapters 1, 2 and 5 are extracted from the annual 
WHO Global Tuberculosis Reports, as well as the annual ECDC-WHO/Europe Tuberculosis 
Surveillance and Monitoring reports, which are available on the public domain and 
can be freely accessed, referenced and disseminated. All WHO surveillance reports are 
indexed, searchable and can be retrieved and re-used. The data used in the chapter 4 
are sourced from the countrywide routine surveillance and monitoring data base in 
line with the approval of the “National Ethics Committee and Review Board” under the 
Ministry of Health of Republic of Uzbekistan. This study satisfied the criteria for reports 
using routinely collected programmatic data set by the Médecins Sans Frontières Ethics 
Review Board, Geneva, Switzerland. The raw data is restored at the Surveillance Unit of 
the national TB programme of Republic of Uzbekistan and can be retrieved upon request. 
Patient identifying information was removed prior to analysis. The data presented in 
the chapters 6, 7 and 8 are based on peer reviewed publications, which are listed in the 
references. The data in the chapter 9 are based on the results of a survey collected from 
the target countries in Europe, with descriptive statistics calculated where appropriate, 
and supplemented with qualitative information provided by responders to the survey. 
The study did not collect individualized information on subjects. 
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Abstract
Tuberculosis (TB), particularly its drug resistant forms and TB/HIV coinfection are major 
public health concerns in many countries of the WHO European Region. Despite progress 
in scale up of rapid molecular TB diagnostics and reduction of TB incidence rates, effective 
treatment for those suffering from drug resistant TB and/or co-infected with HIV are 
suboptimal, leading to unfavorable treatment outcomes and ongoing transmission. On 
26 September 2018, the United Nations (UN) held its first high-level meeting on TB at its 
headquarters in New York and endorsed a political declaration titled "An Urgent Global 
Response to a Global Epidemic". This thesis provides evidence for informed-decision 
making for improving prevention and care for TB in the WHO European region. It covers 
various identified priorities including: introduction and expansion of new TB treatment 
regimens, revamping commitment for health system approaches with people-centered 
care, ensuring cross border continuum of care for migrant populations, and research 
and innovation for new tools and equitable access. All these are key in efforts towards 
attaining the Sustainable Development Goal of Ending TB by 2030.
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History of tuberculosis
Tuberculosis (TB), is caused by bacteria of the Mycobacterium tuberculosis complex, and is 
one of the oldest diseases known to affect humans and a major cause of death worldwide. 
Recent population genomic studies suggest that  Mycobacterium tuberculosis  may have 
emerged about 70,000 years ago in Africa and subsequently disseminated along with 
humans, expanding globally during the Neolithic Age as human density started to 
increase. Progenitors of M. tuberculosis are likely to have affected prehominids.1 TB most 
often affects the lungs, although other organs are involved in up to one-third of cases. If 
properly treated, TB caused by drug-susceptible strains is readily curable. If untreated, the 
disease may be fatal in 50–65% of cases within five years.1 Transmission of Mycobacterium 
tuberculosis mainly takes place through airborne spread of droplet nuclei produced by 
patients with infectious pulmonary TB and its subsequent inhalation.2 
Global burden of tuberculosis and access to treatment
TB is one of the top ten leading causes of death worldwide and the leading cause from 
a single infectious agent, ranking above HIV/AIDS. Based on the global data published 
in 2019, TB caused an estimated 1.2 million deaths (range, 1.1–1.3 million) among HIV-
negative people and there were an additional 251 000 deaths from TB (range, 223 000–281 
000) among HIV-positive people in 2018.3 An estimated 10 million people fell ill with TB in 
2018: 90% were adults, 57% were male, 8.6% were people living with HIV and two thirds 
were in eight countries: India (27%), China (9%), Indonesia (8%), the Philippines (6%), 
Pakistan (6%), Nigeria (4%), Bangladesh (4%) and South Africa (3%). Globally, 7 million 
new cases of TB were notified in 2018 – an increase from 6.4 million in 2017 and a large 
increase from the 5.7–5.8 million notified annually in the period 2009–2012. The latest 
treatment outcome data for new cases of TB show a global treatment success rate of 85% 
in 2017, an increase from 81% in 2016. Drug-resistant TB is a continuing threat. Globally 
in 2018, an estimated 3.4% (95% confidence interval [CI]: 2.5–4.4%) of new cases and 18% 
(95% CI: 7.6–31%) of previously treated cases had multidrug-resistant TB (MDR-TB) or 
Rifampicin Resistant (RR-TB).  In 2018, there were 484 000 incident cases with resistance 
to rifampicin (RR-TB) (range, 417 000–556 000), the most effective first-line drug, of which 
78% had MDR-TB, strains resistant to rifampicin and isoniazid which are the two most 
effective drugs used for first-line treatment. Three countries accounted for almost half of 
the world’s cases of MDR/RR-TB: India (27%), China (14%) and the Russian Federation (9%). 
About 1.7 billion people, 23% of the world’s population, are estimated to have a latent TB 
infection (LTBI) and are thus at risk of developing active TB disease during their lifetime. A 
total of 477 461 TB cases among HIV-positive people were reported, of which 86% were on 
antiretroviral therapy (ART). In 119 low- and middle-income countries that reported data 
(and accounted for 97% of reported TB cases globally), funding reached US$ 6.8 billion in 
2019, up from US$ 6.4 billion in 2018 and US$ 3.5 billion in 2006. However, the amount 
in 2019 was US$ 3.3 billion less than the US$ 10.1 billion estimated to be required in the 
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Stop TB Partnership’s Global Plan to End TB 2018–20224, and only just over half of the 
global target of at least US$ 13 billion per year by 2022 that was agreed at the UN High 
Level Meeting (UNHLM) on TB1. The latest treatment outcome data show success rates of 
85% for TB, 75% for HIV-associated TB, 56% for MDR/RR-TB and 39% for extensively drug-
resistant TB.3
Tuberculosis in the WHO European region 
In 2018, 259 000 incident TB cases (225 000–296 000) estimated in the WHO European 
Region, corresponding to 28 cases (24–32) per 100  000 population. During the period 
2009–2018 and between 2014 and 2018, the average annual decline in the TB incidence 
rate was 5.1%, which is the fastest decline among all WHO Regions. If this pace of decline 
is maintained, the Region will achieve the 2020 End TB Strategy milestone to reduce TB 
incidence rate in 2020 by 20% against the 2015 baseline, even though it will fall slightly 
short of reaching the Regional action plan target of a 25% reduction in the TB incidence 
rate.5 The WHO European region has less than 3% of the global burden of TB. There is also 
a wide variation in notification across the region from zero in Monaco and Saint Marino 
to 116 per 100 000 population in Kyrgyzstan (Figure 1). TB is seen mainly among young 
males in eastern Europe and central Asia. In western Europe, TB is mainly found among 
foreign-born individuals and older adults of the native population. In some low incidence 
countries, up to 90% of TB incident cases are found among foreign born individuals.5
Like other regions, incarceration significantly increases the risk of TB (22 times higher rate 
of TB incidence in prisons than in the general population). The average TB notification rate 
in prisons in the region was 749 per 100 000 population.5
About 85% of incident TB cases in Europe occurs in the 18 high-priority countries2. 
Tuberculosis notification in the WHO European region increased sharply from 1990 
onwards, reaching a peak in 1999. Since 2000, TB notification in the region has been 
decreasing. (Figure 2) 
1 https://www.who.int/tb/unhlmonTBDeclaration.pdf
2 The 18 high-priority countries (HPC) are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, 
Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova, Romania, Russian Federation, 
Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.
Introduction 
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Figure 1. TB notification per 100 000 population, WHO European Region 2018 
Source: European Centre for Disease Prevention and Control/WHO Regional Office for Europe. 
Tuberculosis surveillance and monitoring in Europe 2020 - 2018 data
Figure 2. TB notification per 100 000 population, WHO European Region (1980-2018)
Treatment success rates among combined cohorts of new cases and relapses notified in 
the WHO European Region in 2018 was 78%. There were an estimated 23 000 TB deaths 
among HIV-negative people in the European Region in 2018, equivalent to 2.5 deaths 
per 100  000 population (range 2.4–2.6). Considerable variation was seen across the 
 
TB notification per 100 000 population, WHO European Region 2018  
Source: European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and 
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Region, ranging from less than one TB death per 100 000 population in western European 
countries to more than 10 per 100  000 in High Priority Countries (HPC) of the Region. 
Between 2009 and 2018, the TB mortality rate at regional level fell cumulatively by 57%, 
from 5.8 to 2.5 deaths per 100  000 population, which is a decline of 9.1% per year on 
average. This decline was over 12% between 2017 and 2018, which is notably higher 
than the global rate of decline for TB mortality (3.6% between 2017 and 2018). With a 
cumulative reduction of 26% between 2015 and 2018, the Region is on track to reach the 
End TB Strategy milestone of a 35% reduction in the total number of TB deaths between 
2015 and 2020. The alarmingly high rates of rifampicin resistant and MDR-TB in most of 
the east European and central Asian countries represent one of the main challenges of 
TB control. Nine out of 30 countries with the highest MDR-TB burden in the world are 
in the WHO European Region3.  For 2018, drug-susceptibility testing (DST) reporting 
completeness was 74.6% for the first-line TB drugs, isoniazid and rifampicin.5 Second-line 
DST reporting completeness was 100% for the countries that reported at least one MDR-
TB case. An estimated 18% (95% CI: 16–19%) of newly diagnosed patients and 54% (95% 
CI: 47–61%) of previously treated patients had RR/MDR-TB. 19.2% of pulmonary MDR-TB 
cases had XDR-TB in 2018. In absolute numbers, XDR-TB cases among pulmonary TB cases 
increased from 999 in 2014 to 6 672 in 2018, largely due to the increase in the number of 
countries reporting on second-line DST data.5
In 2018, there were an estimated 77 000 new cases of rifampicin-resistant and multidrug-
resistant TB (RR/MDR-TB) in the Region, with 49  000 estimated among notified 
bacteriologically-confirmed pulmonary TB patients. This represents around 16% of the 
484  000 global RR/MDR-TB burden in the same cohort. The proportion of RR/MDR-TB 
among new and previously-treated TB cases in the Region also significantly exceeds the 
global average, with 18% in new and 54% in previously-treated cases compared to 3.4% and 
18% respectively. 
Of the 49  001 laboratory-confirmed RR/MDR-TB patients notified, 43  813 (89.4%) were 
enrolled into MDR-TB treatment programmes.5 In 2018, treatment success rate of MDR/
RR-TB patients increased compared to previous year from 51.5% to 57.6%, (Figure 3), 
however it is still below the regional target of 75%.6 The treatment success rate for RR/
MDR-TB patients was higher in non-EU/EEA countries than in the EU/EEA (57.6% versus 
49.9%). WHO European Region is the only Region with significant increase in the number 
of new HIV infections.7 Of the 203 006 new and relapse TB patients notified in the reporting 
countries, 185 673 were screened for HIV (91.5%). A total of 24 365 TB cases were detected 
with HIV-positive status, representing 13.1% of those tested. 5
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Figure 3. Treatment outcomes among new and relapse, TB/HIV co-infected, MDR/RR-TB, XDR-
TB patients and children, WHO European Region, 2020 data of 2018 cohorts 
Source: European Centre for Disease Prevention and Control/WHO Regional Office for Europe. 
Tuberculosis surveillance and monitoring in Europe 2020 
Regional and Country Action Plans
To address the challenges, since 2010, the WHO Regional Office for Europe, in consultation 
with national and international partners has developed two consecutive Action Plans. 
The Consolidated Action Plan to Prevent and Combat M/XDR-TB 2011-2015 and the 
Tuberculosis Action Plan for the WHO European Region 2016-2020, which are both 
aligned with the global strategies. The plans take into account the region-specific aspects 
and are endorsed by all Member States at the WHO Regional Committee for Europe in 
September 2010 and September 2015 respectively.6,8 Most countries of the Region have 
adapted these regional plans to their national context. 
The Tuberculosis Action Plan for WHO European Region 2016–2020 sets a regional goal of 
ending the spread of drug-susceptible and drug-resistant TB by achieving universal access 
to quality prevention, diagnosis and treatment in all Member States of the Region.  The 
Plan contains six strategic directions and 13 major activities grouped under three areas of 
intervention: integrated patient-centered care, bold policies and research and innovation 
(Figure 4). The Plan provides national and international partners with a framework for the 
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1. Full scale-up of rapid diagnosis
2. Rapid uptake of new medicines
3. Expanding patient- and people- 
        centered models of care 
4. Shorter and more effective 
        treatment regimens
5. Research for new tools
6. Intersectoral approach to address 
        inequities
Figure 4. Key Strategic directions and operational priorities of the Tuberculosis Action Plan 
for the WHO European Region 2016-2020
Under this Action Plan, targets to be achieved by 2020 are: a 35% reduction in TB deaths, 
a 25% reduction in TB incidence rate and a 75% treatment success rate among MDR-TB 
patients. The region is on track with achieving both reduction of mortality and incidence, 
however treatment success for MDR-TB is well below the target, with only 57% of MDR-TB 
successfully treated. 
Progress and challenges
The WHO European region has the fastest decline of TB mortality and incidence rates 
among all WHO regions.5 Through intensive national and international cooperation and 
collaboration, TB prevention and care efforts are stepped up, treatment success is gradually 
increasing, however not at the desired speed. Drug resistant TB is not fully addressed with 
only about 57% of those patients being successfully treated. Stigmatization leads to poor 
health seeking behavior in many settings.9 Social determinants of the disease are not 
fully addressed, and TB continues to affect marginalized population and the hardest hit 
are the poor. Multisectoral approaches in line with Health 202010 and the UN Common 
Position to end HIV, TB and viral Hepatitis11 are not fully implemented. Overreliance on 
hospitalization is among the underlying factors of nosocomial transmission. Gelmanova 
IY et al in Tomsk in the Russian Federation found out that patients who began treatment 
in the hospital setting or who were hospitalized later during their treatment course had a 
substantially higher risk of developing multidrug-resistant TB than those who were treated 
as outpatients.12 Bonnet M et al have documented in their setting that despite big efforts, 
good hospitalization conditions, social support, and early management of side effects, 
patients had difficulties in coping with long hospitalization stays.13 In most countries, 












WHO European Region 2016–2020
Towards ending tuberculosis and multidrug-resistant tuberculosis
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(how many patients are fully cured). This is a disincentive for ambulatory care and lack of 
adequate patient-friendly services for example by providing treatment at places or times 
that are most convenient to patients. There is no functioning mechanism of cross border 
TB control and care and the migrants in the eastern part of the region often lack services 
they need.14 TB in prisons is another key challenge which can turn into opportunities for 
better impact, if prisons provide quality and timely diagnosis and treatment.  
Evidence gaps for guiding policy adaptation in the WHO European region 
Drug resistant tuberculosis is the major barrier to ending TB in Europe. There are 
evidence gaps in determining the most cost-effective policies and practices to prevent 
and control drug resistant TB. The region has one of the highest rates of unfavorable 
outcomes globally. In addition to unnecessary loss of lives, this can lead to emergence 
of drug resistance, therefore it is important to review various determinants, which play 
role in hindering achievement of the WHO targets of treatment success. In order for TB 
prevention and care efforts to be effective, the national programmes and key partners 
are to address the needs of special populations, who are often left outside the realms of 
routine health services. Migrants and refugees in low to middle incidence countries and 
prisoners in many countries are among the key vulnerable groups for TB infection and 
disease, and there are gaps in effective and efficient strategies for early detection and 
treatment for them. In the absence of a new vaccine, the role of BCG vaccine in prevention 
of TB needs to be examined.
Specific evidence generated by this thesis
This thesis presents an overview of several areas where evidence has been built and 
contributed to policies. These include the cost effectiveness of the five-year Regional 
Action Plan to Prevent and Control M/XDR-TB with a methodology which can be applied 
to future action plans to end and ultimately eliminate TB, drug resistant TB and TB/
HIV coinfection. Building on an in-depth five-year analysis in a high TB priority country 
(Uzbekistan), the factors associated with unfavorable outcomes in new and previously 
treated TB are presented. As unfavorable outcomes result in reduced patient survival 
and development of drug resistant TB, these findings are relevant on a wider level. 
With a thorough analysis of an array of unfavorable outcomes, measures to address the 
laboratory, clinical and programmatic shortcomings at national and subnational levels are 
formulated. This approach can be applied to other countries of the WHO European Region 
to improve performance of national programmes. Reviewing the trends, challenges and 
possible interventions to address the drug resistant TB as a major challenge in the Region 
is presented and this highlights evidence that can be integrated into policies. Improving 
early detection and treatment outcomes for drug resistance and drug susceptible are 
to be prioritized; The TB situation in prisons and the challenges and research gaps in 
implementation of the WHO End TB strategy in prisons are presented. Such evidence is 
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key to reducing missed TB cases and achieving the WHO target of ensuring that 90% of 
detected TB cases achieve treatment success. Following the launch of the global roadmap 
on childhood TB, we reviewed the TB situation in children and relevant policies in the 
18 high TB priority countries. Most countries are under-diagnosing TB among children 
and policies and practices are often outdated. Based on the data and existing evidence, a 
roadmap to address TB in children in Europe is proposed and the role of BCG is reviewed. 
This can guide implementation strategies. With appropriate use of available laboratory 
tests and clinical examination, early and accurate detection of active and latent among 
children are to be further improved. Finally, in response to rapid increase of migration to 
Europe, an overview of TB screening policies and practices among refugees and asylum 
seekers in Europe is presented. This provides an account of country challenges with 
diverse policies and practices, inadequate screening, and insufficient management for TB 
in several countries, calling for more harmonized efforts, and closer collaboration among 
the countries in the Region.  This is a highly topical area and has a bearing on cross-border 
TB transmission and control.
Outline of the thesis 
Aims and objectives
The aim of the research projects that constitute this thesis is to generate and use evidence 
to improve the management of TB in the WHO European region, through implementation 
of the three pillars of the End TB strategy (Integrated patient care, Bold Policies and 
Research and Innovation). These studies were conducted in line with the global End TB 
strategy and the regional action plans. They fit well into the context of the sustainable 
development goals and the principle of ensuring equity (Figure 5). The specific objectives 
are to:
1. To review the epidemiology of tuberculosis in WHO European Region, the public 
 health response and the cost effectiveness of MDR-TB prevention and control 
 Plan: These are covered in the chapters two and three. We specifically review the TB 
 epidemiological situation with the link to localization of the disease and based on data 
 from surveillance, modeling and health financing, the cost effectiveness of 
 interventions is assessed and their impact on lives saved and economic gains.
2. To review how TB treatment outcomes can be improved in various TB categories: This 
 is covered in chapters four and five. In chapter four, we review national and subnational 
 data from a high TB incidence country and discuss the unfavorable outcomes which 
 can lead to increased suffering, unnecessary deaths, ongoing transmission and 
 emergence of drug resistance. Unfavorable outcomes also negatively affect the 
 credibility of the TB programme in the eyes of patients and the community. In chapter 
 five we provide analysis of the situation in the eastern Europe and central Asia.
Introduction 
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3. To review the role of BCG immunization in prevention of TB: In chapter six we discuss 
 the evidence of currently available vaccine in children.
4. To analyze the policies and practices of addressing TB in vulnerable populations: In 
 chapters seven, eight and nine, we analyze these aspects in terms of TB prevention 
 and care in prison setting, in children and among migrant populations.
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Specific setting of the studies
All the studies under this thesis have been conducted in the WHO European Region. 
Globally, WHO Member States are grouped into six regions (Figure 6). The WHO European 
Region consists of 53 Member States expanding from Atlantic Ocean to Pacific Ocean and 
is home to more than 900 million population.15 The countries of the WHO European region 
are among the most diverse regions in terms of gross national income, development 
index and health systems structure. The industrial revolution of the early 20s, the collapse 
of Soviet Union in the 90s, and migration from high TB incidence countries have played 
important roles in changing the tuberculosis epidemic situation in the Region. 
Figure 6. WHO Regions 
Source: https://ourworldindata.org/grapher/who-regions and http://www.who.int/about/
regions/en
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Purpose: To provide an overview of the tuberculosis (TB) and multi-drug resistant 
tuberculosis (MDR-TB) in the WHO European Region and evolution of public health 
response with focus on extra-pulmonary tuberculosis and Pott’s disease.
Methods: Authors reviewed regional strategic documents related to TB. The 
epidemiologic data were reviewed and analyzed. 
Results:  Treatment success rates have been decreasing and MDR-TB rates have been 
increasing in the WHO European Region during the past five years. In the absence 
of associated pulmonary TB, Pott’s disease is reported as extra-pulmonary TB (up to 
47% of all TB cases in some settings). Due to limitations of the surveillance system, 
the epidemiology of Pott’s disease and its treatment success are unknown. The Stop 
TB Strategy and Consolidated Action Plan to Prevent and Combat M/XDR-TB provide 
comprehensive roadmaps to address all types of TB.
Conclusions: The region needs to scale up implementation of effective strategies 
to curb TB and MDR-TB epidemics. There is a need to further analyze country data 
to document the extent of Pott’s disease and develop specific guidelines for timely 
diagnosis and treatment of Pott’s disease. 
Keywords: Pott’s disease, Extra-pulmonary tuberculosis, Multi-drug resistant 
tuberculosis, European Region, Action Plan
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Introduction
The WHO European Region comprises 53 Member States and about 900 million population. 
Tuberculosis (TB) is a major public health in many countries of the Region. There is a wide 
variation in notification of TB from 2.8 (Italy) to 123 (Kazakhstan) per 100 000 population 
(Fig. 1). MDR-TB is a major challenge in the WHO European Region with, 29,000 MDR-
TB cases occurred in the Region in 2010.  MDR-TB among new and previously treated 
patients were 13.7% and 48.7%, respectively during the same year [1]. Extensively drug 
resistant (XDR) TB amounted 12.2% in 2010, although this may not be the true magnitude 
of XDR-TB because of the low coverage of anti-TB drug susceptibility testing for second-
line anti-TB drugs, it is certainly expected to be more than 10%, as was also found in a 
previous study [2]. The percentage of HIV notified among all TB cases was 5.5% in 2010. In 
2010, the treatment success rate among MDR-TB patients was 56.3% [1]. The high rates of 
MDR-TB combined with low-treatment outcomes and an increasing HIV epidemic pose an 
alarming treat to public health in the WHO European Region. 
The trends in TB, drug resistant TB, TB/HIV coinfection with a focus on extrapulmonary TB 
in the region have not been previously documented. Furthermore, it is not clear whether 
there are differences in the rate of extrapulmonary TB across the various countries of the 
region. Just prior to this publication, the internationally recommended TB control strategy 
evolved from DOTS to the Stop TB strategy and yet the implication of the new strategy in 
terms of addressing all forms of the disease including extrapulmonary TB had not been 
previously discussed. In this paper, we thus address these knowledge gaps.
Figure 1. Notification rate of new and previously treated TB patients per 100,000 population,
in the WHO European Region in 2010 [1]
European Economic Area (EU/EEA) countries, a higher
proportion of extra-pulmonary localization of the disease
among all TB cases was observed than in non-EU/EEA
countries; 22 % versus 16 % (Fig. 3). Five countries
reported more than 40 % of extra-pulmonary TB cases: the
United Kingdom (47 %), the Netherlands (45 %), Andorra
(43 %), Norway and Malta (41 % each) [1]. The variances
in the reporting of extra-pulmonary TB may result from
different diagnostic practices across the region or epide-
miological factors, such as immigration or the prevailing
Fig. 1 Notification rate of new
and previously treated TB
patients per 100,000 population,
in the WHO European Region
in 2010 [1]
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In 1991, the World Health Assembly recommended that each National Tuberculosis 
Programme (NTP) work toward two objectives (the ‘‘WHO targets’’) by the year 2000: (1) 
to detect at least 70% of all sputum smear positive cases, and (2) to treat at least 85% of 
them successfully, by the introduction of an effective approach to TB control [3] which 
according to the ‘‘World Development Report 1993’’, is considered to be one of the most 
cost-effective health interventions [4]. As a combination of technical and managerial 
elements, DOTS proved to be effective making the infectious cases as non-infectious 
and breaking the cycle of transmission. In 1993, because of resurgence of TB globally, 
WHO took an unprecedented step and declared TB a global emergency. In 1994, after 
defining the nature and size of the global TB problem through expanded monitoring and 
surveillance, the International Union Against Tuberculosis and Lung Disease (The Union) 
and WHO promoted the technical and managerial approach suggested by Karel Styblo 
in the 1970s. In 1995, the strategy was packaged and branded as ‘‘Directly Observed 
Treatment Short course’’ (DOTS). The DOTS Strategy incorporating the fundamentals of TB 
control focused on a five-point policy package [3]:
1. Government commitment to sustained TB control;
2. Sputum smear microscopy to detect the infectious cases;
3. Standardized and directly observed short-course chemotherapy;
4. Uninterrupted supply of medicines;
5. Supervision, Monitoring and Evaluation.
During the period of 1995–2005, the emphasis was on piloting and expanding the DOTS 
Strategy. DOTS was widely accepted and adopted as a package of essential TB control 
measures, depending on the peculiarities of certain countries and local circumstances 
[5,6].
The number of countries using DOTS expanded from only 10 in 1990 to more than 180 
in 2005, covering more than 80% of the world population [7]. After the collapse of the 
Soviet Union and mainly due to disruption of health services, TB re-emerged in the 
Region. In response, WHO and other partners scaled up their support for implementation 
and expansion of DOTS [6]. In 2002, the WHO/Europe Regional Committee endorsed the 
‘‘DOTS expansion plan to Stop TB in the WHO European Region 2002–2006’’ [8, 9]. 
The DOTS Strategy has led to major progress in global TB control with successful treatment 
of nearly 20 million patients worldwide during 1995–2005 [8]. However, new challenges, 
such as the worsening of the HIV epidemic and rising of TB/HIV co-infection, emergence 
of drug-resistant strains TB and poor access of most vulnerable population, have proved 
that DOTS alone will not be sufficient for effective TB control [7, 9–11]. In 2006, WHO 
developed a new comprehensive strategy for TB control that consists of six components, 
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which builds on and goes beyond DOTS. This strategy addresses the spread of TB and 
HIV co-infections and MDR-TB [12]. Up to the time of this publication, this was a leading 
strategy for TB control worldwide, including in the European Region where the rates of M/
XDR-TB are the highest in the world and HIV is spreading most rapidly [2, 13, 14].
The aim of the Stop TB Strategy is to dramatically reduce the global burden of TB, by 
halting the epidemic and reversing it by 2015, with the ultimate goal to eliminate TB 
as a public health problem by 2050. The aims, detailed objectives and targets of the 
strategy are summarized in Table 1. The six components of the Stop TB Strategy include 
to (1) pursue high-quality DOTS expansion and enhancement; (2) address TB/HIV, MDR-
TB, and the needs of poor and vulnerable populations; (3) contribute to health system 
strengthening based on primary health care; (4) engage all care providers; (5) empower 
people with TB, and communities through partnership; (6) enable and promote research. 
The implementation approaches of these components are listed in Table 2. DOTS as a 
five-point package remains the first component and foundation of the Stop TB Strategy. 
The other components of the Strategy highlight the need to address the challenge of 
drug-resistant TB and the co-epidemics of TB and HIV, the importance of engaging all 
care providers in TB care and control and of contributing to strengthening health systems, 
the role of communities and people with TB, and the fundamental role of research and 
development for new diagnostics, new drugs and new vaccines. 
Table 1. The Stop TB Strategy at a glance
Vision A TB-free world
Goal To dramatically reduce the global burden of TB by 2015 in line with the Millennium Development Goals (MDGs) and the Stop TB Partnership targets
Objectives • Achieve universal access to high-quality care for all people with TB 
• Reduce human suffering and socioeconomic burden associated with TB 
• Protect vulnerable populations from TB, TB/HIV and drug resistant TB 
• Support development of new tools and enable their timely and effective use 
• Protect and promote human rights in TB prevention, care and control
Targets • MDG 6, Target 6.c: Halt and begin to reverse the incidence of TB by 2015 
• By 2015 to reduce prevalence of and deaths due to TB by 50% compared with a 
baseline of 1990 
• By 2050 to eliminate TB as a public health problem
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Table 2. Six-components and implementation approaches of the Stop TB Strategy
1. Pursue high-quality DOTS expansion and enhancement
• Secure political commitment, with adequate and sustained financing
• Ensure early case detection and diagnosis through quality assured bacteriology
• Provide standardized treatment with supervision, and patient support
• Ensure effective drug supply and management
• Monitor and evaluate performance and impact
2. Address TB/HIV, MDR-TB and the needs of poor and vulnerable populations
• Scale-up collaborative TB/HIV activities
• Scale-up prevention and management of multidrug-resistant TB (MDR-TB)
• Address the needs of TB contacts and of poor and vulnerable populations
3. Contribute to health system strengthening based on primary health care
• Help improve health policies, human resource development, financing, supplies, service 
delivery and information
• Strengthen infection control in health services, other congregate settings and households
• Upgrade laboratory networks, and implement the practical approach to lung health
• Adapt successful approaches from other fields and sectors, and foster action on the social 
determinants of health
4. Engage all care providers
• Involve all public, voluntary, corporate and private providers through public–private mix 
approaches
• Promote use of the International Standards for Tuberculosis Care
5. Empower people with TB, and communities through partnership
• Pursue advocacy, communication and social mobilization
• Foster community participation in TB care, prevention and health promotion
• Promote use of the Patients’ Charter for Tuberculosis Care
6. Enable and promote research
• Conduct programme-based operational research
• Advocate for and participate in research to develop new diagnostics, drugs and vaccines
Methods  
We analyzed the annual tuberculosis data submitted by the WHO European Region 
Member States and collected through the annual surveillance system jointly organized 
by the European Center for Disease Prevention and Control (ECDC) and the WHO Regional 
Office for Europe. The data included key variables which enable the countries and the 
WHO European Region to monitor the TB epidemiological situation, annual trends and 
outcomes of the national public health responses. The data were collected retrospectively 
from the cohorts of two years before each reporting cycle. This allows the countries to report 
the treatment outcomes of cohort of the patients and complete the required variables. 
Once the data was cleaned and validated. the results were presented descriptively using 
numbers and proportions. Maps were generated for the WHO region using Excel software 
and graded colors were used to express levels of measured outcomes.  We analyzed each 
of the key epidemiological indicators including incidence, mortality, types of the disease 
(pulmonary and extrapulmonary TB), country of origin, as well as TB/HIV coinfection and 
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drug resistance rates. For the purposes of this study, we selected the data submitted in 
2012 (the 2010 cohort of patients) and reviewed trends in the past five years. 
We further reviewed the evolution of internationally recommended strategy from DOTS 
to the Stop TB strategy and discussed how the new strategy and the Regional Action Plan 
are to address the issue of extrapulmonary TB. Based on this study, we also identified the 
gaps in data which help strengthen surveillance system and analyzed in the future studies.
Results
Comparing the key TB indicators between 2005 to 2010 showed that notification of all 
cases decreased from 54 cases in 100,000 population [15] to 34 in 100,000 population [1]. 
This is while the percentage of MDR-TB among all TB cases had been increasing over the 
period from 4.3% to 7.5%. Likewise, the percentage of HIV notified among all TB cases 
increased from 3.4% which is the first year with regional representative data to 5.5% in 
2010. Over the last 5 years treatment success rates have continued to decrease, falling 
from 72.5% and 50% in 2005 to 68.7% and 47.6% in 2010 among new and previously 
treated cases, respectively (table 3).
Table 3. Trends in key TB indicators 2005-2010
Indicator 2005 2010
Tuberculosis notification per 100,000 population 54 34
Multi-drug resistant TB rate among all TB patients 4.3% 7.5%
TB/HIV coinfection No representative data* 5.5%
Extrapulmonary TB among all TB patients 12% 17%
Treatment success among new TB patients 72.5% 68.7%
Treatment success among retreatment TB patients 50% 47.6%
3.4% (the first comprehensive data available in 2008)
In 2010, among the 388,875 notified TB cases in the WHO European Region, 65,783 (17%) 
cases had extra-pulmonary TB [1]. Most countries have reported less than 1% of cases with 
unknown disease localization (Table 4). Only Turkmenistan, Bosnia and Herzegovina and 
Denmark still need to improve their notification by disease localization; these countries 
reported 8.5%, 11.4%, and 18.1% cases with unknown site of disease, respectively. On 
average, in the European Union/ European Economic Area (EU/EEA) countries, a higher 
proportion of extra-pulmonary localization of the disease among all TB cases was 
observed than in non-EU/EEA countries; 22% versus 16% (Fig. 2). Five countries reported 
more than 40% of extra-pulmonary TB cases: The United Kingdom (47%), the Netherlands 
(45%), Andorra (43%), Norway and Malta (41% each) [1]. Our analysis also showed that the 
percentage of extrapulmonary forms among all TB patients increased from 12% in 2005 
to 17% in 2010.
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Table 4. Notified tuberculosis cases by site of diseases, WHO European region 2010








  N (%) N (%) N (%) N (%) N (%)  
EU/EEA
Austria 497 72.2 60 8.7 557 81 131 19 0 0 688
Belgium 733 65.7 74 6.6 807 72.4 307 27.5 1 0.1 1 115
Bulgaria 1 762 66.5 89 3.4 1 851 69.9 798 30.1 0 0 2 649
Cyprus 40 65.6 0 0 40 65.6 19 31.1 2 3.3 61
Czech Republic 560 82.6 21 3.1 581 85.7 97 14.3 0 0 678
Denmark 227 63.2 24 6.7 251 69.9 43 12 65 18.1 359
Estonia 264 80.2 44 13.4 308 93.6 21 6.4 0 0 329
Finland 241 73.7 - - 241 73.7 86 26.3 0 0 327
France 3 017 59 702 13.7 3 719 72.7 1 361 26.6 36 0.7 5 116
Germany 2 879 66.5 435 10 3 314 76.5 980 22.6 36 0.8 4 330
Greece 361 73.8 59 12.1 420 85.9 69 14.1 0 0 489
Hungary 1 642 94.3 25 1.4 1 667 95.7 74 4.3 0 0 1 741
Iceland 11 50 7 31.8 18 81.8 4 18.2 0 0 22
Ireland 251 58.8 23 5.4 274 64.2 150 35.1 3 0.7 427
Italy 2 423 74.6 262 8.1 2 685 82.6 564 17.4 0 0 3 249
Latvia 788 84.4 58 6.2 846 90.6 88 9.4 0 0 934
Lithuania 1 713 88.4 - - 1 713 88.4 225 11.6 0 0 1 938
Luxembourg 23 79.3 - - 23 79.3 6 20.7 0 0 29
Malta 10 31.3 9 28.1 19 59.4 13 40.6 0 0 32
Netherlands 458 42.7 128 11.9 586 54.6 482 44.9 5 0.5 1 073
Norway 153 45.1 48 14.2 201 59.3 138 40.7 0 0 339
Poland 6 949 92.5 43 0.6 6 992 93.1 517 6.9 0 0 7 509
Portugal 1 732 66 149 5.7 1 881 71.6 727 27.7 18 0.7 2 626
Romania 16 708 79.3 1 300 6.2 18 008 85.4 3 070 14.6 0 0 21 078
Slovakia 337 76.8 35 8 372 84.7 67 15.3 0 0 439
Slovenia 117 68 25 14.5 142 82.6 30 17.4 0 0 172
Spain 5 238 73.9 - - 5 238 73.9 1 851 26.1 0 0 7 089
Sweden 342 50.7 77 11.4 419 62.1 256 37.9 0 0 675
United Kingdom 3 606 42.5 882 10.4 4 488 52.9 3 949 46.6 46 0.5 8 483
Subtotal EU/EEA 53 082 71.7 4 579 6.2 57 661 77.9 16 123 21.8 212 0.3 73 996
Non-EU/EEA
Albania - - - - 275 61.8 170 38.2 0 0 445
Andorra - - - - 4 57.1 3 42.9 0 0 7
Armenia - - - - 1 090 61.2 690 38.8 0 0 1 780
Azerbaijan - - - - 7 274 86.7 1 120 13.3 0 0 8 394
Belarus - - - - 5 107 92 447 8 0 0 5 554
Bosnia and 
Herzegovina - - - - 1 067 76.8 164 11.8 159 11.4 1 390
Croatia - - - - 608 87.5 87 12.5 0 0 695
Georgia - - - - 3 748 64.7 2 048 35.3 0 0 5 796
Israel - - - - 269 78.4 74 21.6 0 0 343
Kazakhstan - - - - 22 614 79.2 5 936 20.8 0 0 28 550
Kyrgyzstan - - - - 4 660 74 1 635 26 0 0 6 295
North Macedonia - - - - 309 73.6 111 26.4 0 0 420
Moldova - - - - 4 934 90.6 513 9.4 0 0 5 447
Monaco - - - - 0 0 1 100 0 0 1
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Montenegro - - - - 100 87.7 14 12.3 0 0 114
Russia - - - - 145 858 89.7 16 695 10.3 0 0 162 553
San Marino - - - - - - - - - - -








- - - - 585 66.2 299 33.8 0 0 884
Switzerland - - - - 366 66.7 183 33.3 0 0 549
Tajikistan - - - - 4 985 65.2 2 656 34.8 0 0 7 641
Turkey - - - - 10 740 64.9 5 811 35.1 0 0 16 551
Turkmenistan - - - - 2 483 76.9 473 14.6 274 8.5 3 230
Ukraine - - - - 32 405 89 3 639 10 365 1 36 409
Uzbekistan - - - - 13 654 67.2 6 676 32.8 0 0 20 330
Subotal non-EU/
EEA - - - - 264 421 84 49 660 15.8 798 0.3 314 879
Total European 
Region - - - - 322 082 82.8 65 783 16.9 1 010 0.3 388 875
Subtotal 18 HPC - - - - 282 278 84.1 52 541 15.7 639 0.2 335 458
Only for EU/EEA countries anti-TB drug resistance was recorded by site of disease. Among 
all 31 644 cases with drug susceptibility available in EU/EEA countries, 6 933 were from 
extra-pulmonary TB cases. The rate of MDR-TB among extra-pulmonary TB cases with drug 
susceptibility available was 2.3% (n = 158). This rate was lower than the rate of 5.2% MDR-
TB among pulmonary TB cases (n = 1 289). 
Figure 2. Percentage of extrapulmonary tuberculosis reported in the WHO European Region in 
2010
objectives (the ‘‘WHO targets’’) by the year 2000: (1) to
detect at least 70 % of all sputum smear positive cases, and
(2) to treat at least 85 % of them successfully, by the
introduction of an effective approach to TB control [3]
which according to the ‘‘World Development Report
1993’’, is considered to be one of the most cost-effective
health interventions [4].
In 1993, because of resurgence of TB globally, WHO
took an unprecedented step and declared TB a global
control measures, depending on the peculiarities of certain
countries and local circumstances [5, 6].
As a combination of technical and managerial elements,
DOTS proved to be effective making the infectious cases
as non-infectious and breaking the cycle of transmission.
The number of countries using DOTS expanded from only
10 in 1990 to more than 180 in 2005, covering more than
80 % of the world population [7].
After the collapse of the Soviet Union and mainly due to
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pulmonary tuberculosis reported
in the WHO European Region
in 2010
Eur Spine J (2013) 22 (Suppl 4):S549–S555 S551
Chapter 240   |
Discussion
TB is still causing a considerable health burden in the WHO European Region, with 
increasing MDR-TB rates. The proportion of extra-pulmonary cases has remained relatively 
stable over the last 4 years. Pott’s disease is reported together with other extra-pulmonary 
TB cases to the joint WHO/ECDC surveillance system and as a result, the exact magnitude 
of the disease is unknown. The variances in the reporting of extra-pulmonary TB may 
result from different diagnostic practices across the region or epidemiological factors, 
such as immigration or the prevailing M. tuberculosis strains [16]. 
M/XDR-TB is a man-made phenomenon that emerges as a result of inadequate treatment 
of tuberculosis and/or poor airborne infection control in health care facilities and 
congregate settings. The spread of M/XDR TB is also an indication to low adherence to 
evidence-based TB control practices [2, 13, 14, 21, 22].
The reasons for lower rate of MDR-TB among extrapulmonary TB with available drug 
susceptibility testing can be due to variety of reasons including quality of samples, the 
limitation of the diagnostic tools used and the more frequent occurrence of extrapulmonary 
forms among patients coming from countries out of the region. The reasons for increase in 
the rate extrapulmonary among all TB patients needs further investigation but could be 
due to changes in migration patterns and/or improvement in diagnosis.  Due to limited 
data on variables specific to disease localization, further analysis of extra-pulmonary 
disease such as HIV status or treatment outcomes are not available. Therefore, there is 
a need to improve surveillance and/or conduct surveys to get a better understanding of 
extrapulmonary TB, the extent of Pott’s disease and the reasons for the wide variation of 
the proportion of extrapulmonary TB among all TB cases across the Region. These findings 
call for inclusion of more indicators and their timely reporting. 
Evidence-based data suggest that improved diagnosis and treatment based on the Stop 
TB Strategy have already saved millions of lives globally [17]. The decline of TB incidence is 
< 1% per year and the long-term elimination target, to reduce incidence to less than one 
case per million by 2050, will not be reached with existing technologies and approaches 
[10, 11]. Trend analysis of the MDG targets in 2010 showed that estimated prevalence in 
the European Region has been declining, but not enough to be able to reach the MDG6 
target by the 2015 deadline. Estimated mortality from TB decreased to 6.8 per 100,000 
population in 2010. To meet the MDG 6 target, TB mortality must further decline to 
6.5 per 100 000 population by 2015 [16]. The WHO Regional Office for Europe held the 
WHO European Ministerial Forum ‘‘All against Tuberculosis’’ on 22 October 2007 in Berlin, 
Germany [18], to accelerate progress towards achieving the MDG’s targets for TB control 
in the WHO European Region. The main outcome of the Forum was the adoption of the 
Berlin Declaration on TB as well as endorsement of the two Regional plans: the WHO/
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Europe Plan to Stop TB in 18 High-priority countries in the WHO European Region 2007–
2015 and ECDC Framework Action Plan to fight tuberculosis in the European Union [19, 
20]. The Forum and the Declaration in particular renewed commitments to take actions 
to control TB in the European Region highlighting that: (1) TB, and MDR-TB in particular, 
is a health security threat; (2) Strengthening political and financial commitment is vital to 
reach the MDGs and (3) to establish adequate fora and mechanisms to assess progress at 
regional level [19].
WHO Regional Office for Europe, in collaboration with technical agencies, Member States, 
civil society organizations and communities, developed a Consolidated Action Plan to 
Prevent and Combat M/XDR-TB in WHO European Region 2011–2015. The Consolidated 
Action plan and its accompanying resolution EUR/RC61/R7 were fully endorsed at the sixty-
first session of the WHO Regional Committee for Europe in Baku, Azerbaijan in September 
2011 [23]. The plan emphasizes on strengthening the quality of implementation of the 
Stop TB Strategy, in particular the essential elements of TB control, such as early detection 
and notification of all TB cases as well as supervised treatment avoiding the misuse of 
anti-TB drugs [23]. The plan calls for accelerated action, working in close partnership 
with member states and all partners, such as the Global Fund to Fight AIDS, Tuberculosis 
and Malaria and the Stop TB Partnership. The goal of the plan is to contain the spread of 
drug-resistant TB by achieving universal access to prevention, diagnosis and treatment 
of M/XDRTB in all member states in the WHO European Region by 2015. The targets of 
the plan are to diagnose at least 85% of all estimated MDR-TB patients, treat successfully 
at least 75% of all patients notified as having MDR-TB and to decrease by 20% points the 
proportion of MDR-TB among previously treated patients [23]. 
The Consolidated Action plan to prevent and combat M/XDR-TB comprises six strategic 
directions and seven areas of intervention. The strategic directions are crosscutting 
and are designed to safeguard the values of the Health 2020 strategy. These include: 
(1) identifying and addressing determinants and underlying risk factors contributing 
to the emergence and spread of drug-resistant TB; (2) strengthening the health system 
response in providing accessible, affordable and acceptable services using patient-
centered approaches; (3) working in national, regional and international partnerships on 
TB prevention, control and care; (4) fostering regional and international collaboration for 
development of new diagnostic tools, medicines and vaccines against TB; (5) promoting 
rational use of existing resources, identifying gaps and mobilizing additional resources 
to fill the gaps; (6) monitoring the trends of M/XDR-TB in the Region and measuring the 
impact of interventions. The areas of intervention are in line with the Global Plan to Stop 
TB 2011–2015 and include the same targets as set by the Global Plan and World Health 
Assembly resolution WHA62.15, namely to provide universal access to diagnosis and 
treatment of MDR-TB: (1) prevent the development of M/XDR-TB cases; (2) scale up access 
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to testing for resistance to first- and second-line anti-TB drugs and to HIV testing and 
counseling among TB patients; (3) scale up access to effective treatment of drug-resistant 
TB; (4) scale up TB infection control; (5) strengthen surveillance, including recording and 
reporting, of drug-resistant TB; (6) expand country capacity to scale up the management 
of drug-resistant TB, including advocacy, partnership and policy guidance; (7) address the 
needs of special populations. The action plan clearly defines milestones and a detailed 
set of recommended activities.  Furthermore, a monitoring framework was developed 
to track progress toward milestones and the eventual achievement of objectives. If the 
Plan is fully implemented, 225,000 MDR-TB patients will be detected and 127,000 of them 
will be successfully treated. As a result of successful implementation of the Plan, 250,000 
MDR-TB and 13,000 XDR-TB cases would be averted and 120,000 lives will be saved. The 
direct economic gain in lives saved by the Plan amounts to US$ 5 billion over the 5 years. 
In addition, US$ 7 billion will be saved directly on costs for detection and care of the M/
XDR-TB cases averted, which would have arisen and needed treatment in the absence of 
improved TB control provisions of the plan. Its implementation will also have an impact on 
preventing transmission, and thus averting many more MDR-TB cases beyond 2015 that 
are as yet undetermined but will go far beyond this number.
To address the lack of international consensus on the role of surgery in pulmonary and 
extrapulmonary TB including tuberculosis spondylitis, the plan foresees that the WHO 
Regional Office in collaboration with the Member States and other partners develop a set 
of evidence-based criteria for surgery for M/XDR-TB patients by the end of 2012.
It is known that TB is a social disease and it is seen frequently in stigmatized and vulnerable 
groups such as the poor, migrants, drug abusers, prisoners. Further work is need to these 
groups, addressing social determinants, ethical values and human rights in collaboration 
with other programmes within WHO as well as national and international partners [10, 11]. 
Countries need to urgently scale up the implementation of the Stop TB Strategy, 
ensuring early diagnosis and proper treatment, strengthening health-system policies, 
establishment of links with the broad economic and health reforms, including addressing 
social determinants of TB, and promotion of research efforts, including the development 
of new diagnostics, anti-TB drugs and vaccines. Adequate interventions addressing 
drug-resistant TB require proper national planning and effective implementation of 
comprehensive approaches with the support from national and international partners. 
Further research on optimal treatment and care for Pott’s disease is needed. 
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Drug-resistant tuberculosis (TB) has increased at an alarming rate in the WHO 
European Region. Of the 27 countries worldwide with a high burden of multidrug 
resistant-TB (MDR-TB), 15 are in the European Region. An estimated 78,000 new 
cases of MDR-TB occur annually in the Region, of which approximately 10% are 
extensively drug-resistant (XDR)-TB. In response, the WHO Regional Office for Europe 
developed a Consolidated Action Plan to Prevent and Combat Multidrug- and 
Extensively Drug-resistant Tuberculosis (2011–2015). Our objective was to analyse 
the cost-effectiveness of implementing the plan, with the expected achievements of 
diagnosing 85% of estimated MDR-TB cases and treating at least 75% successfully. A 
transmission model, using epidemiological data reported to WHO was developed to 
calculate expected achievements. WHO-CHOICE database was used for cost analyses. 
The highly cost-effective plan is expected to prevent the emergence of 250,000 new 
MDR-TB and 13,000 XDR-TB patients respectively, saving US$7 billion and 120,000 
lives. The plan and accompanying Resolution were fully endorsed by the sixty-first 
session of the WHO Regional Committee for Europe in 2011. Member States need 
to continuously improve health system performance and address TB determinants. 
Research and development of new medicines, tools and patient-friendly services are 
also crucial.
Key words: multidrug resistant-TB, extensively drug-resistant-TB, WHO European 
Region
The M/XDR-TB Action Plan 2011-2015: cost-effectiveness analysis 
3
|   49 
1. Introduction
In Europe, tuberculosis (TB) is commonly regarded as a disease of the past. However, as the 
threat of antimicrobial resistance has become a global reality in recent years, one of the 
most alarming examples has become the frequency of multidrug- and extensively drug-
resistant TB (M/XDR-TB). The WHO European Region currently has the highest proportion 
of M/XDR-TB patients, and 15 out of the world’s 27 high M/XDR-TB burden countries, in 
the world.1 Effective treatment for MDR-TB can take up to two years (even longer for XDR-
TB) and is often associated with debilitating side effects. 
Although encouragingly the rates of new TB cases in the Region have been falling since 
2005, a look at the epidemiological situation of M/XDR-TB reveals a daunting picture. In 
2011, there were an estimated 78,000 cases of MDR-TB (in the Region), of which 29,473 
(38%) were detected.2 This accounts for one-fourth of all estimated and more than half 
of all notified MDR-TB cases globally.1 The proportion of MDR-TB amongst newly notified 
TB cases and previously treated cases was 14% and 47% respectively,2 with rates reaching 
significantly higher in some countries.3 XDR-TB is estimated to account for 10% of all MDR-
TB cases.2 The number of countries reporting XDR-TB cases also continues to increase. 
Over 40% of all mortality from communicable diseases in the WHO European Region is 
attributed to TB, largely due to the prevalence of M/XDR-TB; in 2011, 44,000 people in the 
European Region died of TB.2 In addition to the human cost of severe illness and death, 
the prevalence of M/XDR-TB poses an enormous economic burden in areas that are the 
most resource limited. 
In 2011, in consultation with Member States, civil society organizations and stake holders 
including patients’ representatives, a Consolidated Action Plan to Prevent and Combat 
Multidrug- and Extensively Drug-resistant Tuberculosis (2011–2015) was developed 
by the WHO Regional Office for Europe for all 53 Member States. The goal of the Plan is 
to contain the spread of drug-resistant TB by achieving universal access to prevention, 
diagnosis and treatment of M/XDR-TB in all member states in the WHO European Region 
by 2015.3 The Plan has six strategic directions and seven areas of intervention, which are 
aligned with the Global Plan to Stop TB 2011–2015. The specific targets to be met by the 
end of 2015 are to: decrease by 20% the proportion of MDR-TB amongst retreatment 
patients, diagnose at least 85% of all estimated MDR-TB patients, and successfully treat at 
least 75% of all patients notified of having MDR-TB. 
Successful treatment and lives saved have a direct economic benefit in countries most 
affected by M/XDR-TB. The objective of this study was to analyse the cost-effectiveness of 
implementing the Plan, with its expected targets achieved.
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2. Methods
The WHO Regional Office for Europe commissioned the Royal Tropical Institute in 
Amsterdam to estimate the costs for implementation of the Consolidated Action Plan to 
Prevent and Combat M/XDR-TB 2011–2015, on the basis of the expected achievements 
and benefits of implementing the Plan. The study was a collaboration between the Royal 
Tropical Institute in the Netherlands, the WHO Regional Office for Europe and WHO 
headquarters. The findings and methodology were peer-reviewed by experts at Imperial 
College in London, United Kingdom.
The costing methods are described in detail in Annex 4 of the Action Plan.3 In brief, a cost 
model was created using the public health system perspective for budgeting and unit cost 
calculation taking into account the targets for detection and treatment of M/XDR-TB patients 
defined in the Action Plan. Direct costs incurred by the public health care system, and costs 
for stewardship, supervision and capacity-building were included in the model. Indirect costs 
incurred by patients and society were excluded from the model. The estimated number of 
MDR-TB and XDR-TB patients, number of patients screened for M/XDR-TB, and the number 
of patients treated for M/XDR-TB from 2011–2015 were based on linear projections of the 
most recent epidemiological data (from 2007–2009 at the time of the study). 
Cost and epidemiological data were sourced from the WHO Regional Office for Europe, 
European Centre for Disease Prevention and Control (ECDC), the Foundation for Innovative 
New Diagnostics (FIND), Joint United Nations Programme on HIV/AIDS (UNAIDS) and academic 
publications. Budgets were formulated by including the complete treatment costs of all M/
XDR-TB patients envisaged to be enrolled in 2011–2015, including treatment for those cases 
beyond 2015. Budgets were prepared for the 18 high-priority countries (HPC) and 35 non-HPC 
separately because the incidence of M/XDR-TB and unit costs varied significantly between 
the two groups. The 18 HPC are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, 
Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova, Romania, Russian Federation, 
Tajikistan, Turkey, Turkmenistan, Ukraine, and Uzbekistan. As per standard practice, a discount 
rate of 0.03 was chosen in estimating the budget and unit costs.4
Unit costs: The cost of equipment was calculated assuming a 10-year life cycle of costs and 
throughput and a discount rate of 0.03. The annual maintenance costs of equipment were 
fixed at 5% of the total cost of equipment at delivery, except for the Xpert MTB/RIF assay, 
for which FIND has a fixed annual maintenance cost of 8%.5 In order to account for excess 
capacity an idle rate of 10% for all equipment was considered. The cost of staff time was 
based on annual expenditure and throughput. The total amount of staff time available for 
a year was calculated assuming a standard work schedule of 8 hours per day, 22 days per 
month and 11 months per year. Excess staff capacity was estimated at 15%. Staff salaries 
for diagnostics were obtained from the WHO-CHOICE database using 2005 values for the 
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Health Worker category.6 Euro A values were used for non-HPC. The average of Euro B and 
Euro C values was used for HPC. The costs of materials were allocated directly. A wastage 
rate of 5% was considered for consumables. As per the WHO-CHOICE database, the cost of 
delivery of diagnostic tests and equipment was 20% of the free on board cost.7 The costs 
of materials, consumables and equipment as well as the unit cost of a chest X-ray were 
retrieved from the planning and budgeting tool for TB control activities.8
The unit cost of M/XDR-TB treatment was calculated for a regimen comprising 6 months of 
intensive treatment and 18 months of continuation treatment at a dosage recommended 
for a person of average size (60 kg) according to WHO guidelines. The costs of diagnostics 
were based on the average number of laboratory tests a patient would undergo during 
the standard length of treatment. The cost of ambulatory care was based on the average 
number of outpatient visits during the standard length of treatment. The average cost for a 
ten-minute outpatient visit, assuming 50% population coverage, was calculated according 
to the WHO-CHOICE database.6 The cost of inpatient care was based on the percentage of 
patients hospitalized and the average annual length of stay. In line with the aim of the Action 
Plan to improve models of care and promote patient-centred approaches, it was estimated 
that MDR-TB patients would be hospitalized for three months and XDR-TB patients for one 
year, and that 80% of patients in HPC and non-HPC would be hospitalized.9 Since MDR-TB 
patients require sophisticated medical interventions and facilities such as negative pressure 
ventilation rooms, the average cost of a secondary care hospital day was used for the 
calculation of inpatient costs. The cost of therapeutics and diagnostics for the management 
of side-effects and care for M/XDR-TB patients during inpatient stays was estimated at 31% 
of the total inpatient cost.10 For both ambulatory and inpatient unit costs, Euro A costs were 
used for non-HPC and the average of Euro B and Euro C costs for HPC.
Modelling for calculation of expected achievements: Expected achievements of the Action 
Plan were based on the targets for detection and treatment of M/XDR-TB patients as 
defined in the Plan. To estimate the number of M/XDR-TB cases that could be averted 
in the Region the model of direct transmission of TB over the duration of the Plan was 
applied, thus excluding possible averted transmission from secondary and tertiary cases. 
Based on the Styblo model, it was assumed that each untreated sputum smear-positive 
patient could lead to 1.25 new TB cases over one transmission cycle.11 
The estimated number of averted cases was calculated by subtracting the number of 
patients who are successfully treated or died under treatment from the number of patients 
who are spontaneously cured or died without any intervention. The number of M/XDR-TB 
cases that cure spontaneously was assumed to be 5% and the case fatality rate without 
intervention was assumed to be 30%.12 The number of averted cases was calculated 
separately for MDR-TB and XDR-TB cases. The percentage of successfully treated MDR-TB 
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patients used was assumed to be the same as reported by WHO for 2009 (57.4%) and then 
linearly increased to reach the target of 75% in 2015, and the TB fatality rate amongst 
detected cases and under treatment was assumed to be 10.1%, the same as recorded in 
2009,13 and to remain stable for 2011–2015. In order to calculate XDR-TB cases averted it 
was assumed that the number of XDR-TB cases would remain at 10% of MDR-TB cases14 
and that the treatment success and death rates amongst detected XDR-TB were 51% and 
20%, respectively. Data on treatment success and death rates for XDR-TB cases are sparse, 
therefore an average of the rates reported in four scientific publications were used.15-18
The number of lives saved through implementation of the Action Plan was calculated as 
the difference between the projected number of MDR-TB deaths (mortality rate of MDR-TB 
patients under treatment multiplied by the number of MDR-TB cases) and the estimated 
number of TB deaths in the scenario that the Action Plan was not implemented and the 
TB epidemic continued.
Cost-effectiveness: The cost per disability-adjusted life-year (DALY) gained was calculated 
by dividing the cost per death averted by the average of DALYs gained per death averted.19 
An average of 21 DALYs gained per death averted was used as a conservative estimate.7 
The cost per death averted amounted to the total budget divided by the number of deaths 
averted. The cost per DALY gained was determined by dividing cost per death averted 
by the average of DALYs gained per death averted. Cost–efficiency was determined by 
comparing the cost per DALY weighted by the estimated number of MDR-TB cases based 
on the average GDP (2011 figures), weighted by the respective country populations.
Economic gain: Multiplication of GDP per capita and DALYs gained comprises the long-term 
direct economic gain of the lives saved over the period 2011–2015. The DALYs gained per deaths 
averted was determined by multiplication of the number of lives saved by the average of DALYs 
gained per live saved. The short-term direct economic gain up to 2015 was limited to the DALYs 
gained within the time frame of the Plan. Additional indirect short-term gain was restricted to 
the savings from the cost of treatment of M/XDR-TB cases averted by implementation of the 
Plan up to 2015 (direct transmission events). To calculate these treatment costs, a treatment 
unit cost was derived from the total budget by dividing it by the number of cases enrolled 
in treatment. The long-term indirect gain from averting cases by stopping the chain of 
transmission was not determined, as this requires more detailed epidemiological transmission 
modelling. A resources availability assessment and the assumptions for a resource availability 
forecast are further discussed in detail in Annex 4 of the Action Plan.
 
3. Results
Epidemiological modelling indicates that 225,000 cases of MDR-TB will be detected out of 
a total of 367,000 projected cases of MDR-TB through implementation of the Action Plan 
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between 2011 and 2015. Approximately 127,000 cases are expected to be successfully 
treated during the five-year period, and 200,000 MDR-TB patients are expected to be 
enrolled in treatment. The expected trends in MDR-TB incidence, case detection, treatment 
enrollment and treatment success are shown in Figure 1. Consistent with current trends, 
99% of the total detected MDR-TB patients in the WHO European Region are expected to 
be found in the HPC. With the implementation of the Action Plan, 250,000 cases of MDR-
TB and 13,000 XDR-TB cases are expected to be averted, and 120,000 lives are expected to 
be directly saved in the short-term.
2011 2012 2013 2014 2015
Estimated MDR-TB cases emerging
MDR-TB cases detected
MDR-TB patients enrolled on treatment








Figure 1. Expected trends with the implementation of the Action Plan, 2011–2015
Costs: When the M/XDR-TB costing tool was applied to the epidemiological model, it was 
found that implementation of the Action Plan would cost US$ 5.2 billion, with an annual 
budget range between US$ 453 million for 2011 and US$ 1.7 billion for 2015. This includes 
treatment completion of the cohort of 2015 M/XDR-TB patients. HPC are estimated to 
account for approximately 96% of the total financing. The resources required according to 
budget item are shown in Table 1.
The direct cost of treating an MDR-TB patient undergoing a standard treatment cycle of 
24 months was calculated to be US$ 25,400 in HPC and US$ 56,300 in non-HPC. Inpatient 
treatment represented 43% and 68% of the treatment cost for MDR-TB and XDR-TB cases, 
respectively. The Xpert MTB/RIF assay appeared to be the least expensive diagnostic tool 
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for the screening of first-line anti-TB drug resistance. This assay incurs a cost of US$ 24.1 
and US$ 71.7 per screened patient in HPC and non-HPC, respectively. The least expensive 
diagnostic test for second-line DST was solid media culture. Solid media DST costs US$ 
46.6 and US$ 62.2 per drug in HPC and non-HPC, respectively.
Table 1. Resources required according to budget item per year of the Action Plan, 2011–2015 
(US$ million and in percentage).
Budget item 2011 2012 2013 2014 2015 Total * %
Drugs 91 142 203 276 360 1,072 21
Diagnostics 74 104 138 177 221 713 14
Ambulatory care 101 156 223 302 394 1,177 23
Inpatient care 155 250 367 505 667 1,943 38
Patient support costs 16 24 34 47 61 181 4
Additional costs for HIV treatment 2 3 4 5 7 20 <1
Stewardship expenditure 15 15 15 15 15 73 1
Total 454 694 984 1,327 1,725 5,179 100
* Yearly amounts have been rounded for ease of interpretation, and therefore do not always equal 
the five-year period totals.
Cost-effectiveness and Economic gain: An overview of the cost-effectiveness and economic 
gain from the Plan is shown in Table 2. Comparison of the costs per DALY gained with GDP 
per capita showed that the intervention was highly cost-effective. The direct economic 
gain from saving 120,000 lives amounted to US$ 5 billion in the short term (DALYs gained 
up to 2015) and US$ 48 billion in the long term. The short-term indirect economic gain 
from averting 263,000 M/XDR-TB cases amounted to about US$ 6.9 billion. The long-term 
economic indirect gain has not been determined, but will be far greater than the short-
term amount because many future transmission events were not considered in this study.
4. Discussion
Results of this study show that interventions described in the Action Plan are highly cost-
effective. Implementation of the Action Plan in 2011–2015 in the WHO European Region 
would prevent of the emergence of 250,000 new MDR-TB and 13,000 XDR-TB cases 
respectively, saving nearly US$7 billion and 120,000 lives in the short-term. This study also 
found that implementation of the Action Plan was highly cost-efficient with an average 
cost of US$ 2044 per DALY gained versus an average GDP per capita of US$ 24,346 in the 
Region. 
It is important to note that these findings represent benefits that are restricted to 
predicted transmission events within the five-year time frame of the Plan and are thus 
an underestimation of its overall (future) benefits. Health system changes, for example 
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in criteria for hospitalization and adaptation of models of care with treatment in 
ambulatory services, day-care centres and home-/community-based treatment rather 
than hospitalization have the potential to decrease costs significantly. In addition, there 
are likely to be long-term benefits of addressing social determinants related to M/XDR-TB, 
which is an important component of the Plan. 






Overview of the cost-
effective analysis of 
the Action Plan
Number of lives saved 120,105 119,220 885
Budget of the Plan (US$ million) 5,179* 4,970 135
Cost per death averted (US$) 42,916 41,502 149,647
Average of DALYs gained per 
death averted (years) 21 21 21
Costs per DALY gained (US$) 2,044 1,976 7,126








Economic gain from 
lives saved 2011–2015 
by implementation of 
the Plan (short-term 
direct impact)
Number of lives saved 120,105 119,220 885
Average of DALYs gained per life 
saved (years) 5 5 5
DALYs gained per deaths averted 
(years) 275,569 272,359 3,210
GDP per capita (US$) 32,887 18,699 43,704
Gain (US$ million) 5,233 5,092 140
Economic gain from 
lives saved 2011–2015 
by implementation of 
the Plan (long-term 
direct impact)
Number of lives saved 120,105 119,220 885
Average of DALYs gained per life 
saved (years) 21 21 21
DALYs gained per deaths averted 
(years) 2,522,195 2,503,609 18,586
GDP per capita (US$) 32,887 18,699 43,704
Gain (US$ million) 47,628 46,815 812
Economic gain from 
M/XDR-TB cases 
averted up to 2015 
by implementation of 
the Plan (short-term 
indirect impact)
Budget of the Plan (US$ million) 5,179* 4,970 135
Number of M/XDR-TB patients put 
on treatment 198,898 197,600 1,298
Unit cost per M/XDR-TB patient 
care (US$) 26,038 25,156 104,377
Number of M/XDR-TB cases 
averted 263,442 260,767 2,675
Gain (US$ million) 6,838 6,559 279
* Regional budget amount does not equal to the sum of HPC and non-HPC amounts due to rounding 
in the Regional budget model.
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The Consolidated Action Plan comprises a comprehensive and integrated approach 
to controlling the problem of M/XDR-TB in the Region with an extensive monitoring 
framework and key indicators.3,20 There are 11 core (key) indicators, for which data is 
collected and measured annually, and that allow for the monitoring of performance in 
the main areas and interventions in the Action Plan. These 11 core indicators are part of a 
comprehensive full set of indicators that correspond to the seven areas of intervention of 
the Action Plan, and for which data has and will continue to be collected throughout the 
five-year period of the Plan. The WHO Regional Office for Europe has just completed a full 
study of the indicators of the Action Plan for all 53 Member States in the Region in 2011-
2013. Forthcoming results of that study will give a key indication of the progress since 
the implementation of the Action Plan and challenges that remain to be addressed. In 
addition, this study will allow for further monitoring of the cost-effectiveness of the Plan.
Strengths and limitations: This study represents a rigorous and robust cost-effectiveness 
analysis that utilized the latest epidemiological and cost data from the Region. As a measure 
of the reliability of this study, results were within rage of those found in other studies. For 
example, Diel and colleagues recently calculated the average cost of treatment of MDR-
TB amongst old European Union (EU)-15 countries, plus Cyprus, Malta and Slovenia to be 
€57,213 and €24,166 for M/XDR-TB in new EU states.21 White and Moore-Gillon previously 
estimated the mean direct cost of managing an MDR-TB patient in the United Kingdom to 
be £60,000,22 and Rajbhandary and colleagues estimated the mean direct cost of treating 
an MDR-TB patient in the United States to be US$ 45,000.10 
This study, however, was limited by availability of data. Laboratory management costs 
and specimen transport costs were not included due to lack of data and are likely to vary 
widely between countries. Owing to the high variation of criteria availability and cost in 
the countries, the cost of surgery (which is normally performed on 2–5% of M/XDR-TB 
patients) was not considered. The costs of active contact-tracing and testing of contacts 
were also excluded. The budget and unit cost estimates are prone to changes in efficiencies 
of screening and treating M/XDR-TB patients, variations in inpatient care as well as 
epidemiological trends in M/XDR-TB. There were also limitations imposed by the absence 
of extended transmission dynamics modelling; neither the number of lives that would 
be saved amongst those cases averted by the Plan, nor the number of lives that would 
be saved by the prevention of transmission by these averted and successfully treated 
cases were included. Other limitations on the calculation of the expected epidemiological 
achievements include: that no account was taken of the fact that M/XDR-TB cases are also 
averted by improved interventions for drug-susceptible and mono-resistant TB cases, 
and that consideration was not given to delays in detection or treatment because of the 
absence of data on these variables. 
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Conclusions and future perspectives: This study demonstrates that the Consolidated Action 
Plan is a cost-effective answer to the threat of M/XDR-TB in the Region. These results 
are not only relevant to the short-term future – In the long-term from a regional and 
global perspective, M/XDR-TB if left uncontrolled has the potential to impose a post-
antibiotic era,23 which will be hundreds of times more costly to tackle. Currently, there is 
a considerable projected funding gap of over 60% in order to fully implement the Plan. 
In countries supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria, 78% 
of M/XDR-TB patients are successfully treated compared to 20% in other settings. This 
is powerful evidence that mobilization of substantial funding from Global Fund, other 
international donors and national resources can make the difference in reaching the goals 
of the Action Plan. The current economic climate has placed an even greater burden on 
the social determinants of M/XDR-TB. There is a great need, therefore, to invest in health 
systems that place emphasis on patient-centred models of care that are in line with the 
WHO Action Plan and the European policy framework, Health 2020. The costs associated 
with these changes not only have immeasurable life-saving benefits, but also strategic 
short-term and long-term economic benefits that we cannot afford to overlook.
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Background: TB is one of the main health priorities in Uzbekistan and relatively high 
rates of unfavorable treatment outcomes have recently been reported. This requires 
closer analysis to explain the reasons and recommend interventions to improve the 
situation. Thus, by using countrywide data this study sought to determine trends 
in unfavorable outcomes (lost-to-follow-ups, deaths and treatment failures) and 
describe their associations with socio-demographic and clinical factors.
Method: A countrywide retrospective cohort study of all new and previously treated 
TB patients registered in the National Tuberculosis programme between January 
2006 and December 2010.  
Results: Among 107,380 registered patients, 67% were adults, with smaller 
proportions of children (10%), adolescents (4%) and elderly patients (19%). Sixty 
per cent were male, 66% lived in rural areas, 1% were HIV-infected and 1% had a 
history of imprisonment. Pulmonary TB (PTB) was present in 77%, of which 43% 
were smear-positive and 53% were smear-negative.  Overall, 83% of patients were 
successfully treated, 6% died, 6% were lost-to-follow-up, 3% failed treatment and 
2% transferred out. Factors associated with death included being above 55 years 
of age, HIV-positive, sputum smear positive, previously treated, jobless and living 
in certain provinces. Factors associated with lost-to-follow-up were being male, 
previously treated, jobless, living in an urban area, and living in certain provinces. 
Having smear-positive PTB, being an adolescent, being urban population, being 
HIV-negative, previously treated, jobless and residing in particular provinces were 
associated with treatment failure.
Conclusion:   Overall, 83% treatment success rate was achieved. However, our study 
findings highlight the need to improve TB services for certain vulnerable groups and 
in specific areas of the country. They also emphasize the need to develop unified 
monitoring and evaluation tools for drug-susceptible and drug-resistant TB, and call 
for better TB surveillance and coordination between provinces and neighbouring 
countries
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Introduction
Tuberculosis (TB) remains a public health challenge worldwide and particularly in Central 
Asian countries. TB is one of the main health priorities in Uzbekistan and since 2004 the 
DOTS (directly observed treatment, short course) strategy has been progressively rolled 
out in the country. A recent study conducted in Tashkent, the capital city of Uzbekistan, 
showed that, of 1087 pulmonary TB patients started on treatment in 2005, 228 (21%) were 
lost to follow up [1]. Treatment failure among TB patients in certain provinces in Uzbekistan 
has also been relatively high (over 5-8%), and the prevalence of multidrug resistant TB 
(MDR-TB) among new cases has tended to increase over the years (Drug resistance survey 
- 14.2% in 2005 and 23.2% in 2011), [2, 3, 4]. 
Given the high rate of unfavorable treatment outcomes reported in some provinces, there 
is a need to analyze unfavorable outcomes countrywide and identify possible trends 
and associated risk factors that could guide the National TB programme (NTP) in further 
improvements. The NTP uses an individual-patient electronic database and this therefore 
allows for detailed analysis beyond the conventional monitoring and evaluation reports 
that are reliant on aggregate data. All TB patients registered in electronic database were 
on first-line treatment regimen. Of the drugs, isoniazid (H), rifampin (R), ethambutol (E), 
and pyrazinamide (Z) are considered first-line anti-TB drugs and form the core of standard 
treatment regimens for drug susceptible TB patients
Using countrywide TB data from Uzbekistan on TB patients receiving first-line treatment, 
the aim of our research was to determine a) trends in lost to follow-up, deaths and 
treatment failures between 2006 and 2010 and b) the socio-demographic and clinical risk 
factors associated with each of these unfavorable treatment outcomes. 
Methods
Ethics
The study was approved by the “National Ethics Committee and Review Board” under 
the Ministry of Health (MoH) of Republic of Uzbekistan. The study satisfied the criteria for 
reports using routinely collected programmatic data set by the Médecins Sans Frontières 
Ethics Review Board (ERB), Geneva, Switzerland. Patient identifying information was 
removed prior to analysis. As this was a study of routinely collected monitoring data, 
patient consent was not required. 
Study design
This was a retrospective cohort study of routinely collected NTP data for all TB patients 
registered and commenced on first-line treatment between January 2006 and December 
2010. All patients were followed up until the end of treatment (6-8 months) to ascertain 
treatment outcomes. 
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Study setting
Previously part of the former Soviet Union, Uzbekistan is a country in Central Asia with 
an estimated population of more than 30 million. The country is divided into twelve 
provinces, the Republic of Karakalpakstan and the metropolitan area of Tashkent, the 
capital city. 
The National TB Program (NTP)
TB control activities are coordinated countrywide by the Republican Specialized Scientific 
Practical Medical Center of Phthisiology and Pulmonology (RSSPMCPP), which is essentially 
the NTP. TB diagnosis and treatment are provided free of charge within the NTP – there 
are no private TB services. Nonetheless, first and second line anti-TB drugs are available 
on the open market as a result of there being no governmental regulations to forbid the 
selling of these drugs. All registered TB patients receive treatment in accordance with the 
Stop TB Strategy. The latest WHO Global TB Report [5] reports that only 35-50% of the 
national cases in Uzbekistan were detected between 2005 and 2010, implying that there 
may be a large number of TB cases left untreated or receiving ‘unregistered’ inefficacious 
treatments regimens in the country.  
TB diagnosis and treatment
An established TB laboratory network in the country includes two National Reference 
Laboratories (NRL), five bacteriological laboratories and more than 300 smear microscopy 
laboratories, the latter of which perform direct microscopy of sputum collected in primary 
healthcare facilities. The mainstay of TB diagnosis in most provinces in Uzbekistan was 
through sputum smear microscopy or X-ray investigations. In accord with national guidelines 
[6], TB type was categorized as either pulmonary TB (PTB) or extrapulmonary TB (EPTB). PTB 
was defined as TB lesions involving the lung parenchyma, while TB lesions of the intra-
thoracic lymph nodes (mediastinal and /or hilar), or tuberculosis pleurisies in the absence 
of radiographic changes in the lungs, were considered to be EPTB.  If a patient presented 
with PTB and EPTB, they were recorded as having PTB when the pulmonary TB lesions were 
prominent; if however the patient had severe EPTB lesions (e.g. tuberculous meningitis) with 
limited forms of PTB lesions (smear-negative PTB), the patient was recorded as having EPTB.
Drug susceptibility testing (DST) during the study period could only be performed in two 
laboratories in Tashkent and Nukus. DST was performed using solid and liquid culture 
media and line probe assay (LPA) tests to determine type of drug resistance. Quality 
control in the two laboratories was ensured through routine checks by the Supra National 
Reference Laboratories (SNRL) in Borstel and Gauting, Germany. During the study period 
MDR-TB treatment was only available in Tashkent city, Nukus and the penitentiary system, 
and on account of limited bed capacity and resources, access to such treatment was not 
available for people residing in other provinces. 
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At the provincial level, TB treatment is provided under the supervision of the MoH and 
NTP at TB hospitals; at the district level, TB treatment is overseen by the TB dispensaries 
(outpatient care during the intensive phase and/or continuation phase of treatment) 
and also at the primary health care level (continuation phase of treatment) for both 
drug susceptible and MDR-TB patients in pilot areas. The Global Fund to Fight AIDS, 
Tuberculosis and Malaria (The Global Fund) provides all first-line anti-TB drugs and, since 
2013, has provided all second-line drugs countrywide for treatment of drug resistant 
tuberculosis (DR-TB). A recent Drug Resistance Survey (DRS) showed high rates of 
MDR-TB among new and previously treated patients, 23% and 62% respectively (3). In 
response to the high levels of MDR-TB, the NTP developed the “Updated National Plan on 
prevention and control of M/XDR-TB for 2012-2015 in Uzbekistan” [7] which is in line with 
the “The Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively 
Drug-Resistant Tuberculosis in the WHO European Region, 2011-2015”. This plan aims to 
decrease by 20 percentage points the proportion of MDR-TB among previously treated 
patients by the end of 2015; to diagnose at least 85% of all estimated MDR-TB patients by 
the end of 2015; to treat successfully at least 75% of all patients notified as having MDR-TB 
by the end of 2015. [8]      
NTP monitoring system
Since 2005, an Epi-Info based-TB-ESCM (Tuberculosis Electronic Surveillance and Case 
Management) system has been implemented countrywide for disease surveillance and 
case management. All diagnosed patients are individually recorded in this electronic 
register with a unique registration number, and all of their clinical data are captured here. 
TB treatment outcomes are in accord with WHO recommendations and described in 
national guidelines [6].  
Study population
The study population included all TB patients on first line treatment (new and retreatment 
cases) registered countrywide in the NTP between January 2006 and December 2010.  
Data collection and analysis
All data pertaining to this study were sourced from the TB ESCM electronic register. Patient 
characteristics were reported using summary statistics. Age categories were defined as 
follows: less than 15 years – child; 15-18 years – adolescent, 19-55 years – adult; 56 years 
or above – elderly. Unfavorable treatment outcomes were defined as death, treatment 
failure and lost to follow up, and each of these outcomes was assessed separately. Risk 
factors for unfavorable TB treatment outcomes were determined by crude odds ratios 
(ORs) and adjusted ORs, comparing the odds of having that outcome of interest with the 
odds of not having that outcome of interest (i.e. having any other outcome). Adjusted 
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ORs were determined through multivariate logistic regression using a backward stepwise 
elimination approach until all remaining variables in the model were significant at P=0.05 
or less. All related P-values were based on the Walds test and 95% confidence intervals 
were used throughout. Due to the incomplete ascertainment of transfer outs (many of 
which were considered to be failures secondary to MDR-TB), a sensitivity analysis was run 
in which all transfer outs were assumed to be failures.  
The study was carried out between June 2013 and June 2014 using EpiData Analysis 
software (version 2.2.2.182, EpiData Association, Odense, Denmark) and STATA/IC 11 
software (Stata corporation, College Station, Texas 77845, USA).
Results
Characteristics of the study population: Between 2006 and 2010, 110,146 TB patients on 
first-line drug regimen were registered in Uzbekistan. Of these, one percent (1,226) had 
treatment outcome missing and 1.4% (1540) did not have a confirmed TB diagnosis; as such 
these patients were excluded from the analysis. Table 1 shows the baseline demographic 
and clinical characteristics of the 107,380 patients included in the study. Adults (19-55 
years) made up 67% (71,522) of the patients, while 10% (11,519) were children (<15 
years) and 4% (4764) were adolescents (15-18 years). Almost 60% were male and 66% 
from rural areas (70,705). New patients made up 75% (81,016) of the caseload, while 
25% (26364) were previously treated patients. One percent (984) of patients was human 
immunodeficiency virus (HIV) positive and less than one percent (586) had a history of 
imprisonment. Seventy seven percent (82,686) of patients had pulmonary tuberculosis 
(PTB), of which 43% (35,178) were sputum smear positive, 53% (44,205) sputum smear 
negative and 3,303 with no or unknown sputum results. 
Table 1. Socio-demographic and clinical characteristics and treatment outcomes of 




Children (<15) 11519 (11)
Adolescent (15-18) 4764 (4)
Adults (19-55) 71522 (67)
Elderly patients (>55) 19575 (18)
Sex
Male 63724 (59)
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Republic of Karakalpakstan 13905 (13)
Tashkent city                             8504 (8)
Andijan province 8525 (8)
Bukhara province 4857 (4)
Jizzakh province 4873 (5)
Kashkadarya province 8593 (8)
Navoi province 4258 (4)
Namangan province 8062 (8)
Samarkand province 11202 (10)
Surkhandarya province 5455 (5)
Syrdarya province 2601 (3)
Tashkent province 11314 (11)
Fergana province 9830 (9)
Khorezm province 5164 (5)
Navoi mining company 229 (<1)
Unknown 8 (<1)  
HIV status
HIV positive 984 (1)




Smear positive 35178 (33)
Smear negative 44205 (41)
No sputum/no sputum result    3303 (3)
EPTB 24694 (23)
History of TB treatment
New cases 81016 (75)







History of contact with TB patient
No 90673 (85)
Yes 5590 (5)
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Treatment completed 64218 (60)
Died 5953 (6)
Loss to follow up 6768 (6)
Failure  3312 (3)
Transferred out 1725 (2)
TB, Tuberculosis; PTB, Pulmonary TB; EPTB, Extrapulmonary TB;
Treatment outcomes and their trends
Overall, 83% (89,622) of patients were successfully treated (cured or treatment completed), 
6% (5,953) died, 6% (6,768) were lost to follow up, 3% (3,312) failed treatment and 2% 
(1,725) were transferred out. Trends in the different unfavorable outcomes between 2006 
and 2010 are shown in Fig. 1. Deaths and treatment failures have remained stable over 
time, while lost to follow up decreased from 7.8% in 2006 to 5.7% in 2010. Table 2 shows 
a breakdown of treatment outcomes by TB type and TB retreatment history. Of note, new 
smear positive cases had a treatment success rate of 82%, new EPTB cases had a treatment 
success rate of 93%, and retreatment cases had a treatment success rate of 73%.
Table 2. Treatment outcomes of all registered tuberculosis patients by TB type and treatment 
history, Uzbekistan 2006-2010
n Treatment 
success      
n (%)
Died            
n (%)
Treatment 
Failure           
n (%)
Lost to 
follow up  
n (%)
Transferred 
out               
n (%)
New cases
Smear positive 24480 19971 (82) 1437 (6) 1322 (5) 1257 (5) 493 (2)
Smear negative 32240 28198 (87) 1513 (5) 405 (1) 1750 (5) 374 (1)
No sputum/no result 1940 1572 (81) 129 (7) 100 (5) 101 (5) 38 (1)
Extrapulmonary 22356 20704 (93) 414 (2) 31 (0.1) 1054 (5) 153 (0.7)
Retreatment cases 26364 19177 (73) 2460 (9) 1454 (6) 2606 (10) 667 (3)
Total 107380 89622 (83) 5953 (6) 3312 (3) 6768 (6) 1725 (6)
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Figure 1. Unfavorable treatment outcomes over five years in Uzbekistan 2006-2010
 
Factors associated with deaths, lost to follow-ups and treatment failures
Based on a multivariate analysis, factors found to be associated with death included being 
elderly (>55), being male, living in an urban area, having smear positive PTB, having a 
history of TB treatment, being HIV positive and being jobless, a pensioner or handicapped. 
The three provinces with the highest mortality were Samarkand province, Surkhandarya 
province and Tashkent city (Table 3). Being a child or adolescent, and having EPTB, was 
protective for dying.
Factors associated with deaths, lost to follow-ups and treatment failures
Based on a multivariate analysis, factors found to be associated with death included being
elderly (>55), being male, living in an urban area, having smear positive PTB, having a history
of TB treatment, being HIV positive and being jobless, a pensioner or handicapped. The three
provinces with the highest mortality were Samarkand province, Surkhandarya province and
Tashkent city, (Table 3). Being a child or adolescent, and having EPTB, was protective for
dying.
Fig 1. Unfavorable treatment outcomes over five years in Uzbekistan 2006–2010.
doi:10.1371/journal.pone.0128907.g001
Table 2. Treatment outcomes of all registered tuberculosis patients by TB type and treatment history, Uzbekistan 2006–2010.













24480 19971 (82) 1437 (6) 1322 (5) 1257 (5) 493 (2)
Smear negative 32240 28198 (87) 1513 (5) 405 (1) 1750 (5) 374 (1)
No sputum/no result 1940 1572 (81) 129 (7) 100 (5) 101 (5) 38 (1)
Extrapulmonary 22356 20704 (93) 414 (2) 31 (0.1) 1054 (5) 153 (0.7)
Retreatment cases 26364 19177 (73) 2460 (9) 1454 (6) 2606 (10) 667 (3)
Total 107380 89622 (83) 5953 (6) 3312 (3) 6768 (6) 1725 (6)
doi:10.1371/journal.pone.0128907.t002
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Factors associated with lost to follow-up were being male, living in an urban area, being 
HIV positive, having previous TB treatment history, being jobless, and living in the 
following provinces: Bukhara province, Tashkent province, Andijan province, (Table 4). 
Being an adolescent was protective for being lost to follow-up.
Table 4. Factors associated with loss to follow-up among TB patients in Uzbekistan 2006-2010
Variable N Loss to follow 
up n (%)
Crude OR  
(95% CI)
Adjusted ORa  
(95% CI)
P-value
Total 107380 6768 (6) - - -
Age (years)
Children (<15) 11519 455 (4) 0.5 (0.5-0.6) 0.8 (0.6-1.0) 0.06
Adolescent (15-18) 4764 190 (4) 0.5 (0.5-0.6) 0.7 (0.6-0.8) <0.001
Adults (19-55) 71522 5083 (7) 1 1
Elderly patients (>55) 19575 1040 (5) 0.7 (0.7-0.8) 0.9 (0.8-1.0) 0.11
Sex
Male 63724 4645 (7) 1.5 (1.5-1.6) 1.4 (1.4-1.5) <0.001
Female 43656 2123 (5) 1 1
Place of residence
Urban 32752 2800 (9) 1.8 (1.7-1.9) 1.8 (1.7-2.0) <0.001
Rural 70705 3560 (5) 1 1
Unknown 3923 408 (10) 2.2 (2.0-2.4)
Province
Republic of Karakalpakstan 13905 693 (5) 1.4 (1.2-1.7) 0.9 (0.7-1.2) 0.54
Tashkent city                     8504 528 (6) 1.8 (1.5-2.1) 0.8 (0.6-1.0) 0.03
Andijan province 8525 722 (8) 2.5 (2.1-2.9) 2.1 (1.6-2.6) <0.001
Bukhara province 4857 564 (12) 3.5 (2.9-4.2) 3.3 (2.6-4.1) <0.001
Jizzakh province 4873 177 (4) 1.0 (0.8-1.3) 1.0 (0.7-1.3) 0.83
Kashkadarya province 8593 239 (3) 0.8 (0.6-0.9) 0.7 (0.6-0.9) 0.02
Navoi province 4258 154 (4) 1 1
Namangan province 8062 467 (6) 1.6 (1.4-2.0) 1.4 (1.1-1.7) 0.01
Samarkand province 11202 585 (5) 1.5 (1.2-1.8) 1.1 (1.1-1.7) 0.008
Surkhandarya province 5455 377 (7) 2.0 (1.6-2.4) 1.8 (1.4-2.3) <0.001
Syrdarya province 2601 116 (5) 1.2 (1.0-1.6) 1.0 (0.8-1.4) 0.93
Tashkent province 11314 1195 (11) 3.1 (2.7-3.7) 2.4 (1.9-3.0) <0.001
Fergana province 9830 636 (7) 1.8 (1.5-2.2) 1.6 (1.3-2.0) <0.001
Khorezm province 5164 300 (6) 1.6 (1.3-2.0) 1.4 (1.1-1.8) 0.01
Navoi mining company 229 11 (5) 1.3 (0.7-2.5) 1.1 (0.5-2.1) 0.85
Unknown 8 2 (25) 8.9 (1.8-44.4)
HIV status
HIV positive 984  81 (8) 1.5 (1.2-1.8)
HIV negative 96524 5607 (6) 1
Unknown 9872 1080 (11) 2.0 (1.9-2.1)
TB type
PTB
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Smear positive 35178 2416 (7) 1.1 (1.0-1.1)
Smear negative 44205 2893 (7) 1
No sputum/no result    3303 277 (7) 1.1 (0.9-1.2)
EPTB 24694 1232 (5) 0.7 (0.7-0.8)
History of TB treatment
New cases 81016 4162 (5) 1 1
Retreatment cases 26364 2606 (10) 2.0 (1.9-2.1) 1.8 (1.7-1.9) <0.001
TB treatment category
0b 93 7 (8) 1.5 (0.7-3.3)
I 76548 3911 (5) 1
II 25986 2580 (10) 2.0 (1.9-2.2)
III 4752 270 (6) 1.1 (1.0-1.3)
Unknown 1 0 (0) -
History of contact with TB patient
No 90673 309 (6) 1.4 (1.3-1.5)
Yes 5590 5415 (6) 1
Unknown 11117 1044 (9)
History of imprisonmentc
No 44147 2614 (6) 1
Yes 586 62 (11) 1.9 (1.4-2.5)
Unknown 62647 4092 (7) 1.1 (1.1-1.2)
Occupational status
Worker 12105 531 (4) 1 1
Jobless 48569 3492 (7) 1.7 (1.5-1.9) 1.7 (1.6-1.9) <0.001
Pre-school age 2994 140 (5) 1.1 (0.9-1.3) 1.5 (1.1-2.0) 0.02
Pupil/student 11186 399 (4) 0.8 (0.7-0.9) 1.2 (0.9-1.5) 0.25
Pensioner 13898 674 (5) 1.1 (1.0-1.2) 1.3 (1.1-1.6) 0.002
Handicapped 5996 423 (7) 1.7 (1.5-1.9) 1.3 (1.1-1.5) 0.001
Unknown 12632 1109 (9) 2.1 (1.9-2.3)
TB, Tuberculosis; PTB, Pulmonary TB; EPTB, Extrapulmonary TB; OR, Odds Ratio, CI, 
Confidence Interval
aAdjusted odds ratios only presented for variables included in the multivariate model; 
92812 records included in the multivariate model
b0- patients who refused treatment, or treatment category not defined, or where TB 
diagnosis was based on the findings of a post-mortem
cData should not be considered relevant as unknown cases more than 50% in this group 
of patients
Factors associated with treatment failure included being adolescent, urban area 
population, having positive sputum result, previous treatment history, being HIV negative, 
being jobless, and residing in the following provinces:  Fergana province, Tashkent city, 
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Republic of Karakalpakstan, (Table 5). Being a child and having EPTB, was protective for 
failing treatment.
Table 5. Factors associated with treatment failure in TB patients in Uzbekistan, 2006-2010
Variables n (%) Treatment 




Adjusted ORa   
(95% CI)
P-value
Total 107380 3312 (3)
Age (years)
Children (<15) 11519 32 (<1) 0.07 (0.05-0.1) 0.6 (0.3-0.9) 0.02
Adolescent (15-18) 4764 170 (4) 0.9 (0.8-1.1) 1.3 (1.1-1.7) 0.01
Adults (19-55) 71522 2716 (4) 1 1
Elderly patients (>55) 19575 394 (2) 0.5 (0.5-0.6) 0.8 (0.7-1.0) 0.07
Sex
Male 63724 2070 (3) 1.2 (1.1-1.2)
Female 43656 1242 (3) 1
Place of residence
Urban 32752 1462 (5) 2.0 (1.9-2.2) 1.5 (1.4-1.7) <0.001
Rural 70705 1590 (2) 1 1
Unknown 3923 260 (7) 3.2 (2.7-3.5)
Province
Rep of     Karakalpakstan 13905 682 (5) 3.6 (2.7-4.5) 2.6 (1.9-3.7) <0.001
Tashkent city                  8504 427 (5) 3.6 (2.7-4.7) 2.1 (1.4-2.9) 0.001
Andijan province 8525 304 (4) 2.5 (1.9-3.3) 1.9 (1.4-2.8) <0.001
Bukhara province 4857 78 (2) 1.1 (0.8-1.5) 1.2 (0.8-1.8) 0.42
Jizzakh province 4873 61 (1) 0.9 (0.6-1.2) 0.6 (0.4-0.9) 0.02
Kashkadarya province 8593 17 (<1) 0.1 (0.1-0.2) 0.1 (0.1-0.2) <0.001
Navoi province 4258 62 (2) 1 1
Namangan province 8062 181 (2) 1.6 (1.2-2.1) 1.4 (1.0-2.0) 0.09
Samarkand province 11202 239 (2) 1.5 (1.1-2.0) 1.4 (1.0-1.9) 0.09
Surkhandarya province 5455 79 (2) 1.0 (0.7-1.4) 0.8 (0.5-1.1) 0.20
Syrdarya province 2601 85 (3) 2.3 (1.6-3.2) 1.7 (1.1-2.5) 0.01
Tashkent province 11314 492 (4) 3.1 (2.4-4.0) 2.1 (1.5-3.0) <0.001
Fergana province 9830 447 (5) 3.2 (2.5-4.2) 2.8 (2.0-3.9) <0.001
Khorezm province 5164 151 (3) 2 (1.5-2.7) 1.2 (0.8-1.8) 0.27
Navoi mining 229 6 (3) 1.8 (0.8-4.3) 2.7 (1.1-6.5) 0.03
Unknown 8 0 (0) - -
HIV status
Positive 984  23 (2) 1 1
Negative 96524 2656 (3) 1.2 (0.8-1.8) 1.6 (1.1-2.5) 0.02
Unknown 9872 635 (7) 2.9 (1.9-4.4) 
TB type
PTB
Smear positive 35178 2482 (7) 5.5 (5.0-6.0) 5.5 (4.9-6.0) <0.001
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Smear negative 44205 606 (1) 1 1
No sputum/no result    3303 192 (6) 4.4 (3.8-5.2) 4.3 (3.5-5.3) <0.001
EPTB 24694 32 (0.1) 0.09 (0.07-0.1) 0.2 (0.1-0.2) <0.001
History of TB treatment
New cases 81016 1858 (2) 1 1
Retreatment cases 26364 1454 (6) 2.5 (2.3-2.7) 1.7 (1.5-1.8) <0.001
Treatment category
0b 93 1 (1) 0.4 (0.06-3.1)
I 76548 1856 (2) 1
II 25986 1447 (6) 0.07 (0.03-0.1)
III 4752 8 (0.2) -
Unknown 1 1 (0)
TB contact
No 90673 2425 (3) 1.6 (1.4-1.8) 1.6 (1.4-1.8) <0.001
Yes 5590 887 (6) 1 1
Unknown 11117 0 (0)
History of imprisonmentc
No 44147 1037 (2) 1
Yes 586 19 (3) 1.4 (0.9-2.2)
Unknown 62647 2256 (4) 1.6 (1.4-1.7)
Occupational status
Worker 12105 345 (3) 1 1
Jobless 48569 1712 (4) 1.3 (1.1-1.4) 1.1 (1.0-1.3) 0.03
Pre-school age 2994 1 (0.03) 0.01 (0.002-
0.8)
0.1 (0.01-0.8) 0.03
Pupil/student 11186 103 (0.9) 0.3 (0.3-0.4) 0.9 (0.6-1.2) 0.37
Pensioner 13898 225 (2) 0.6 (0.5-0.7) 0.7 (0.5-0.9) 0.005
Handicapped 5996 247 (4) 1.5 (1.2-1.7) 1.1 (0.9-1.3) 0.22
Unknown 12632 679 (6) 2 (1.7-2.3) - -
TB, Tuberculosis; PTB, Pulmonary TB; EPTB, Extrapulmonary TB; OR, Odds Ratio, CI, 
Confidence Interval
aAdjusted odds ratios only presented for variables included in the multivariate model; 
92055 records included in the multivariate model
b0- patients who refused treatment, or treatment category not defined, or where TB 
diagnosis was based on findings of a post-mortem 
cData should not be considered relevant as unknown cases more than 50% in this group 
of patients
Discussion
This is the first report from Uzbekistan, and one of the first from a former Soviet Union 
Country, describing the association of risk factors with treatment outcomes of the patients 
under first-line drug regimen over the course of five years. Systematic reviews have 
highlighted that there are limited large-scale data on TB treatment outcomes. Another 
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systematic review of national-level TB treatment outcomes among the 30 European Union 
/European Economic Area countries indicated the same [9]. The WHO Global TB Report 
provide such data at national level; however detailed analysis of individual patient data, as 
well as associations between unfavorable treatment outcomes and selected demographic 
and clinical characteristics, are not reported [5].
Our study has shown promising treatment success (83%) among registered TB patients 
on first line treatment in Uzbekistan, with these data closely corroborating the data 
on treatment outcomes reported by WHO for Uzbekistan [5].  The overall treatment 
success rate that we report is marginally higher that reported by WHO because WHO 
only considers new smear positive cases in its analysis, whereas we have reported on all 
registered patients. This includes new smear negative and EPTB cases who have higher 
rates of treatment success than new smear positive cases. Moreover, we have been able to 
describe in detail patient characteristics together with certain factors that are associated 
with unfavorable treatment outcomes. These findings may help the national programme 
to define strategies and targeted interventions for the most vulnerable populations in 
order to further improve TB control.  
Trends in unfavorable TB outcomes remained relatively stable over the five-year period. 
Interestingly however, despite stable treatment failure rates, a recent DRS survey revealed 
alarmingly high rates of DR TB among new and previously treated cases [3]. Various factors 
may underpin this situation, including low case detection rate. Recent estimates presented 
in the latest WHO Global TB Report [5] suggest that only 50% of TB cases in Uzbekistan are 
being detected and put on ‘registered’ treatment. This indicates that a large number of TB 
cases are either going untreated or, due to factors such as stigma, are seeking treatment 
from ‘unofficial’ sources, the latter of which may be associated with patients receiving 
inefficacious treatment regimens. We can only speculate, but ‘unregistered’ cases may 
be a prime driver of the MDR-TB epidemic and this calls for urgent measures to improve 
case detection in Uzbekistan. In the context of Uzbekistan, this could be addressed by a) 
strengthening the capacity of primary health care facilities in TB case detection, given 
that these facilities are usually the first point of contact for most patients; b) improving 
the performance of microscopy laboratories located in rural places; c) raising community 
awareness on TB. During the study period, access to MDR-TB diagnosis and treatment 
was only guaranteed for patients residing in Tashkent city, Nukus city and in penitentiary 
system. It is encouraging to see that since 2013, MDR-TB treatment has become available 
for everyone in the country and, since 2014, Xpert MTB/RIF has become available in all 
provinces.
In our analysis we went beyond the usual convention of just stratifying patients according 
to whether they were adults or children, and also considered adolescents (15-18 years) 
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and elderly patients (>55 years) – two groups that are rarely examined despite there being 
evidence that these are particularly vulnerable sub-groups in the context of other diseases 
[10]. In our study, adolescents had a higher likelihood of treatment failure and elderly 
patients had higher mortality. The latter has been reported in other settings [11,12,13] 
and may be due to age-related factors such as co-existing morbidities, like diabetes 
mellitus (which has been shown to increase the case fatality rate during TB treatment) 
[14],  immunosuppression and a greater likelihood of unfavorable drug reactions [15,16].
The degree of unfavorable treatment outcomes between provinces varied quite notably, 
with higher mortality, lost to follow-up and treatment failure observed in the capital city 
Tashkent, Fergana, and in the Republic of Karakalpakstan which is also known to have 
the highest rate of drug-resistant TB in the world [3, 17, 18].  The differences between 
provinces may be explained by a number of factors such as i) variations in drug resistance 
prevalence and resistance patterns (for example, the highest rates of MDR-TB have 
been reported in the Republic of Karakalpakstan [3] which in turn, is the province with 
the highest treatment failure; in contrast, the lowest rates of MDR-TB are reported in 
Surkhandarya province which concordantly has a relatively low odds of treatment 
failure compared with other provinces, ii) the performance of the local programme in 
terms of directly observed treatment (DOT) management, (i.e. poor supervision at the 
primary health facilities of patients’ anti-TB drug intake during the continuation phase of 
treatment), iii) the performance of the local primary health care services in relation to TB 
case detection of TB through microscopy, iv) the availability of first and second line anti 
TB drugs on the open market (which may be inappropriately used by doctors (private and 
public based) who are treating ‘unregistered’ TB patients (NB. This is forbidden by national 
regulations) [6], and/or v) patient characteristics such as migration and population 
mobility. Operational research at the level of the province may help to identify these 
specific factors. Qualitative research methods in particular (such as direct observation, 
in-depth interviews with local key stake holders, and “content analysis” of local reports 
and archives), may provide additional information that quantitative data currently do 
not reveal. We have hypothesized several factors; of these, differences in performance 
between provinces, availability of TB-drugs on the “open market”, and migration and 
mobility patterns, could be explored with qualitative or mixed methods.
There were disparities across all unfavorable outcomes when comparing urban and rural 
areas.  This finding has not been reported in other similar settings and thus we can only 
speculate on possible reasons for it. Deaths, lost to follow-ups, and treatment failures 
were all more common among urban than rural patients. Possible reasons for this may be 
related to differences in patients and/or differences in TB control activities between urban 
and rural areas. Co-morbidities such as diabetes mellitus may be more prevalent in urban 
rather than rural communities [19], the latter of which is known to be associated with a 
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higher likelihood of unfavorable TB outcomes [20]. Identifying what these specific reasons 
are would require further investigation. 
As shown in previous studies [21, 22, 23], treatment outcomes were worse among HIV-
positive TB patients compared to HIV negative TB patients, especially death. In contrast, 
HIV-positive TB patients had lower lost to follow-up and treatment failure. This could be 
partially accounted for by the higher mortality among HIV positive TB patients – i.e. these 
patients are more likely to die before it becomes evident that they have been lost to follow-
up or failed treatment [24]; it may also reflect better adherence to treatment among these 
patients. It is important to note that HIV-testing uptake was high in this national TB cohort 
and the country should maintain and further improve this, even though Uzbekistan is a 
low prevalence country.
Our study shows that treatment outcomes are poor among pulmonary sputum positive 
cases, and among previously treated patients rather than patients with negative sputum 
results and new TB cases. Our findings reflect what many other studies have shown [25, 
26].
The main strength of the study relates to the large countrywide size and national 
representativeness of the data. It is one of the first studies to have used countrywide 
TB data to assess risk factors associated with unfavorable treatment outcomes, and to 
have analyzed individual patient data rather than aggregate data. Most national TB 
programmes report only aggregate data as maintaining electronic databases that collect 
individual patient data is too resource demanding. 
There are several study limitations. First, the study was reliant on routinely collected data 
which may have been subject to reporting errors typically encountered in programmatic 
settings (such as incomplete data, inaccurate data, typing errors etc.). Second, we were 
not able to analyze some particularly interesting subgroups of patients such as inmates, 
as large amounts of these data were incomplete. Finally, a major limitation was the 
misclassification of ‘transfer-outs’. Between 2003 and 2005, two MDR-TB pilot programmes 
were started in Karakalpakstan and the capital city Tashkent. Patients diagnosed with 
MDR-TB were transferred to the pilot clinics and their records were transferred to the 
MDR-TB register. In many instances, these patients were classified in the national database 
as “transferred out” rather than “treatment failure”. Furthermore, for patients who were 
transferred out to a different district/province, the national database should have been 
updated to reflect the final outcome for that patient. This however never happened. 
Therefore, in this study the outcome “transferred out” consisted of patients for whom the 
final outcome was not ascertained and patients who were transferred into the MDR TB 
register after failing standard treatment. As such, a proportion of the transfer outs were 
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essentially treatment failures, although this proportion remains unknown. To take account 
of this discrepancy we ran a sensitivity analysis in which all transfer outs were considered 
to be failures. When transfer-outs were combined with failures like this however, there 
were no notable differences in the factors associated with this combined outcome in 
comparison to those factors identified as being associated with treatment failure alone. 
This misclassification in standard treatment outcome reporting needs to be addressed 
going forwards. 
In conclusion, this study has demonstrated how countrywide data can be used to monitor 
trends in TB outcomes and guide the NTP in identifying areas where targeted strategies 
need to be deployed for vulnerable groups and in certain parts of the country. We also 
highlight the need to unify the monitoring and reporting of TB outcomes between the 
national database for standard TB treatment and the database for MDR-TB. Finally, as 
migration between countries continues to increase surveillance of treatment failures 
and coordination of TB case management between neighboring countries needs to be 
reinforced.
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Introduction
Encouragingly, global rates of new tuberculosis (TB) cases have been falling since 2005, 
in line with the Millennium Development Goal targets; however, cases of multidrug- 
resistant (MDR-) and extensively drug-resistant TB (XDR-TB) have been increasing. 
Fifteen of the world’s 27 high MDR- and XDR-TB burden countries are in the World Health 
Organization (WHO) European Region, of which 10 are in Eastern Europe (including Baltic 
and Caucasus countries). To address the MDR- and XDR-TB situation in the WHO European 
Region, a Consolidated Action Plan to Prevent and Combat M/XDR-TB (2011–2015) was 
developed for all 53 Member States and implemented in 2011. Since the implementation 
of the Action Plan, the proportion of MDR-TB appears largely to have levelled off among 
bacteriologically confirmed TB cases in high-burden countries with universal or near 
universal (>95%) first-line drug susceptibility testing (DST). The treatment success rate, 
however, continues to decrease. A contributing factor is the substantial proportion of 
MDR-TB cases that are additionally resistant to either a fluoroquinolone, a second-line 
injectable agent or both (XDR-TB); high-burden country proportions range from 12.6% 
to 80.4%. Proportions of XDR-TB range from 5% to 24.8%. Despite much progress in 
Eastern Europe, critical challenges remain as regards access to appropriate treatment 
regimens; patient hospitalisation; scale-up of laboratory capacity, including the use of 
rapid diagnostics and second-line DST; vulnerable populations; human resources; and 
financing. Solutions to these challenges are aligned with the Post-2015 Global TB strategy. 
As a first step, the global strategy should be adapted at regional and country levels to 
serve as a framework for immediate actions as well as longer-term ways forward.
More than 50 years after the first anti-tuberculosis chemotherapeutic drugs were 
introduced, tuberculosis (TB) remains a leading cause of death and life-threatening illness, 
disproportionately affecting low- and middle-income countries. In 2012, there were 
approximately 8.6 million new cases of TB worldwide, and 1.3 million people died from the 
disease.1 In addition, treatment success rates have been severely compromised in recent 
years due to the increasing prevalence of multidrug-resistant (MDR-) and extensively 
drug-resistant TB (XDR-TB).1,2 Although, encouragingly, global rates of new TB cases have 
been falling since 2005, in line with Millennium Development Goal (MDG) targets,3 MDR- 
and XDR-TB cases have been increasing, with an estimated 450 000 new cases in 2012.1 
This review will focus on drug-resistant TB in the eastern European sub-region (including 
Baltic and Caucasus countries), which has one of the highest rates of MDR- and XDR-TB in 
the world; the challenges to MDR- and XDR-TB control; and potential ways forward.
Countries included in this review
The high MDR-TB burden countries in Eastern Europe (including Baltic and Caucasus 
countries) that have been included in this review and which are within the World Health 
Organization (WHO) European Region, are Armenia, Azerbaijan, Belarus, Estonia, Georgia, 
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Latvia, Lithuania, the Republic of Moldova, the Russian Federation and Ukraine.1 We limited 
the scope of this review geographically to countries from this sub-region, as they were 
eligible to participate in the Structured Operational Research and Training Initiative (SORT 
IT) Eastern European Programme 2012–2014,4 through which the research presented in 
this supplement of Public Health Action was conducted.
Background to the MDR- and XDR-TB situation in the WHO European Region
MDR-TB is caused by Mycobacterium tuberculosis that is resistant to at least isoniazid 
(INH) and rifampicin (RMP), the two most potent anti-tuberculosis drugs. XDR-TB is 
defined as MDR-TB plus any fluoroquinolone and at least one injectable second-line 
drug (i.e., amikacin, kanamycin or capreomycin). Drug-resistant TB can occur due either 
to transmission of already resistant strains of M. tuberculosis5 or to suboptimal treatment 
of susceptible strains, which can develop resistance. 6 The duration of treatment is longer 
for MDR-TB (up to 2 years) than for drug-susceptible TB (6–9 months), with a significantly 
higher risk of adverse drug reactions7,8 and unsuccessful treatment outcomes, particularly 
death.9–12 These risks are even higher for XDR-TB.13,14
Fifteen of the world’s 27 countries with a high MDR- and XDR-TB burden are in the WHO 
European Region (Figure 1).15,16 With the dissolution of the Union of Soviet Socialist Republics 
in the early 1990s, TB and MDR-TB case rates began to increase in the newly independent 
states, largely due to the ensuing socio-economic crisis and deterioration of the health care 
system (Figure 2).17,18 Currently, all high-burden MDR-TB countries in the WHO European 
Region are in the east, and 99% of the region’s MDR-TB cases occur in these countries.15,16
In 2010, to address the MDR- and XDR-TB situation in the Region, a Consolidated Action 
Plan to Prevent and Combat M/XDR-TB (2011–2015) was developed for all 53 member 
states.16 The goal of the plan is to contain the spread of drug-resistant TB by achieving 
universal access to prevention, diagnosis and treatment of MDR- and XDR-TB in all member 
states in the Region by 2015.16 The plan, which has six strategic directions and seven areas 
of intervention, is aligned with the Global Plan to Stop TB 2011–2015,19 with the following 
specific targets to be met by the end of 2015: reduce by 20% the proportion of MDR-TB 
among retreatment patients, diagnose at least 85% of all estimated MDR-TB patients, and 
successfully treat at least 75% of all patients notified as having MDR-TB. The plan is also 
designed to address causal determinants of and barriers to TB control, including the use 
of operational research to inform policy guidance and models of care to reach the targets 
set forth. Endorsement and implementation of the plan began in 2011.
The burden of MDR- and XDR-TB in the WHO European Region
Currently, while only approximately 4% of the global burden of TB is found in the WHO 
European Region, atotal of 25% of the world’s burden of MDR-TB is also found here, 
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indicating the crucial importance of MDR-TB for this region.1 The current estimated annual 
incidence and proportion of MDR-TB among new and previously treated TB cases in the 
high-burden MDR-TB countries by subregion are shown in Table 1. MDR-TB rates among 
new and previously treated cases are significantly higher in these countries than in the 
top three high MDR-TB burden countries in other WHO regions. In 2012, the highest rates 
were in Belarus, where respectively 35% and 69% of new and previously treated cases 
were estimated to have MDR-TB.15 A drug resistance survey conducted in 2010–2011 in 
Belarus found that respectively 32.3% and 75.6% of new and previously treated patients 
had MDR-TB, of which 12% had XDR-TB.20
Figure 1. Notification rates of MDR-TB cases/100 000 population, European Region, 2012 
(reproduced with permission from Tuberculosis Surveillance and Monitoring in Europe 
201411). MDR-TB = multidrug-resistant tuberculosis.
XDR-TB accounts for approximately 9% of drug-resistant cases, with the majority also 
occurring in the region’s 15 high-burden countries.15 However, the added burden of 
pre-XDR-TB, defined as MDR-TB plus resistance to either a fluoroquinolone or a second-
line injectable, is much higher. A recent study utilising regional data found that of those 
MDR-TB patients who underwent second-line drug susceptibility testing (DST), a total of 
41.1% (95% confidence interval [CI] 32.3–50.0) had resistance to either a fluoroquinolone 
or a second-line injectable agent or both (i.e., either pre-XDR or XDR-TB).21 Concurrently, 
among new and previously treated cases, MDR-TB treatment success rates have 
decreased from respectively 72.5% and 50% in 2005 to 66.1% and 46.5% in 2010.15,22 In 
care system (Figure 2).17,18 Currently, all high-burden 
MDR-TB countries in the WHO European Region are 
in the east, and 99% of the region’s MDR-TB cases oc-
cur in these co ntries.15,16
In 2010, to address the MDR- and XDR-TB situa-
tion in the Region, a Consolidated Action Plan to Pre-
vent and Combat M/XDR-TB (2011–2015) was devel-
oped for all 53 member states.16 The goal of the plan 
is to contain the spread of drug-resistant TB by achiev-
ing universal access to prevention, diagnosis and 
treatment of MDR- and XDR-TB in all member states 
in the Region by 2015.16 The plan, which has six stra-
te ic directions and seven areas of in ervention, is 
aligned with the Global Plan to Stop TB 2011–2015,19 
with the following specific targets to be met by the 
end of 2015: reduce by 20% the proportion of 
MDR-TB among retreatment patients, diagnose at 
least 85% of all estimated MDR-TB patients, and suc-
cessfully treat at least 75% of all patients notified as 
having MDR-TB. The plan is also designed to address 
causal determinants of and barriers to TB control, in-
cluding the use of operational research to inform pol-
icy guidance and models of care to reach the targets 
set forth. Endorsement and implementation of the 
plan began in 2011.
THE WHO EUROPEAN REGION
Currently, while only approximately 4% of the global 
burden of TB is f und in t e WHO Europea  Region, a 
total of 25% of the world’s burden of MDR-TB is also 
found here, indicating the crucial importance of 
MDR-TB for this region.1 The current estimated annual 
incidence and proportion of MDR-TB among new and 
previously treated TB cases in the high-burden 
MDR-TB countries by subregion are shown in Table 1. 
MDR-TB rates among new and previously treated cases 
are significantly higher in these countries than in the 
top three high MDR-TB burden countries in other 
WHO regions. In 2012, the highest rates were in Be-
larus, where respectively 35% and 69% of new and 
previously treated cases were estimated to have 
MDR-TB.15 A drug resistance survey conducted in 
2010–2011 in Belarus found that respectively 32.3% 
and 75.6% of new and previously treated patients had 
MDR-TB, of which 12% had XDR-TB.20
XDR-TB accounts for approximately 9% of drug-re-
sistant cases, with the majority also occurring in the 
region’s 15 high-burden countries.15 However, the 
added burden of pre-XDR-TB, defined as MDR-TB plus 
resistance to either a fluoroquinolone or a second-line 
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FIGURE 1 Notification rates of MDR-TB cases/100 000 population, European Region, 2012 (reproduced with permission from Tuberculosis 
Surveillance and Monitoring in Europe 201411). DR-TB = multidrug-resistant tuberculosis. 
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total, only 49% of people diagnosed with MDR-TB had a successful treatment outcome, 
well below the 75% target. 15,16 Despite these trends in treatment success, there has been 
a steady decline in mortality rates from TB since 2002, also in line with the MDG targets. 
The estimated mortality for 2012 was 3.9 per 100 000 population (95% CI 3.8–4.0) in the 
region, corresponding to approximately 35 000 deaths.15
Figure 2. TB notification rate and estimated incidence in the WHO European Region, 1980–
2012. MS = Member States (53 in the WHO European Region); HPC = high-priority countries 
(i.e., high MDR- and XDR-TB burden countries in the WHO European Region, plus Bulgaria, 
Romania, Turkey and Turkmenistan); EU = European Union; EEA = European Economic Area; 
MDR-TB = multidrug-resistant tuberculosis; XDR-TB = extensively drug-resistant TB.
The burden of MDR- and XDR-TB in eastern european countries
Ten of the European Region’s high MDR-TB burden countries are in Eastern Europe (Figure 
1, Table 1). The TB incidence rate has been falling in most Eastern European countries, 
except for Azerbaijan and Ukraine.15 Utilising national data routinely reported to the 
WHO,15  trends in the proportion of MDR-TB among all notified TB cases (new and previously 
treated) with first-line DST plotted against treatment success rates for each of these 
countries are shown in Figure 3. It should be noted that year-to-year trend assessments 
may not be reliable in some cases, given overlapping CIs; however, observations from 








FIGURE 2 TB notification rate and estimated incidence in the WHO 
European Region, 1980–2012. MS = Member States (53 in the WHO 
European Region); HPC = high-priority countries (i.e., high MDR- and 
XDR-TB burden countries in the WHO European Region, plus Bul-
garia, Romania, Turkey and Turkmenistan); EU = European Union; EEA 
= European Economic Area; MDR-TB = multidrug-resistant tuberculo-
sis; XDR-TB = extensively drug-resistant TB.
TABLE 1 






High MDR-TB burden and high-priority countries in the WHO European Region
 High MDR-TB burden countries in Eastern Europe
  Ar enia 250 (220–280) 9.4 (7.0–12)
  Azerbaijan 2 800 (2 600–3 000) 22 (19–27)
  Belarus 2 200 (2 100–2 200) 35 (33–37)
  Estonia 70 (56–85) 20 (14–26)
  Georgia 630 (570–690) 9.2 (7.9–11.0)
  Latvia 120 (100–140) 11 (8.8–14)
  Lithuania 300 (270–330) 11 (9.5–14)
  Republic of Moldova 1 700 (1 600–1 800) 24 (21–26)
  Russian Federation 46 000 (43 000–49 000) 23 (21–25)
  Ukraine 6 800 (6 500–7 000) 14 (14–15)
 High MDR-TB burden countries in Central Asia
  Kazakhstan 7 000 (6 900–7 200) 23 (22–24)
  Kyrgyzstan 1 800 (1 600–2 000) 26 (23–30)
  Tajikistan 910 (800–1 000) 13 (9.8–16)
  Uzbekistan 4 000 (3 700–4 300) 23 (18–29)
 High-priority countries in the WHO European Region
  Bulgaria 100 (78–130) 2.3 (1.3–3.8)
  Romania 800 (610–980) 2.8 (1.8–4.2)
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Figure 3. Proportion of MDR-TB among all notified TB cases with first-line DST and treatment 
success rates in countries in Eastern Europe, 2009–2012. Note: Trend-line not drawn where 
fewer than 4 data points are available. x-axis = year; y-axis = proportion;  = proportion of 
MDR-TB among all notified TB cases with firstline DST;  = proportion of all notified MDR-
TB cases with a successful treatment outcome for that year. MDR-TB = multidrug-resistant 
tuberculosis; DST = drug susceptibility testing.
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FIGURE 3 Proportion of MDR-TB among all notified TB cases with first-line DST and treatment success rates 
in countries in Eastern Europe, 2009–2012. Note: Trend-line not drawn where fewer than 4 data points are 
available. x-axis = year; y-axis = proportion; ♦ = proportion of MDR-TB among all notified TB cases ith first-
line DST;  = proportion of all notified MDR-TB cases with a successful treatment outcome for that year. 
MDR-TB = multidrug-resistant tuberculosis; DST = drug susceptibility testing.
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Of the countries that have universal or near universal (95%) first-line DST coverage among 
bacteriologically confirmed TB cases (Armenia, Belarus, Estonia, Georgia, Latvia, Lithuania 
and the Russian Federation), the proportion of MDR-TB appears to have largely levelled off, 
with the exception of Belarus. The Russian Federation has also experienced a slight but steady 
increase in MDR-TB since 2009. However, given the large population size of the country, and 
therefore the number of TB cases (Table 1), even a slight increase in the proportion of MDR-
TB represents a large absolute number of cases. Data from the country are, however, only 
available and reported on a subnational level from certain geographic areas; the currently 
known burden of MDR-TB may therefore not be representative of the entire country.21
Table 1. Estimated annual incidence of MDR-TB and estimated proportion of new and 
previously treated TB cases with MDR-TB among all notified TB cases in the 15 high MDR- and 
XDR-TB burden countries and high-priority countries in the WHO European Region, compared 
to the top three high MDR- and XDR-TB burden countries in other WHO Regions in 2012
Estimated annual 
incidence of MDR-TB
Estimated % of TB cases with MDR-








High MDR-TB burden and high-priority countries in the WHO European Region
   High MDR-TB burden countries in Eastern Europe
     Armenia 250 (220–280) 9.4 (7.0–12) 43 (38–49)
     Azerbaijan 2 800 (2 600–3 000) 22 (19–27) 56 (50–62)
     Belarus 2 200 (2 100–2 200) 35 (33–37) 69 (66–71)
     Estonia 70 (56–85) 20 (14–26) 50 (35–65)
     Georgia 630 (570–690) 9.2 (7.9–11.0) 31 (27–35)
     Latvia 120 (100–140) 11 (8.8–14) 32 (23–42)
     Lithuania 300 (270–330) 11 (9.5–14) 44 (39–49)
     Republic of Moldova 1 700 (1 600–1 800) 24 (21–26) 62 (59–65)
     Russian Federation 46 000 (43 000–49 000) 23 (21–25) 49 (44–53)
     Ukraine 6 800 (6 500–7 000) 14 (14–15) 32 (31–33)
High MDR-TB burden countries in Central Asia
     Kazakhstan 7 000 (6 900–7 200) 23 (22–24) 55 (54–56)
     Kyrgyzstan 1 800 (1 600–2 000) 26 (23–30) 68 (65–72)
     Tajikistan 910 (800–1 000) 13 (9.8–16) 56 (52–60)
     Uzbekistan 4 000 (3 700–4 300) 23 (18–29) 62 (52–71)
High-priority countries in the WHO European Region
     Bulgaria 100 (78–130) 2.3 (1.3–3.8) 23 (17–31)
     Romania 800 (610–980) 2.8 (1.8–4.2) 11 (8.0–15)
     Turkey 520 (460–580) 3.2 (2.7–3.7) 22 (19–25)
     Turkmenistan* 3.8 (1.1–9.5) 18 (11–27)
High MDR-TB burden countries in other WHO regions (top 3)
     India 64 000 (49 000–79 000) 2.2 (1.9–2.6) 15 (11–19)
     China 59 000 (52 000–66 000) 5.7 (4.5–7.0) 26 (22–30)
     Philippines 12 000 (9 300–15 000) 4.0 (2.9–5.5) 21 (14–29)
* No data reported for the estimated annual incidence of MDR-TB.
MDR-TB = multidrug-resistant tuberculosis; XDR-TB = extensively drug-resistant TB; WHO = World 
Health Organization; CI = confidence interval.
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Country* Year results n (%) n (%) n (%)
Armenia 2007 199 25 (12.6) — 10 (5.0)
Azerbaijan (Baku City) 2007 431 125 (29.0) — 55 (12.8)
Belarus 2011 612 128 (20.9) 235 (38.4) 73 (11.9)
Estonia 2012 55 12 (21.8) 10 (18.2) 4 (7.3)
Georgia 2012 341 51 (15.0) 149 (43.7) 30 (8.8)
Latvia 2012 106 21 (19.8) 61 (57.5) 17 (16.0)
Lithuania 2012 210 68 (32.4) 90 (42.9) 52 (24.8)
Russian Federation 2005 201 — — 11 (5.5)
   (Tomsk Oblast)
* No data available for the Republic of Moldova or Ukraine.
XDR-TB = extensively drug-resistant tuberculosis; MDR-TB = multidrug-resistant tuberculosis; DST = 
drug susceptibility testing; — = none reported.
In some countries, as the absolute number of TB cases continues to decrease, so too has the 
number of MDR-TB cases. Countries that have experienced a levelling-off or a reduction in 
the proportion of MDR-TB (Armenia, Estonia, Georgia, Latvia and Lithuania) may represent 
a success in the control of MDR-TB, given the decreasing TB incidence rate and universal 
DST coverage in these countries; however, data on early deaths that may occur before 
notification are not available. While the proportion of MDR-TB in the Republic of Moldova 
and Ukraine also appears to have decreased, first-line DST coverage in these countries is 
below 80%; the true rates of MDR-TB may therefore be greater than currently reported. 
Trends in Azerbaijan are also difficult to interpret, as DST coverage is below 80% in the 
country and no data were reported for 2009.
The decreasing treatment success in MDR-TB patients is a continuing problem. Georgia 
experienced an increase in treatment success rates from 2009 to 2010, which has since 
levelled off. The rate in Latvia has remained relatively stable, with an increase in 2012 over 
the previous year. Estonia also experienced an increase in 2012 over the previous year; 
however, this is after a downward trend since 2009. Critically, apart from a few subsettings, 
including penitentiary services in Azerbaijan, none of the 10 Eastern European countries 
have reached the WHO target of a 75% treatment success rate. Contributing to this 
problem are substantial levels of additional drug resistance and XDR-TB (Table 2).21,23,24
The countries with the highest mortality rates due to TB in the WHO European Region 
(and the eastern European subregion) are the Republic of Moldova (18 cases/100 000), 
the Russian Federation (13/100 000) and Ukraine (also 13/100 000).15 These rates are well 
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above both the estimated mortality rate for the region and the mortality rate for the 
European Union/European Economic Area, which is below 1 case/100 000.
Progress in MDR-TB control in Eastern Europe 
Much progress has been achieved in efforts to control TB in Eastern Europe since the 
implementation of the Action Plan in 2011. A complete review of national programmatic 
advances as a result of the Action Plan is beyond the scope of this review. However, several 
large initiatives have been implemented at regional level, including in Eastern Europe, in 
response to the MDR- and XDR-TB crisis.
All countries in Eastern Europe have developed national MDR and XDR-TB response 
plans in consultation with the WHO. These plans are based on country TB drug resistance 
surveys, resource availability, human immunodeficiency virus (HIV) burden and other 
national contexts.25 Several technical advisory mechanisms have also been established in 
the region to achieve the comprehensive goals of the Action Plan and national MDR- and 
XDR-TB response plans. These mechanisms include the Green Light Committee/ Europe 
(GLC/Europe), an independent technical advisory body to support countries with state-of-
the-art clinical advice and to scale up programme management of MDR- and XDR-TB;26 the 
European Respiratory Society-WHO Electronic Consilium (consilia are multidisciplinary 
teams of specialists organised to give expert clinical consultation for MDR- and XDR-TB 
and other difficult- to-treat TB cases, such as TB-HIV and paediatric cases);27 the European 
Tuberculosis Laboratory Initiative (ELI) to improve and expand second-line DST and scale 
up diagnostic capacity, including the use of rapid molecular tests such as Xpert® MTB/RIF 
(Cepheid, Sunnyvale, CA, USA);28 and the Regional Interagency Collaborating Committee 
on TB Control (RCC-TB), to improve partnerships and strengthen coordination among 
partners.29
Ongoing monitoring and evaluation will reveal the full impact of the Action Plan including 
these initiatives and others on the control of MDR-TB in the Region. However, several 
indicators of overall progress are already evident, such as the reduction in TB incidence 
rates and stabilisation of MDR-TB rates in many of the countries in the Eastern European 
subregion. In addition, treatment coverage for MDR-TB patients increased from 63% of 
estimated MDR-TB patients in 2011 to 96% in 2013.25 Extensive progress has also been 
made in the coverage and quality of TB surveillance. Since 2010, nationwide representative
data on levels of MDR-TB in Belarus, and now Azerbaijan (in addition to other countries 
in the WHO European Region), have been made available through nationwide drug 
resistance surveys.20,21,30
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Challenges remaining
Despite progress and good impetus in efforts to control MDR-TB rates in Eastern Europe in 
recent years, critical challenges remain. These challenges are most often interconnected 
and multifaceted; in addition, some are highly specific to the country context, while 
others are apparent throughout Eastern Europe and all high-burden countries in the WHO 
European Region. While not intending to be an exhaustive list, some of the most critical of 
these latter challenges are discussed below.
MDR-TB with additional resistance
The high levels of pre-XDR-TB and XDR-TB in Eastern Europe (Table 2) are of great concern. 
Despite widespread coverage of second- line drugs, there is still inadequate treatment 
and insufficient patient support mechanisms in some Eastern European countries, 
including some member states of the European Union.25 Evidence of this is seen in 
projects that are not supported internationally by technical agencies such as the WHO 
or the GLC, where treatment success among MDR-TB patients is extremely low (28% in 
some settings).31 This is mainly due to incomplete treatment regimens and lack of full 
access to all necessary second-line anti-tuberculosis drugs. Adverse drug events leading 
to poor treatment adherence during the long course of MDR- and XDR-TB treatment 
also severely compromise treatment success.32 Despite the recent conditional approval 
of two new medicines (bedaquiline and delamanid) by the international drug regulatory 
authorities, their full-scale use is not in place, as there is a need for the establishment of 
strong pharmacovigilence systems.
Patient hospitalisation
Contributing to the spread of drug-resistant forms of TB, some countries hospitalise 
patients unnecessarily while awaiting DST results or during the intensive phase of drug-
susceptible anti-tuberculosis treatment.33–38 Ambulatory services and other models of 
care, including home-based treatment, are not fully functional in these countries.25 In the 
absence of adequate airborne infection control, hospitalisation can lead to nosocomial 
transmission to health care workers, ancillary staff and other patients, and secondary 
infection with MDR- or XDR-TB strains.39 A recent meta- analysis found no difference 
in treatment outcomes of patients treated in ambulatory vs. hospitalised settings, and 
the WHO currently recommends minimising unnecessary hospitalisations and using 
ambulatory rather than hospital-based models of care for MDR-TB treatment.11 This is also 
likely to be much more acceptable to patients in the longer term.
Rapid diagnostics for first-line DST
New rapid molecular tests for MDR-TB, such as Xpert, play a vital role in the rapid 
identification and control of drug-resistant TB:40 in theory, the quicker the detection of 
drug-resistant strains, the faster patients can be initiated on appropriate treatment 
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regimens, thereby minimising the window of transmission, although this also depends on 
good linkages and referral systems to care. Rapid diagnostic technologies, however, are 
not yet universally available in all Eastern European countries.16,32,41 Reduced funding due 
to the financial crisis in some countries has also exacerbated the difficulties in scaling up 
diagnostic capacities, including the use of molecular tests and improving biosafety.
Second-line DST and surveillance
Data on second-line DST are still limited, and electronic data management is lacking 
in many countries in Eastern Europe, adding to difficulties in analysing programme 
performance.25 Some countries in Eastern Europe collect second-line anti-tuberculosis 
drug resistance data only during subnational surveys, which are not repeated, while other 
countries have limited or no data.21 Rapid second-line DST is essential so that treatment 
can be adapted to resistance patterns in a timely manner. However, only Armenia, Georgia 
and Latvia currently have universal or near universal coverage of second-line DST.15
Vulnerable populations
Another serious challenge to MDR- and XDR-TB control is reaching vulnerable populations 
such as children, migrants, prisoners and people living with HIV, who are at greater risk 
for contracting and developing MDR- or XDR-TB.42 Considerable efforts have been made 
on this front since 2011, with the development of a minimum package for cross-border 
TB control and care in 2012,43 and in 2013 the International Union Against Tuberculosis 
and Lung Disease (Paris, France), the WHO and other international stakeholders issued an 
official statement of 12 action points to improve TB prevention and control in prisons.44 
However, many countries in Eastern Europe have yet to implement the recommendations 
put forth in these statements.
Children 
Children are often a neglected and vulnerable group with regard to MDR- and XDR-TB. 
This is due to the low number of bacilli in sputum among children,45 which makes TB, MDR- 
and XDR-TB harder to diagnose with sputum smear microscopy, culture and molecular 
tests.46 In 2011, only approximately 4% of the estimated cases of childhood TB in the 10 
high-burden Eastern European countries were detected and reported,45 and reporting on 
paediatric MDR- and XDR-TB is currently very limited. WHO guidelines on childhood TB, 
including paediatric diagnostics and drug formulations, have recently been updated;47 
however, these need to be adopted into national strategic TB plans and practice in Eastern 
Europe.
Migrants 
Migrants often face a myriad of challenges such as discrimination, economic adversity, 
language barriers, stigma and fear of deportation. 48 These challenges, combined with the 
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migratory nature of the population, pose enormous barriers and difficulties in accessing 
diagnosis and continuous anti-tuberculosis treatment services.48 Both internal and cross-
border migration enhance TB transmission. Many migrants also live in close proximity 
with family members or other individuals, as is the case with refugees and seasonal 
migratory workers living in temporary housing. All of these factors increase the risk of 
developing, contracting and transmitting drug-resistant forms of TB. Complicating the 
situation, some countries in both Eastern and Western Europe deport migrants with 
TB without considering the public health and human rights issues involved, or without 
taking adequate infection control measures, thereby increasing the risk of cross-border 
transmission.43,49 Levels of migration vary substantially across Eastern Europe, as do 
reported rates of TB among migrants; in 2010, 2.4% of notified TB cases in Lithuania were 
foreign-born, compared to 17.6% in Estonia.50 In the Russian Federation in 2011, less than 
5% of notified cases were reported as foreign-born through routine surveillance; however, 
an earlier study from 2005 found that 26.9% of detected TB cases in Moscow were among 
migrants.51
Prisoners 
Similar to migrants, incarcerated patients have a much higher risk for developing or 
contracting drug-resistant TB compared to the general population. In 2011, the pooled 
rate of TB in prisons (from all reporting sites) in the Russian Federation was 14 times that 
of the general population. Rates in Azerbaijan and Georgia were respectively 23 and 26 
times higher in prisons than in the general population.15 Prisons in Eastern Europe are 
often poorly ventilated and crowded, and incarcerated patients spend long periods of 
time in these environments.52 Other determinants are high rates of HIV infection, injecting 
drug use and poor nutritional status.44 Human and financial resources for TB and MDR-TB 
prevention and control in prison are often scarce in Eastern Europe, and there are still gaps 
in coordination between civilian and penitentiary TB services.25 There are, however, recent 
best practice examples of TB and MDR- and XDR-TB control in the Azerbaijan prison sector, 
and effective continuity of TB care for released prisoners in Azerbaijan and the Republic of 
Moldova,53 which should be scaled up in the region.
Persons living with HIV 
Individuals living with HIV are highly susceptible to TB,54 and Eastern Europe has one of the 
fastest growing HIV epidemics in the world.55 Approximately 65% of new HIV infections 
in the region in 2010 occurred in the Russian Federation and Ukraine.56 These countries 
also had the highest rates in the region in 2011, with respectively 44 and 36 cases per 
100 000 population.56 Most countries, however, lack a functioning TB-HIV coordinating 
mechanism to facilitate the delivery of integrated TB and HIV services, including those 
related to narcology services for those with drug or alcohol dependency.25
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Human resources
Lack of human resources is an important challenge that affects all levels of MDR- and XDR-
TB prevention control and care in Eastern Europe. There is particular need for specialised 
human resources to manage cases of drug-resistant TB in both children and adults, deliver 
adequate services for case detection and scale up diagnostic and laboratory capacity.25,57
Funding
In 2011, there was a considerable projected funding gap of over 60% to fully implement 
the Action Plan for M/XDR-TB in the European Region.16 This funding gap has still not been 
met. In countries financially supported by the Global Fund to Fight AIDS, Tuberculosis 
and Malaria (The Global Fund, Geneva, Switzerland), the treatment success rate among 
MDR- and XDR-TB patients is 78% compared to 20% in other settings without Global 
Fund support. 58 This is strong evidence of the need for funding from The Global Fund 
and other international donor agencies to address the current challenges to MDR- and 
XDR-TB control. A critical challenge in Eastern Europe will be the gradual shift in funding 
to national mechanisms, which is a requirement under The Global Fund’s New Funding 
Model, and to ensure that progress is not lost due to financial gaps.
Ways forward
The 2015 MDG deadline is fast approaching, as are the deadlines for the Global Plan to Stop 
TB and the Consolidated Action Plan for M/XDR-TB in the European Region. In response 
to this, and the continuing challenges facing the control of TB and MDR- and XDR-TB, an 
ambitious Post-2015 Global TB Strategy has recently been developed by the WHO and 
approved by the World Health Assembly.59 The strategy, which has several milestones for 
2025 and 2035, comprises three main pillars summarised in Table 3. It is imperative that 
the Post-2015 Global TB Strategy be adapted to regional and country-specific contexts so 
that there is a framework for continued efforts to prevent and combat TB and MDR and 
XDR-TB, and that there is a seamless transition between preand post-2015 plans. This is 
particularly the case in Eastern Europe and the WHO European Region as a whole, which 
has the world’s largest proportion of high MDR- and XDR-TB burden countries.
In Eastern Europe, as M. tuberculosis strains resistant to firstand second-line drugs 
increasingly replace drug-susceptible strains, TB cases will become increasingly difficult to 
treat. This may already explain the falling treatment success rates seen across the region. 
In line with the current regional Action Plan and the post-2015 Global Strategy, several 
immediate actions are needed to address the challenges to MDR- and XDR-TB control in 
Eastern Europe. First, to address the spread of primary infection with drug-resistant strains 
of M. tuberculosis, improved infection control is needed. In line with this, it is essential that 
hospital financing mechanisms be revised to promote free ambulatory care instead of a 
‘fee-per-bed’ policy, which promotes hospitalisation and ongoing transmission of drug-
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resistant TB.60,61 A new vaccine is also needed. Second, to address acquired resistance, 
prompt and improved treatment is necessary. Full access to all necessary second-line anti-
tuberculosis drugs needs to be ensured. In addition, emphasis should be placed on shorter 
and more effective treatment regimens and psychosocial support mechanisms to improve 
adherence in the face of adverse side effects. Countries should make particular effort to 
address populations and projects that are not supported by technical agencies such as 
the WHO and GLC. Bedaquiline and other new TB medicines also need to continue to be 
developed urgently and introduced under specific conditions, such as compassionate use 
and with special attention to pharmacovigilance. To guard against resistance to these new 
drugs, it is critical that international regulations on their use be strengthened, and that 
availability of drug regimens be ensured so that drug stockouts and subsequent misuse 
of new drugs be prevented. Third, and vital to curbing both routes of infection with drug-
resistant TB, is early and rapid detection. Central to this is strengthening laboratory capacity 
to improve the use of current rapid diagnostics and second-line DST. In addition, there is a 
need for improved, easily applicable and affordable molecular tests in high-burden areas. 
Fourth, vulnerable populations are at highest risk for contracting or developing MDR- and 
XDR-TB, and also pose a risk for transmitting and sustaining disease transmission if not 
properly treated. If an end to the TB epidemic is to be realised, MDR- and XDR-TB among 
vulnerable populations should be addressed urgently.
A longer-term approach to addressing MDR- and XDR-TB among vulnerable populations, 
and in line with Pillars 1 and 2 of the Post-15 Global TB Plan, is strengthening the health 
systems.62 This implies a move away from vertical TB service delivery mechanisms, which 
are often difficult for vulnerable populations such as migrants and persons living with 
HIV to access or to receive appropriate care, to a coordinated/integrated health care 
system adapted to client needs. This approach would need intensified collaboration and 
joint action by HIV and TB control programmes. In addition, such a model would enable 
greater emphasis to be placed on social determinants of health, such as poor living and 
working conditions, HIV infection, malnutrition, smoking, diabetes and drug and alcohol 
use disorders, which are major drivers of the TB and MDR- and XDR-TB epidemic.42,63,64 A 
health systems approach could also alleviate the challenge of specific human resources 
and financing currently needed for TB services. Great care must be taken, however, for 
health systems strengthening to be implemented cautiously, systematically and with 
appropriate financial backing to avoid suboptimal hastily introduced health care reforms, 
which could have a negative effect on TB programmes.57
Pillar 3 of the Post-15 Global TB Plan will also play a critical role in the future of MDR- and 
XDR-TB control. One third of the population is estimated to be latently infected with TB; 
as long as there is latent tuberculous infection, there is the possibility of the development 
and transmission of TB disease. If the vision of the Post-15 Global TB Strategy is to be met, 
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there is an urgent need for research and development on vaccines and new medicines 
for TB, MDR- and XDR-TB. In addition to basic sciences research, there is also a need 
for operational research. The role of operational research has been successfully and 
extensively demonstrated in numerous settings.4,65–67 Through surveillance and routine 
data collection, it is currently possible to understand the burden and trends in TB and 
MDR- and XDR-TB, although improvements in reporting are needed. It is envisaged that 
the operational research agenda will be greatly strengthened and expanded under Pillar 
3; this should have an enormous impact on improving programme performance and 
serve as an evidence base for policy and practice.
Table 3. Post-2015 global tuberculosis strategy framework (reproduced with permission from 
the draft global strategy and targets for tuberculosis prevention, care and control after 2015 
(A67/11)59
Vision A world free of TB 
– Zero deaths, disease and suffering due to TB
Goal End the global TB epidemic
Milestones for 2025 75% reduction in TB deaths (compared with 2015) 
50% reduction in TB incidence rate (<55 TB cases/100 000) 
– No affected families facing catastrophic costs due to TB
Targets for 2035 95% reduction in TB deaths (compared with 2015) 
90% reduction in TB incidence rate (<10 TB cases/100 000) 
– No affected families facing catastrophic costs due to TB
Principles
   1 Government stewardship and accountability, with monitoring and evaluation 
   2 Strong coalition with civil society organisations and communities 
   3 Protection and promotion of human rights, ethics and equity 
   4 Adaptation of the strategy and targets at country level, with global collaboration
Pillars and components
   1 Integrated, patient-centred care and prevention 
      A Early diagnosis of TB, including universal drug susceptibility testing; and systematic screening of  
          contacts and high-risk groups 
      B Treatment of all people with TB, including drug-resistant TB, and patient support 
      C Collaborative TB-HIV activities and management of comorbidities 
      D Preventive treatment of persons at high risk, and vaccination against TB 
   2 Bold policies and supportive systems 
      A Political commitment with adequate resources for TB care and prevention 
      B Engagement of communities, civil society organisations, and public and private care providers 
      C Universal health coverage policy, and regulatory frameworks for case notification, vital registration,  
          quality and rational use of medicines, and infection control 
      D Social protection, poverty alleviation and actions on other determinants of TB 
   3 Intensified research and innovation 
      A Discovery, development and rapid uptake of new tools, interventions and strategies 
      B Research to optimise implementation and impact, and promote innovations
Conclusion
The burden of MDR- and XDR-TB in Eastern Europe is high. While much progress has been 
made in controlling drug-resistant TB since the launch of the Consolidated Action Plan in 
2011, the prevalence of second-line drug resistance has severely threatened treatment 
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success and continued progress in controlling MDR and XDR-TB in Eastern Europe. While 
mortality rates do not appear to have been affected yet, vigilance and intensified efforts 
are needed as we head into 2015 if decreasing mortality rates are to be kept on track. 
There are several current challenges in MDR-TB and XDR-TB control in Eastern Europe as 
regards access to appropriate treatment regimens, patient hospitalisation, scale-up of 
laboratory capacity, including the use of rapid diagnostics and second-line DST, vulnerable 
populations, human resources and TB financing.
Solutions to these challenges are aligned with the Post-2015 Global TB strategy. As a first 
step, the global TB strategy must be adapted at regional and country levels to serve as a 
framework for immediate actions as well as ways forward in the longer term. Longer-term 
solutions include strengthening health systems as a way to ensure adequate TB care for 
vulnerable populations and to address social determinants of health, which are drivers of 
the TB epidemic.42 In addition to initiatives and continued efforts under Pillars 1 and 2 of 
the Post-2015 Global TB Strategy, Pillar 3, research, will play a critical role in achieving a 
vaccine and new medicines for MDR- and XDR-TB, improving TB programme performance 
and creating an evidence base for effective policy as we head into a new era of TB control.
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Tuberculosis is a major public health priority. This is not only because of its daunting morbidity 
and mortality rates, both globally and in Europe (summarised in figs 1 and 2) [1, 3–5], but 
also because of the natural history of the disease. Active (contagious) tuberculosis disease 
occurs after a period of latency (or subclinical infection), and different risk factors [6–13], 
in combination with latent infection, introduce challenges to prevention, diagnosis and 
treatment of the disease. Vaccination against tuberculosis, if effective, would be therefore 
critical to control and elimination strategies [14–16]. The bacille Calmette– Guérin (BCG) 
vaccine is, from a historical perspective, a milestone of tuberculosis control (figs 3–7). During 
the first half of the 20th century, it was administered ubiquitously throughout Europe, but 
is now recommended by the World Health Organization (WHO) to be given once at birth, 
specifically in tuberculosis-endemic areas.
The BCG is currently the only available vaccine to provide protection against 
haematogenous spread and subsequent severe clinical forms of tuberculosis, including 
meningitis [17–19]. It is included in national childhood immunisation programmes in 
most high-burden countries in Europe, and is also administered to high-risk populations 
in nonendemic areas [17]. In western Europe, as in other low-incidence regions, 
discontinuation of national BCG vaccination began following initial pilot studies in 
the former Czechoslovakia (1961–1972) and Sweden (1975) [20–22]. These studies 
demonstrated the decline in risk of serious forms of tuberculosis in children, evidence 
of the weak protective effect of BCG in adults and lack of impact on the global incidence 
of tuberculosis. Usage of BCG by country in the WHO European Region is summarised 
in table 1.
Given that a more effective vaccine against tuberculosis does not currently exist [26], 
BCG remains an important prevention tool, particularly in children. Unfortunately, some 
countries have recently faced problems with adverse events (table 2) due to shifting from 
one strain of BCG to another [27]. Meanwhile, other countries are debating a shift away 
from national BCG vaccination to selective vaccination, although previous discontinuation 
experiences have produced transient increases in severe forms of tuberculosis, particularly 
tuberculous meningitis [20–22]. As countries weigh the impact of current and future BCG 
practices, guidance for BCG policy making is needed.
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Figure 1. Global estimated TB incidence rates, 2011. Reproduced from [1] with permission 
from the publisher 
Figure 2. WHO European Region estimated TB incidence rates per 100,000 population, 2011*. 
Reproduced from [2] with permission from the publisher.
* Data from UN Administrated Province of Kosovo (in accordance with Security Council Resolution 
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FIGURE 2 World Health Organization European Region estimated tuberculosis incidence rates per 100 000 population, 2011. Data from the United Nations
Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia. Reproduced
from [2] with permission from the publisher.
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FIGURE 2 World Health Organization European Region estimated tuberculosis incidence rates per 100 000 population, 2011. Data from the United Nations
Administrated Province of Kosovo (in accordance with Security Council Resolution 1244 (1999)) is not included in the figures reported for Serbia. Reproduced
from [2] with permission from the publisher.
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Figure 3. Wooden mask worn by health workers to announce a forthcoming vaccination 
campaign (Republic of Benin). Image courtesy of J.P. Zellweger.
The purpose of this editorial is to summarise current policy on administration and 
management of adverse events of the BCG vaccine from the WHO European regional 
perspective. The editorial will briefly summarise what the BCG vaccine is, the history of its 
development and production, its safety, as well as incidence and management of adverse 
events. Finally, it will provide guidance on BCG policy development.
The BCG vaccine and its history
The BCG vaccine provides protection against severe forms of tuberculosis, particularly 
tuberculous meningitis and disseminated tuberculosis in infants and young children [17–19]. 
It does not prevent primary infection and, more importantly, it does not prevent reactivation 
of latent pulmonary infection, the principal source of spread of Mycobacterium tuberculosis in 
the community. The impact of BCG vaccination on transmission is therefore limited.
BCG contains a live, attenuated strain of Mycobacterium bovis, which primarily causes 
tuberculosis in cattle. M. bovis was originally isolated in 1908 from a cow with bovine 
The purp se of this editorial is t summarise current policy on administratio and management of adverse
events of the BCG vaccine from the WHO Europ an regional perspective. The editorial will briefly
summarise what the BCG vaccine is, the history of its development and production, its safety, as well as
incidence and management of adverse events. Finally, it will provide guidance on BCG policy development.
The BCG vaccine and its history
The BCG vaccine provides protection against severe forms of tuberculosis, particularly tuberculous
meningitis and disseminated tuberculosis in infants and young children [17–19]. It does not prevent
primary infection and, more importantly, it does not prevent reactivation of latent pulmonary infection, the
principal source of spread of Mycobacterium tuberculosis in the community. The impact of BCG vaccination
on transmission is ther fore limited.
BCG contains a l ve, attenuated strain of Mycobacterium bovis, which primarily causes tuberculosis in cattle.
M. bovis was originally isolated in 1908 from a cow with bovine tuberculosis by Calmette and Guérin at the
Pasteur Institute in Lille, France. In order to attenuate the strain, it was carefully subcultured every 3weeks
for ,13 years. During this time, many genetic changes (or point mutations) occurred making the strain less
virulent in animals such as cows and guinea pigs. The resulting altered strain was named BCG. After
extensive safety testing in animals, BCG was first used as a vaccine in human infants in 1921 [18]. The
vaccine was used extensively and for many years, as there were no other treatment options against
tuberculosis until the development of isoniazid in the 1940s, and confidence in the preventive effect of BCG
vaccination was high both in the medical and the patients’ communities (figs 3–7).
Today, there are several different substrains of the original BCG strain. The reason for this is that during the
early years of the vaccine, all BCG cultures were maintained at the Pasteur Institute in Paris, France (fig. 5).
However, from 1924 to 1931, the BCG strain was distributed to several laboratories throughout the world
where they were maintained by continuous subculture [18, 28]. After many years, it became clear that the
FIGURE 3 Wooden mask worn by health
workers to announce a forthcoming
vaccination campaign (Republic of Bénin).
Image courtesy of J.P. Zellweger.
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tuberculosis by Calmette and Guérin at the Pasteur Institute in Lille, France. In order to 
attenuate the strain, it was carefully subcultured every 3 weeks for ,13 years. During this 
time, many genetic changes (or point mutations) occurred making the strain less virulent 
in animals such as cows and guinea pigs. The resulting altered strain was named BCG. 
After extensive safety testing in animals, BCG was first used as a vaccine in human infants 
in 1921 [18]. The vaccine was used extensively and for many years, as there were no other 
treatment options against tuberculosis until the development of isoniazid in the 1940s, 
and confidence in the preventive effect of BCG vaccination was high both in the medical 
and the patients’ communities (figs 3–7).
Today, there are several different substrains of the original BCG strain. The reason for this is 
that during the early years of the vaccine, all BCG cultures were maintained at the Pasteur 
Institute in Paris, France (fig. 5). However, from 1924 to 1931, the BCG strain was distributed 
to several laboratories throughout the world where they were maintained by continuous 
subculture [18, 28]. After many years, it became clear that the various strains maintained 
in different laboratories were no longer identical to each other. Indeed, it is likely that all 
the various strains maintained by continuous subculture continued to undergo genetic 
changes. Even the original BCG strain maintained in Paris continued to change during 
the subculturing needed to maintain the viability of the strain. To limit these genetic 
mutations, procedures used to maintain the strains were modified. Today, the strains are 
maintained using a seed lot production technique to limit further genetic variation using 
lyophilised cells so that each batch starts with the same substrain [18, 29].
Figure 4. “To defeat tuberculosis is easy with the BCG”. Advertisement in a peripheral TB 
dispensary, dating from the time of French colonization, about 1950 (Republic of Benin). 
Image courtesy of Jean Pierre Zellweger
various strains maintained in different laboratories were no longer identical to each other. Indeed, it is likely
that all the various strains maintained by continuous subculture continued to undergo genetic changes.
Even the original BCG strain maintained in Paris continued to change during the subculturing needed to
maintain the viability of the strain. To limit these genetic mutations, procedures used to maintain the
strains were modified. Today, the strains are maintained using a seed lot production technique to limit
further genetic variation using lyophilised cells so that each batch starts with the same substrain [18, 29].
BCG production and substrains
The BCG vaccines that are currently in use are produced at .40 sites throughout the world [29], many for
local use within the country of production. These vaccines are not identical. Some differences in molecular
and genetic characteristics are known; however, the extent to which they differ in efficacy and safety in
FIGURE 4 ‘‘To defeat tuberculosis is
easy with the BCG’’. Advertisement in
a peripheral tuberculosis dispensary,
dating from the time of French
colonisation (circa 1950) (Republic
of Benin). Image courtesy of J.P.
Zellweger.
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BCG production and substrains
The BCG vaccines that are currently in use are produced at 40 sites throughout the world 
[29], many for local use within the country of production. These vaccines are not identical. 
Some differences in molecular and genetic characteristics are known; however, the extent 
to which they differ in efficacy and safety in humans is not clear [18, 29]. Globally, the most 
widely used BCG vaccine substrains include Connaught, Danish, Glaxo, Moreau, Moscow, 
Pasteur and Tokyo [28]. In high-incidence eastern European countries and former Soviet 
states, the predominant substrain is BCG Moscow. Although BCG Danish and Pasteur 
have been found to be more immunogenic [27], greater efficacy of these strains has not 
been demonstrated in field trials [30]. Therefore, there are currently no recommendations 
advising the use of one strain over another [29].
Although there are no formally recommended vaccines, ,25% of the world supply of 
BCG is purchased by the United Nations (UN) Children’s Fund and other UN agencies for 
distribution to developing countries [29]. These substrains are purchased according to 
a WHO pre-qualification process, which determines their eligibility for use in national 
immunisation programmes (table 3) [31]. Vaccines are added to the prequalification list 
after extensive quality control evaluations and manufacturing site audits performed 
by the WHO. The list is not exhaustive, and the fact that certain BCG substrains are not 
included in the list does not mean that, if evaluated, they would not be found to comply 
with pre-qualification standards and operational specifications.
Figure 5. French Ministry of Health educational poster supporting BCG vaccination. Image 
courtesy of J.P. Zellwegernot mean that, if evaluated, they would not be found to comply with pre-qualification standards and
operational specifications.
Safety
The BCG vaccine is the oldest vaccine still in use. It has been administered to .4 billion people worldwide
since 1921 [18, 28, 29] and the risk of adverse events has generally been considered to be low. Recently,
however, it has been found that use of the vaccine in persons who are immunocompromised (such as those
18, 32, 33]. As BCG is a live vaccine, there is
FIGURE 5 French Ministry of Health
educational poster supporting bacille
Calmette–Guérin vaccination. Image
courtesy of J.P. Zellweger.
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Safety
The BCG vaccine is the oldest vaccine still in use. It has been administered to .4 billion 
people worldwide since 1921 [18, 28, 29] and the risk of adverse events has generally been 
considered to be low. Recently, however, it has been found that use of the vaccine in persons 
who are immunocompromised (such as those with HIV) may result in an infection caused by 
the BCG itself [18, 32, 33]. As BCG is a live vaccine, there is an increased risk of mycobacterial 
circulation in the absence of a competent immune response. This can lead to disseminated 
BCG disease [34]. There is also concern that BCG vaccination may accelerate HIV disease 
progression amongst HIV-infected infants by triggering an immune response that leads 
to the spread of the virus [35]. In addition, even among immunocompetent persons, local 
reactions, including ulceration at the site of vaccination, may result in shedding of live 
organisms, which could, in turn, infect others who may be immunocompromised.
Figure 6. Tuberculosis/HIV-infected children in Myanmar. 
2012 Matthieu Zellweger (with AIDSpartners.org)/ matthieuzellweger.com
Figure 7. Romania, 1974. Six-year-old children are re-vaccinated against tuberculosis (according 
to the guidelines available at the time; at present no evidence of any protection of re-vaccinating 
with BCG is available, so re-vaccination is not recommended by WHO). WHO image, courtesy of 
the United States National Library of Medicine, History of Medicine Division.
not mean that, if evaluated, they would n t be found to comply with pre-qua ification standards and
operational specifications.
Safety
The BCG vaccine is the oldest vaccine still in use. It has been administered to .4 billion people worldwide
since 1921 [18, 28, 29] and the risk of adverse events has generally been considered to be low. Recently,
however, it has been found that use of the vaccine in persons who are immunocompromised (such as those
with HIV) may result in an infection caused by the BCG itself [18, 32, 33]. As BCG is a live vaccine, there is
an increased risk of mycobacterial circulation in the absence of a competent immune response. This can
lead to disseminated BCG disease [34]. There is also concern that BCG vaccination may accelerate HIV
disease progression amongst HIV-infected infants by triggering an immune response that leads to the
spread of the virus [35]. In addition, even among immunocompetent persons, local reactions, including
ulceration at the site of vaccination, may result in shedding of live organisms, which could, in turn, infect
thers who may be immunocompromised.
FIGURE 5 French Ministry of Health
educational poster supporting bacille
Calmette–Guérin vaccination. Image
courtesy of J.P. Zellweger.
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WHO position on BCG vaccination
The core WHO policy recommendations are summarised in table 4. Currently, the WHO position is that a
single dose of BCG vaccine should be given to all infants as soon as possible after birth in countries with a
high burden of tuberculosis (o40 cases per 100 000 population). Contraindications are infants or persons
known to have HIV or other immunosuppressive conditions (fig. 6) [35, 36]; in settings with adequate HIV
services, BCG vaccination should be delayed for infants born to mothers known to be infected with HIV
until these infants are confirmed to be HIV negative. Although BCG might be potentially useful in other
groups (e.g. health care workers, travellers to endemic areas and contacts of multidrug-resistant cases) the
available evidence is not sufficient to recommend its use. The WHO does not recommend BCG
FIGURE 7 Romania, 1974. 6-year-
old children are re-vaccinated against
tuberculosis (according to the guide-
lines available at the time; at present,
no evidence of any protection of re-
vaccinating with bacille Calmette–
Guérin is available, so re-vaccination is
not recommended by the World Health
Organizaiton (WHO)). WHO image,
courtesy of the United States National
Library of Medicine, History of
Medicine Division.
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WHO position on BCG vaccination
The core WHO policy recommendations are summarised in table 4. Currently, the WHO 
position is that a single dose of BCG vaccine should be given to all infants as soon as 
possible after birth in countries with a high burden of tuberculosis > 40 cases per 100 
000 population). Contraindications are infants or persons known to have HIV or other 
immunosuppressive conditions (fig. 6) [35, 36]; in settings with adequate HIV services, BCG 
vaccination should be delayed for infants born to mothers known to be infected with HIV 
until these infants are confirmed to be HIV negative. Although BCG might be potentially 
useful in other groups (e.g. health care workers, travellers to endemic areas and contacts 
of multidrug-resistant cases) the available evidence is not sufficient to recommend its use. 
The WHO does not recommend BCG revaccination as there is little or conflicting evidence 
of whether this confers additional protection, and revaccination may increase the risk for 
adverse events.
Adverse events
Amongst immunocompetent infants and children, mild events such as localised skin 
reactions following BCG vaccination are common; almost all recipients of BCG develop a 
bluish-red pustule accompanied by pain, swelling and erythema within 2–4 weeks after 
vaccination [37, 38], with ulceration and drainage in 70% of vaccinated individuals [29, 
30]. Abscess and regional lymphadenitis occur in 1–2% of vaccinated individuals [29, 39]. 
Severe adverse events occur very rarely. The absolute risks of severe adverse events are 
summarised in table 2. Importantly, although there are currently no recommendations 
for the use of certain strains, the Pasteur and Danish strains are known to induce more 
adverse reactions [30, 38, 40].
Among HIV-infected or other immunocompromised infants and children, the absolute risk 
of severe adverse events from BCG vaccination has been found to be hundreds of times 
higher compared to immunocompetent children. Rates of disseminated BCG disease are 
estimated to approach 1% of HIV-infected infants vaccinated with BCG [41] and has an 
all-cause mortality rate of 75–86% [32–34, 42]. Additionally, BCG immune reconstitution 
inflammatory syndrome occurs in up to 15% of HIV-infected children who receive the BCG 
vaccine [32–34, 43].
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Management of adverse events
Management of local lymphadenitis remains controversial, with no consensus on the best 
strategy [29]. Treatment strategies range from observation (wait-and-see approach), to 
surgical drainage or resection, to treatment with antituberculosis drugs, to a combination 
of these approaches [29, 44]. In general, nonsuppurative BCG-induced lymphadenitis is a 
benign condition and regresses spontaneously without any treatment in 4–6 months [33]. 
For suppurative BCG lymphadenitis, needle aspiration is recommended in some countries, 
and may prevent discharge and associated complications such as fistulation. A common
practice in many countries is direct injection or local instillation of antituberculosis drugs to 
the lesion; however, there is a poor quality of evidence to demonstrate a benefit from this 
practice [33], which might also promote drug resistance. Surgical incision is additionally 
not recommended for suppurative BCG lymphadenitis. Where needle aspiration has 
failed to relieve symptoms and suppurative nodes have already drained surgically or 
spontaneously with sinus formation, surgical excision is occasionally practiced, but carries 
additional risks associated with general anaesthesia needed for the procedure. Literature 
on the benefit of oral/systemic antituberculosis drug treatment without surgical drainage 
is conflicting, and a recent Cochrane review found no evidence of any benefit of using oral 
antibiotics to treat local or regional BCG-induced disease [33].
In general, oral antituberculosis medications should be reserved for infants developing 
rare systemic adverse reactions, such as disseminated BCG disease. In these cases, the 
criteria for M. tuberculosis should be used and the strain should be considered to be of 
intermediate susceptibility. Management should therefore include the appropriate 
combination of antituberculosis drugs; however, pyrazinamide should not be included in 
the drug regimen as all BCG strains have inherent resistance to this drug [29]. In addition, 
there is variable BCG resistance to isoniazid, which is one of the main antimycobacterial 
drugs available in tuberculosis-endemic settings, as well as possible acquired resistance 
to other first-line antituberculosis drugs [45–47]. Single-drug therapy, particularly with 
isoniazid, is therefore not recommended. It should also be noted that the clinical features 
of disseminated BCG disease are similar to those of severe tuberculosis, and sophisticated 
laboratory facilities may be needed to distinguish between M. tuberculosis and M. bovis 
BCG [42], as well as to test drug susceptibility.
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Table 2. Summary of mild and severe adverse events*
Nature of Adverse event Description Rate/doses
Mild Injection site papule (onset 2-4 weeks)






Suppuration (onset 2-6 months) 1 per 1,000-10,000
Systemic (1-12 months onset time)
Cutaneous skin lesions Case reports only
Osteitis 1 per 3,333-108
Disseminated BCG 1 per 230,000-640,000
Immune Reconstitution Syndrome 1 per 640,000
Table 1. Summary of mild and severe adverse events* 
*From: Modified from WHO, Observed rate of vaccine reactions of Bacillus Calmette-Guérin (BCG) 
vaccine, April 2012(11)
Table 3. Guidelines for BCG Vaccine
Revised BCG vaccination guidelines for infants at risk for HIV infection
http://www.who.int/immunization/wer8221bcg_May07_position_paper.pdf
Information Sheet, Observed rate of vaccine reactions of Bacillus Calmette-Guérin (BCG) vaccine, April 2012 
http://www.who.int/vaccine_safety/initiative/tools/BCG_Vaccine_rates_information_sheet.pdf
Prequalification of vaccines - further information
http://www.who.int/immunization_standards/vaccine_quality/vq_index/en/index.html
Fact sheets, BCG Vaccine
http://www.cdc.gov/tb/publications/factsheets/prevention/BCG.htm
Guidance for national tuberculosis and HIV programmes on the management of tuberculosis in HIV-
infected children: Recommendations for a public health approach
Guidance for national tuberculosis and HIV ... - The Union
Consensus statement on the revised World Health Organization recommendations for BCG 
vaccination in HIV-infected infants.
http://www.theunion.org/images/stories/resources/RESS_BCG_Working_Group_Statement_IJTLD_D
ecember_2008.pdf
Guidance for National Tuberculosis Programmes on the management of tuberculosis in children
http://www.stoptb.org/wg/dots_expansion/assets/documents/IJTLD_OS_ChildhoodTB_Chapter3.pdf
BCG Atlas provides detailed information on current and past BCG policies and practices for over 180 
countries. If your country profile needs to be updated please contact Alice Zwerling at 
alice.zwerling@mail.mcgill.ca or Dr Madhukar Pai at madhukar.pai@mcgill.ca
http://www.bcgatlas.org/index.php
BCG Atlas





Legend: BCG: Bacillus Calmette-Guérin
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Table 4. Summary of the World Health Organization policy recommendations on BCG vaccination
Core Policy Recommendations
1 A single dose of BCG vaccine should be given to all infants as soon as possible after birth in 
countries with a high burden of tuberculosis
2 Contraindications are infants or persons known to have HIV or other immunosuppressive 
conditions. In settings with adequate HIV services, BCG vaccination should be delayed for 
infants born to mothers known to be infected with HIV until these infants are confirmed to 
be HIV negative
3 BCG revaccination is not recommended as there is little or conflicting evidence of whether 
this confers additional protection, and revaccination may increase the risk for adverse 
events.
Legend: BCG: Bacillus Calmette-Guérin; HIV: Human Immunodeficiency Virus
When to stop BCG blanket vaccination
The risk of stopping BCG vaccination in a low-incidence country should be carefully 
balanced against the risk of an increase in tuberculosis among children. There is no 
evidence of a threshold incidence; however, International Union Against Tuberculosis 
and Lung Disease expert opinion suggests less than five in 100 000 new sputum smear 
positive pulmonary cases as a threshold for stopping herd BCG vaccination [48]. It is 
noteworthy that even in low-incidence countries, there may be a subset of the population 
with a higher risk of tuberculosis; therefore, BCG vaccination should be made available to 
this group [49]. In low-incidence settings, it is advisable to make BCG available for children 
who are born of parents coming from highincidence countries or who may have lived for 
prolonged periods in a high-burden country.
Conclusions
In summary, BCG is currently the only available vaccine against tuberculosis. Despite its 
limitations, it offers reasonable protection against severe forms of tuberculous disease 
among children. The current policy document offers a rapid guidance on how to procure 
BCG, plan its use based on the epidemiological situation in the country and manage 
adverse events (tables 2–4).
This document also represents a further step in the collaboration between the European 
Respiratory Society (ERS) (and the European Respiratory Journal (ERJ)) and WHO on 
tuberculosis-related activities. Started in 1999 with the development of the ERS 
tuberculosis guidelines [50] and the publication of the entire series of Wolfheze documents 
(which helped to modernise the present system of tuberculosis control in Europe) [16], 
it continued with the publication of two core documents on tuberculosis elimination in 
Europe [15, 51], guidance on tuberculosis trans-border migration control [52], the ERS/
WHO Consilium [4], and a series of important articles on multidrug-resistant tuberculosis 
[53–55]. In addition, two other important European Centre for Disease Prevention and 
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Control documents reflecting collaboration with WHO have been published in the ERJ, 
including the European standards for tuberculosis care [56, 57] and the Tuberculosis in 
Children roadmap documents [58].
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Background: Tuberculosis (TB) in penitentiary services (prisons) is a major challenge 
to TB control. This review article describes the challenges that prison systems 
encounter in TB control and provides solutions for the more efficient use of limited 
resources based on the three pillars of the post-2015 End TB Strategy. This paper also 
proposes research priorities for TB control in prisons based on current challenges.
Methods: Articles (published up to 2011) included in a recent systematic review on 
TB control in prisons were further reviewed. In addition, relevant articles in English 
(published 1990 to May 2014) were identified by searching keywords in PubMed 
and Google Scholar. Article bibliographies and conference abstracts were also hand-
searched.
Results: Despite being a serious cause of morbidity and mortality among incarcerated 
populations, many prison systems encounter a variety of challenges that hinder TB 
control. These include, but are not limited to, insufficient laboratory capacity and 
diagnostic tools, interrupted supply of medicines, weak integration between civilian 
and prison TB services, inadequate infection control measures, and low policy priority 
for prison healthcare.
Conclusions: Governmental commitment, partnerships, and sustained financing 
are needed in order to facilitate improvements in TB control in prisons, which will 
translate to the wider community.
Key words: Tuberculosis, Prisons, MDR-TB, End TB Strategy, Xpert MTB/RIF, Research
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1. Introduction
Tuberculosis (TB) remains a major public health problem, posing specific challenges in 
numerous geographical areas, particularly in low- and middle-income countries (LMICs) 
where more than 80% of the global TB burden resides.1 Additionally, with the current 
slow (2%) annual decline in TB incidence and the emergence of drug-resistant TB and TB/
HIV co-infection, most LMICs will not meet the Millennium Development Goals (MDGs) 
for TB control by 2015 set by the United Nations.1 Despite recently gained increased 
public and political awareness, TB remains a major infectious disease in prison systems, 
such as in Eastern Europe, for several reasons. These include, but are not limited to, the 
high prevalence of drug-resistant TB forms, i.e. multi- and extensively drug-resistant TB 
(M/XDR-TB),1–14 and intravenous drug use among HIV-infected individuals, which makes 
prison populations more susceptible to the development of TB.15
Prisons are considered reservoirs facilitating Mycobacterium tuberculosis (MTB) 
transmission within their walls, as well as to the community at large. Transmission occurs 
through prison staff, visitors, and released inmates. The estimated prevalences of latent 
TB infection (LTBI) and active TB disease in prison systems are reported to be much higher 
than the average estimates in the general population, irrespective of the economic status 
and the population TB burden of the country.16 In European prisons, the prevalence of 
TB is estimated to be up to 17 times higher than in the general population.17 A similar 
epidemiological situation has been described in LMICs, including Bangladesh, Thailand, 
Ethiopia, and Brazil, where TB prevalence has been reported to be almost four-, eight-, 
seven-, and 64-times higher, respectively, among prisoners compared to the general 
population.18–27 Factors known to contribute to the transmission of MTB strains and that 
hamper TB control are overcrowding, delayed case detection, poor contact detection, 
inadequate treatment of infectious cases, high turnover of prisoners, and poor implemen- 
tation of TB infection control (IC) measures.28,29 In addition, limited access to timely and 
quality health care services further exacerbate the situation.
In response to the continuing challenges facing the control of TB and M/XDR-TB, and as 
the current Global Plan to Stop TB (Stop TB Strategy) 2011–2015 is in its final year, the 
World Health Organization (WHO) has recently developed the post-2015 End TB Strategy 
with the goal to end the TB epidemic by 2035.30 In order to define strategies that efficiently 
address the End TB Strategy targets, knowledge about solutions for improved TB control 
in prison systems is needed. In this review, we summarize published knowledge on the 
challenges of TB control in prison systems and discuss potential solutions, including 
research priorities for TB control in prisons, in relation to the three pillars of the End TB 
Strategy.
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2. Methods
Articles included in a recently published systematic review on TB control in prison services 
by Vinkeles Melchers et al.31 were reviewed; these publications were dated up to June 
2011. In addition, relevant articles in English were identified by searching PubMed and 
Google Scholar, with a temporal range of 1990 to May 2014. Studies were identified using 
combinations of the search terms ‘‘Tuberculosis or TB’’, ‘‘TB Control’’, ‘‘Management’’, ‘‘Public
Health’’, ‘‘Prison* or Jail*’’, and ‘‘Prisoner* or Inmate*’’. Studies in languages other than 
English and studies published before 1990 were excluded. Articles were also excluded 
if they described challenges in TB control among populations other than prisoners (e.g., 
TB contact tracing in the community, health care workers). The selection of articles was 
based on their public health relevance to TB control in prisons. The references of selected 
articles were also evaluated to identify additional relevant publications. In addition, 
conference abstracts of the International Union Against Tuberculosis and Lung Diseases 
and publications from the WHO over the last 23 years were screened for relevant articles. 
A total of 637 citations and 332 abstracts were screened, resulting in the inclusion of 
96 publications in this review. Because no systematic variables were extracted from the 
publications included, the challenges and solutions have not been rated on the quality 
and validity of the evidence.
3. Results and discussion: current evidence
Barriers to tackling TB in prisons are complex and linked strongly to other aspects of both 
the health and criminal justice systems, and with the cultural, historical, and economic 
situations of each country. These barriers are summarized in Table 1,32 and are discussed 
below in relation to the three pillars of the End TB Strategy.
3.1. Pillar 1: Integrated, patient-centred care and prevention
3.1.1. Universal drug-susceptibility testing and systematic screening of contacts 
and high-risk groups
The lack of well-equipped laboratory facilities in prisons is well documented.1,4,20,22,33,34 In 
addition, a systematic review found that approximately 21% of all studies reporting on TB 
screening in prisons described the lack of a well-organized health system,31 potentially 
leading to the ongoing spread of TB to other prisoners, prison staff, visitors, and to 
the general population upon release from the prison.23,35,36 In the absence of adequate 
diagnostic tools in the prison services, health professionals attempt to use the diagnostic 
capacity of the civilian sector through national TB programmes (NTPs), such as sputum 
smear microscopy, chest radiography, and sputum culture.34 The use of diagnostic services 
external to the prison system may, however, lead to a delay in diagnosis due to a lack of 
coordination between the prison and the civilian sector laboratory networks.17,37,38
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Table 1. Key barriers to tackling tuberculosis in prisons according to the three pillars of the 
End TB Strategy
Pillar 1: Integrated, patient-centred care and prevention
Lack of laboratory capacities, insufficient quality control and absence of new and improved 
diagnostic methods
Interrupted supply of quality medicines
Absence of efficient mechanism for direct observation of treatment
Lack of adequate medical facilities
Lack of collaborative TB/HIV activities
Emerging drug resistance
Intravenous drug use among prison populations
Lack of drug substitution and needle exchange programs
Lack of safer sex programs for HIV prevention
Limited social support of vulnerable populations
Limited attention to comorbidities (HIV, hepatitis, psychiatric diseases)
Weak integration between civilian and prison TB services, continuum care of released prisoners
High incarceration rate
Pillar 2: Bold Policies and supportive systems
Low priority that policymakers give to health care (including TB) within the prison system.
Insufficient commitment of prison authorities to address TB prevention, control and care
Unclear responsibilities of different ministries and health authorities
Stewardship of prison health, mismanagement of TB control in penitentiary institutions.
Shortage of qualified and motivated human resources
Shortage of staff training/education and appreciation
Limited or poor patient education
Stigmatization of prisoners with TB
Lack of access to prisons by community representatives, NGOs and organizations with the 
capacity to support the vulnerable population
Insufficient surveillance, supervision, monitoring and evaluation systems
Inadequate infection control (IC) measures, due to overcrowding and/or organizational and 
legal challenges in timely separation of patients
Pillar 3: Intensified research and innovation
Lack of funding
Lack of commitment by research institutes
Legal difficulties with research in prison systems
Another main challenge to TB diagnosis is the quality of the bacteriological services. 
Sputum smear microscopy is not always performed with quality control. Microscopes 
are poorly maintained, staff may lack quality training in the use of diagnostic tools,22 and 
quality assurance including proficiency testing is rarely done.22,39 The introduction of the 
GeneXpert MTB/RIF assay is considered an important breakthrough in the fight against 
TB and multidrug-resistant (MDR-TB). For the first time, a molecular test is simple and 
robust enough to be introduced outside the conventional or reference laboratory setting, 
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detecting TB and rifampicin-resistant TB as a proxy for MDR-TB.40,41 The assay provides 
results directly from the sputum sample within 2 h and performs well, particularly in 
sputum smear-positive patients, with an overall sensitivity of 90.4% and specificity of 
98.4%.42 The GeneXpert MTB/RIF assay is suitable for use at the district and sub-district 
levels, including within the prison system, and should not be restricted to the central/
reference laboratory level only.
The current availability of GeneXpert machines in prisons is unclear and this likely differs 
from country to country. Although testing with GeneXpert MTB/RIF does not require 
additional laboratory equipment, the sophisticated nature of the device requires care in 
handling, i.e., a stable and uninterrupted electrical or battery supply to avoid interruption 
of the procedure and subsequent loss of results, security against theft, adequate storage 
space for the cartridges, and dedicated staff to perform testing.40 Addressing this challenge 
requires general health system strengthening, 5,6,43,44 including the prison sector and 
especially in LMICs. High-quality laboratory services with up-to-date biosafety measures, 
19 updated and renewed detention centres45 and TB prison hospitals, and continuous 
training programmes for both staff and prisoners should also be emphasized.24,34,46
3.1.2. Ensure equitable access to quality treatment for all people with TB, including 
drug-resistant TB, and to patient support
Although the Stop TB Strategy entails standardized supervised treatment and 
uninterrupted pharmaceutical supplies,47,48 several prisons still encounter challenges in 
implementing supervised treatment,38 the uncontrolled circulation and use of suboptimal
quality TB drugs,23,38,46,49 and TB/HIV treatment interactions in prisons with a high 
co-infection prevalence.37 Some prisons report that the provision of an effective 
pharmaceutical supply may be in place, but that prisoners cannot afford treatment as 
they pay out-of-pocket for health services.38,49 In addition, there are often other factors 
affecting treatment adherence in prisons. These may stem from a specific criminal 
culture among prisoners, the concern of being cured and then referred back to prisons 
with greater restriction, as well as the hierarchy among prisoners. Approximately 30% of 
the studies included in a recent systematic review described unsupervised treatment.31 
Therefore, TB control efforts should focus on the provision of effective treatment and/
or increasing effectiveness of treatment to TB patients,22,23,38,50 treatment adherence, and 
clinical case management.19,35
The high turnover of the prison population, between prisons and to the wider community, is 
a major challenge. This facilitates transmission and consequently the spread of both drug-
sensitive and drug-resistant forms of TB.19,23,51,52 Data from a systematic review identified 
that 31.2% of studies struggled with effective TB control due to loss to follow-up and a 
high turnover of prisoners.31 Consequently, difficulties may be encountered in diagnosing 
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and treating TB, leading to the further spread of infection to other prisoners, prison staff, 
and visitors.23 In addition, approximately 26% of studies in the systematic review reported 
that TB control in prisons was hampered by a ban on the prisoners attending local clinics 
or hospitals for ‘security reasons’.31 Within most prison systems, the follow-up of released 
prisoners is limited or does not occur at all. In Eastern European countries, approximately 
60–70% of prisoners are not referred to TB facilities after their release.53
3.1.3. Collaborative TB/HIV activities and the management of comorbidities
A core challenge to TB control in prison systems is dealing with the dual epidemics 
of HIV and TB, as well as other co-infections such as with hepatitis B or C virus. Given 
the impact that HIV has on TB cases and vice versa, coordination between TB and HIV 
programmes is vital.54 However, this may be limited due to poor surveillance of HIV among 
prisoners with TB,37 challenges in the diagnosis of TB among people living with HIV,54,55 a 
lack of joint planning and mobilization for TB/HIV co-infection, and inadequate human 
resources capacity for managing TB/HIV.56,57 In many prisons, the burden of HIV and 
hepatitis infections among TB patients may be unknown, as periodic surveys or sentinel 
surveillance are not performed and diagnostic testing and counselling of TB patients is 
not implemented in all settings.56,58 Not all TB and HIV/AIDS programmes systematically 
coordinate plans for the management of dual infections. There is a lack of proper TB/HIV 
counselling and practice training for counsellors, and of public education and awareness 
programmes for voluntary HIV testing for individuals, resulting in TB patients not attending 
HIV clinics. A lack of awareness and education also increases stigmatization among 
prisoners, and the fear of HIV test results leads to HIV testing being refused.57 Similar issues 
are seen for hepatitis and other co-morbidities frequently detected among prisoners. The 
epidemiological and clinical intertwining of other determinants such as excessive alcohol 
use or injecting drug abuse and chronic liver disorders (associated with hepatitis B or C 
virus) with TB places a high burden on the health of prisoners, and also after prisoners are 
discharged into the community.
Collaborative TB/HIV/hepatitis activities by NTPs and national HIV/AIDS programmes 
should prioritize prisons, where the prevalence of these infections is high. In addition, a 
coordinated system, supported by the ministries of health, welfare, and justice or interior, 
should implement a holistic approach to patients in correctional facilities. Furthermore, 
preventive activities, including wider health education (e.g. needle exchange or cleansing 
programmes, or safe sex), should be promoted in order to minimize the harms associated 
with high-risk behaviours.
3.1.4. Preventive treatment of persons at high risk
Despite the established evidence of the efficacy of isoniazid preventive therapy (IPT) in 
preventing TB among both HIVinfected and HIV-uninfected individuals, this intervention 
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has not been fully explored in prisons. A systematic review of published reports showed 
that only 18 studies were designed to address the intervention in such settings.59 IPT 
may effectively interrupt the progression of infection to active TB disease, but questions 
remain regarding whether IPT should be started in a facility with short imprisonment 
stays or in settings with high isoniazid resistance, and also which institution should take 
responsibility for the completion of IPT in the community once the prisoner is released.19,60
3.2. Pillar 2: Bold policies and supportive systems
3.2.1. Political commitment with adequate resources for TB care and prevention
Prison health services often have small budgets,45,60,61 which, in addition to the lack of 
skilled and motivated manpower,19,22,38 may jeopardize successful TB control programmes 
in prisons. Public health attention from donors and other stakeholders towards 
populations at risk of TB has increased in recent years following the emergence of HIV/
AIDS, the more stringent application of human rights principles, health inequalities, and 
health governance.62 Nevertheless, there are still challenges in TB control in prisons due to 
logistical complications, a lack of political commitment, and public indifference towards 
the prison population, 45 which undermine TB control programme efforts in prison systems.
Improved and strengthened political commitment, including sustainable funding,38,39,52 
is therefore strongly recommended.31 The significance of ensuring adequate funding 
for TB control in prison systems is particularly important in Eastern Europe, considering 
the increased need for MDR-TB diagnostics and treatment. Besides the external funding 
provided by donors (e.g., Global Fund, US Agency for International Development, 
International Federation of Red Cross and Red Crescent Societies, the World Bank, and 
bilateral donors), countries themselves should allocate more local resources in order 
to gain sustained TB control in prisons.63 As part of building political commitment, it 
is essential to ensure that both legislation and national guidelines facilitate TB control 
in prisons. In particular, the following areas should have a supportive legal basis with 
minimum standards: (1) guidelines in line with NTPs, (2) a sufficient area per inmate to 
avoid overcrowding, (3) adequate nutrition, (4) comprehensive IC planning, (5) policies 
on the release of prisoners with TB and/or their transfer to other facilities, and (6) and 
integration/collaboration with health care services in the civil sector.64
Stewardship of prison health is defined as ‘‘all issues concerning governance and 
responsibility affecting the provision of prison health services of an agreed standard’’.65 The 
question arising here is which ministry should ideally be responsible for the stewardship 
of health in prisons. This differs by country, and the general health of prisoners may come 
under the responsibility of the ministry of justice,66 the ministry of health, or the ministry 
of internal affairs.65 The WHO Regional Office for Europe Health in Prison Project (HIPP) 
provides overall guidance to improve prison health services.65 Presently, the ministries of 
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health are in charge of health in prisons in most settings.65 In other settings, there is a 
need for close cooperation and collaboration between the ministries of health and the 
ministries responsible for prisons to plan common activities to improve TB control.
3.2.2. Engagement of communities, civil society organizations, and public and 
private care providers
Prisoners belong disproportionately to population groups already at high risk of TB (e.g., 
people who abuse substances, the homeless, migrants from high endemic areas, and 
other marginalized groups stricken by poverty with little or no access to healthcare), 
which may partially explain the high prevalence of TB in these settings.25,28,67 Education 
and counselling are fundamental to improving patient adherence to treatment. In some 
settings, community representatives engage inmates in health education and prepare 
them for treatment follow-up after their release from prison. However, it is clear that 
prison health services alone may not be able to fully respond to the TB situation in most 
settings; therefore working in partnership on different levels needs to be encouraged. 
Prison health services should collaborate closely with other sectors, including civil society 
and community representatives and health services outside prisons, in order to share 
diagnostic facilities and improve the referral and support of patients. Prison systems 
should also partner various ministries on a political level, NGOs, donors, and health 
experts for improved public awareness and knowledge-sharing.
3.2.3. Infection Control
Many prisons worldwide are overcrowded, well beyond their official capacity.68 
Overcrowded prisons facilitate the spread of mycobacterial strains, as prisoners are in 
close contact with one another, often for 12 h or more each day without access to fresh air. 
In some countries, the living conditions of prisoners are poor: spaces in prison cells of less 
than one square meter per person, bunks stacked three tiers high, and prisoners sleeping 
in turn, even during daytime hours when they have access to an outside area, or they are 
kept in isolation cells for long periods without spending time outside at all.53,68
Overcrowding, poor ventilation, and prolonged confinement inside cells are all factors 
conducive to the transmission of airborne infections. Poor ventilation may be due to 
inadequate prison infrastructure (e.g., lack of windows, no mechanical ventilation), or 
caused by the prisoners themselves covering the windows to block cold air from entering 
the room in cold climates, or by hanging clothes on the bars. The lack of mechanical 
ventilation systems is another major risk factor for contracting TB.45 Furthermore, many 
prisoners may be heavy smokers, adding to the unhealthy environment of overcrowded 
cells.68
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Overcrowding leading to significantly higher rates of TB transmission in prisons also has 
implications for rates of TB in the community. Using longitudinal TB and cross-sectional 
MDR-TB data from 26 Eastern European and Central Asian countries, Stuckler et al.28 found 
that each percentage increase in incarceration rate related to an increased TB incidence 
of 0.34% (population attributable risk, 95% confidence interval 0.10–0.58%, p < 0.01), 
after controlling for several confounders. Conversely, a reduction in custodial sentencing 
would impact favourably on risk reduction of TB and MDR-TB in the general population.69
In light of the challenge of overcrowding associated with increased rates of TB in both the 
prison and community setting, TB IC is a fundamental element for improved TB control.70 TB IC 
is a combination of measures aimed at minimizing the risk of MTB transmission and includes 
the early and rapid identification of individuals with suspected or known TB, separation of 
prisoners according to their TB disease type, and effective treatment of infection or disease,69,71 
building design or engineering methods to improve ventilation, disinfecting of the air, and 
the use of protective measures for staff and visitors in contact with TB patients. TB IC is also a 
fundamental element of Pillar 2 of the post- 2015 End TB Strategy.30 A list of IC measures to be 
conducted in prisons in consideration of these factors is summarized in Table 2.72
3.3 Pillar 3: Intensified research and innovation
One of the three main pillars of the End TB Strategy includes research. With the current 
2% decline in TB incidence, the MDGs for TB control will not be met by 2015.73 The need 
to develop new technologies to accelerate TB control resulted in the launch of the TB 
Research Movement, with the development of a roadmap for global TB research as its main 
objective.73,74 Despite its impact on public health, TB control in prisons has been given a 
low priority by national health authorities worldwide, particularly in LMICs. This is reflected 
negatively in the fund allocation, and consequently in research output.75–77 A recent review 
of published documents describing TB research priorities showed that 33 documents were 
published from 1998 to 2010 describing the importance of research on new medicines and 
diagnostics.78 None of the documents retrieved directly addressed TB research in prisons.
Table 2. Summary of infection control measures to be conducted in prisons 
Preventing spread of infection from community to prison by using intensified TB screening for 
new or transferred prisoners and preparing special blocks “Quarantine” or cells (to be used for 1-2 
weeks) for new or transferred prisoners.
Preventing TB infection among prisoners (transmission from one TB prisoner to other prisoners) or 
to prison’s staff by conducting a contact investigation for TB suspects and cases, improving infection 
control (e.g. implementing organizational, administrative, and environmental interventions) in 
prisons and using IC for prisoners.
Preventing infection of family members and the community by a released prisoners or prison staff 
by examining prisoners before release and examining prison staff regularly.
Isolation measures for TB cases and/or suspects when patients are screening or diagnosed within 
the prison system.
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Table 3. Priorities for research related to TB control in prisons.
Epidemiological research
Actual burden of tuberculosis (drug susceptible and resistant strains) and TB/HIV in prisons 
worldwide 
Best tools to measure the TB burden
Social determinants of TB infection and transmission inside prisons
Prevalence of LTBI in high-burden-countries 
Impact of scaling-up current preventive regimens on TB prevalence in prisons
Contribution of TB in prison to TB transmission in the community (attributable risk)
Operational (health services) research
Best operational model to enhance case-finding and its impact on mortality and transmission in 
prisons
Definition of optimal algorithms for diagnosis of all forms of active TB and best model to rule out 
TB among high risk group (particularly HIV-infected)
Barriers of achieving treatment adherence and strategies to improve treatment management 
particularly after prisoners’ release after short detention
Impact of individual infection control methods and proper cost-effective methods of its 
implementation 
Cost-effectiveness studies of the scaling-up of TB/HIV and MDR-TB services in prisons
Best model to integrate TB/HIV/STD services
Proper reporting and recoding system suitable for prisons
Diagnostics
New, point of care, same-day diagnostic tool to diagnose active TB
Rapid tests for diagnosing drug-resistant TB
Feasibility, impact and cost-effectiveness of new automated nucleic acid amplification test (e.g. 
GeneXpert) for use in prisons of remote and/or resource-limited settings, particularly for new 
arrival screening
Optimal and cost-effective modelling of diagnosing LTBI and active TB
Developing a proper diagnostic tool to differentiate between LTBI and active TB, particularly 
among HIV-infected prisoners
Treatment
Newer and safer TB medications to combat the growing epidemic of TB and M/XDR-TB in prisons
Shorter treatment regimens to treat LTBI and active TB
Effectiveness and safety of currently available LTBI treatment regimens in correctional settings vis 
a vis the high prevalence of blood-borne co-infections (i.e. HIV, Hepatitis C, Hepatitis B) 
Safety, efficacy and cost-effectiveness of new shorter LTBI regimens (e.g. combination of isoniazid 
and rifapentine once weekly for 12 weeks)
Optimal time to start ARV and exploration of possible drug-drug interactions with newer TB 
medications
TB, tuberculosis; LTBI, latent tuberculosis infection; MDR, multidrug-resistant; STD, sexually 
transmitted disease; M/XDR-TB, multi- and extensively drug-resistant TB; HCV, hepatitis C virus; HBV, 
hepatitis B virus; ARV, antiretroviral.
In order to better allocate economic and human resources, it is important to adequately 
estimate the burden of disease and the risk of developing TB in prison.79 Given the 
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difference in dynamics and population, guidelines outlining TB research priorities need 
to be developed specifically for correctional institutions.76 The areas for research to be 
addressed in relation to prisons, as listed in Table 3, are of high priority.74,75,78 There are still 
concerns about conducting studies among vulnerable populations, including prisoners, 
and ethical considerations related to prisoners need to be addressed properly when 
conducting research in these settings.
4. Conclusions
Currently, a complex range of activities is required to tackle the alarming situation of TB, M/
XDR-TB, and TB/HIV control in prisons. The requirements for enhanced TB control in prisons 
are good governance, clear strategies to diagnose and treat TB patients, adherence to 
internationally established IC policies, and the performance of cost-effectiveness analyses 
to evaluate screening procedures and other control strategies. Released prisoners with 
active TB disease need to be followed-up by health authorities in the civilian sector and 
NTP-based local health centres, or organizations collaborating with NTPs. To minimize 
the interruption of treatment for released prisoners, implementation of the following 
interventions is recommended: (1) discharge or referral planning, (2) post-release follow-
up, and (3) notification of unplanned releases and monitoring of referrals. If NTPs or 
ministries of health are responsible for TB control in the prison system, the establishment 
of follow-up mechanisms is probably more likely to occur, and gaps between public health 
and prisons are less likely to exist.
In addition, it is crucial to prepare effective plans for human resource development 
covering entire processes, such as basic education (in- and pre-service), retraining, on-
the-job training, supervision, career development, salary scales, job descriptions, and 
enhanced IC measures. Although the Directly Observed Treatment Short-course (DOTS) 
has been declared the most cost-effective health strategy available by the World Bank, 
there is still work to be done to improve general TB management among prisoners. It 
is argued that if there is a failure to implement TB control successfully in prisons, it will 
affect prison and public health services dramatically in the near future, due to increased 
numbers of cases within the prison services and community, as well as higher numbers 
of M/ XDR-TB and/or TB/HIV cases. New tools, such as the GeneXpert MTB/RIF, should be 
implemented in central prison hospitals, or facilities where prisoners receive TB treatment.
Although we are entering an exciting period of innovation, e.g. introduction of GeneXpert 
MTB/RIF and new medicines like delamanid and bedaquiline,41,80,81 TB control in prisons 
remains a neglected priority. In addition, the increased cost of new drugs (USD 900 and 
USD 3000 for bedaquiline in LMICs and high-income countries, respectively, for a 6-month 
course)82 and the resources needed for pharmacovigilance and the management of side 
effects, remain a barrier to utilization, particularly in the prison sector where resources 
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are even more limited. No real improvement can be facilitated without clear commitment 
from national governments and partnerships and sustained financing, in line with the 
End TB Strategy. In order to achieve this, the principle ‘‘good prison health is good public 
health’’83 needs to be fully recognized.
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On Oct 1, 2013, WHO and global partners launched a roadmap to end tuberculosis deaths 
in children worldwide.1 The roadmap identifi es key actions that must be taken, including 
increased and targeted research, partnerships between key stakeholders, and strategic 
economic investment. The roadmap also shows the crucial lack of global emphasis on 
tuberculosis prevention and treatment for one of the most vulnerable populations. This 
intervention comes at a pivotal juncture because rates of drugresistant tuberculosis 
have been increasing worldwide, particularly in the WHO European Region, with severe 
implications for child tuberculosis morbidity and mortality.
Globally, children younger than 15 years account for about 6% of the 8·6 million cases 
of tuberculosis, and about 5% of the 1·4 million deaths that occur annually from the 
disease.2,3 Children have been traditionally viewed to pose less of a risk for transmission 
than adults because they often have paucibacillary disease, which is also harder to 
diagnose with sputum smear microscopy, culture, and molecular tests.4 If tuberculosis is 
undetected and untreated, children are at high risk of death, especially in the context 
of multidrugresistant and extensively drug-resistant tuberculosis. 15 of the 27 countries 
with a high burden of multidrugresistant and extensively drug-resistant tuberculosis 
worldwide are in the WHO European Region,2 with 99% of the regional disease burden 
in 18 high-priority countries (Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, 
Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, 
Turkmenistan, Ukraine, and Uzbekistan).5 6% of the total estimated incidence of new 
and relapsed tuberculosis cases occurred in these countries (376 200 cases),2,5 in 2011, an 
estimated 23 000 children had tuberculosis, of whom nearly 5000 are estimated to have 
had multidrug-resistant or extensively drug-resistant disease. These estimates contrast 
sharply with the fewer than 1000 cases of childhood tuberculosis that were detected and 
reported in these countries.2,5
In response to the alarming increase in multidrugresistant and extensively drug-resistant 
tuberculosis in the WHO European Region, in 2011 the Consolidated Action Plan to 
Prevent and Combat Multidrug and Extensively Drug Resistant Tuberculosis (2011–15) 
was endorsed by the sixty-fi rst Regional Committee for Europe, and implemented 
in all 53 member states.6,7 The plan includes essential milestones and activities for 
childhood tuberculosis, with the aim to scale-up access to treatment; prioritise childhood 
tuberculosis in member states’ national strategic plans; and develop a special response for 
diagnosis and treatment of tuberculosis in children, including identifying policies (or lack 
of policies) that contribute to underdiagnosis.
The table summarises data on national childhood tuberculosis policies collected by 
the WHO Europe task force for childhood tuberculosis from 15 (of the 18) high-priority 
countries that provided policy information from September, 2012, to January, 2013.3 
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At present, the 15 countries have policies that adhere to the 2006 WHO guidelines for 
childhood tuberculosis4 with regard to contact-tracing of close household contacts, 
detection with tuberculin skin testing, and provision of isoniazid preventive treatment 
for children with a close household tuberculosis contact. However, only eight countries 
have policies for contact tracing for children with a close non-household contact (as 
recommended by WHO for children younger than 5 years8). Additionally, four countries 
recommend a multidrug-resistant tuberculosis treatment regimen only in children 
with bacteriologically confirmed multidrug-resistant tuberculosis. However, since 
bacteriological confi rmation is often diffi cult in children, WHO recommends that, if active 
tuberculosis disease develops in children with a close contact with multidrug-resistant 
tuberculosis,  a multidrug-resistant tuberculosis drug regimen should be promptly 
started. Although 11 countries have this policy in place, its efficacy is predicated on eff 
ective contact investigation. For children who are detected with active tuberculosis or 
are given preventive therapy for latent infection, several countries require hospital 
admission for either the initial 2 month phase or the entire length of preventive and active 
tuberculosis treatment (three and seven countries, respectively). However, admission of 
children to tuberculosis wards for an unnecessarily long duration places them at high risk 
of primary infection or reinfection with multidrug-resistant or extensively drug-resistant 
tuberculosis.9,10 Forthcoming updated WHO guidelines for the management of childhood 
tuberculosis will add clarity for countries about these and other issues, including detection 
with molecular diagnostics and use of paediatric drug formulations.
In the context of multidrug-resistant and extensively drug-resistant tuberculosis, a 
priority in the WHO European region is to accelerate the adoption of updated childhood 
tuberculosis guidelines into national strategic tuberculosis policies. Additionally, eff orts 
to ensure that policy is aligned with practice remain at the core of eff ectively detecting 
disease and saving lives of children with tuberculosis. In high-priority countries, there is 
a crucial scarcity of qualifi ed human resources to manage childhood tuberculosis and 
multidrugresistant and extensively drug-resistant tuberculosis, and irregular access 
to second-line drugs is still a challenge. The new roadmap for childhood tuberculosis 
importantly serves as a call to action for all stakeholders in child health to urgently address 
these issues.
Key actions to increase awareness and capacity for contact investigation, management 
of childhood tuberculosis, and surveillance are in line with the Consolidated Action Plan. 
These actions will be vital to shift policy and place a spotlight on prevention and combat 
of multidrug-resistant and extensively drugresistant tuberculosis in the most vulnerable 
populations.4
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 Number of 
high-priority 
countries (n=15)*
Case detection  









Radiograph of the chest 14
Fluorography 3
CT 9
Other blood analyses 10
Preventive treatment  
Preventive treatment for latent tuberculosis†  
Children with tuberculosis contact, irrespective of age and irrespective of TST results 7
Children with tuberculosis contact, irrespective of age with a positive TST 8
Children with tuberculosis contact, with positive TST of certain age range 2
Children detected through mass tuberculin skin testing with a positive TST, 
irrespective of age
2
Children with HIV 8
Other 7
Type of preventive treatment†  
Isoniazid 15
Other 4
Preventive treatment for child contacts of MDR tuberculosis patients (individualised 
treatment on the basis of drug-resistance pattern of index case)
 4
Preventive admission to hospital  
Yes, for the entire treatment period 3
Yes, for the initial period 3
No, treatment is given ambulatory for the full period 6
Ambulatory for the full period with a proportion of children referred to sanatoriums 3
(Continues on next page)
Comment
task force for childhood tuberculosis from 15 (of 
the 18) high-priority countries that provided policy 
information from September, 2012, to January, 2013.3 
extensively drug-resistant tuberculosis.9,10 
formulations. 
core of eff
there is a crucial scarcity of qualifi
 Number of 
high-priority 
countries (n=15)*
(Continued from previous page)
Treatment for active tuberculosis disease  
Paediatric national guidelines 14
Standardised treatment for active or assumed drug-sensitive tuberculosis 15
Children prescribed MDR regimen  
Only children with bacteriologically confi rmed MDR tuberculosis 4
Both children with bacteriologically confi rmed MDR tuberculosis and children with 
active tuberculosis in close contact with patients with infectious MDR tuberculosis
11




Admission to hospital for active tuberculosis†  
Yes, for the entire treatment period 7
Yes, for the initial period 3
No, ambulatory for the full period 5
Ambulatory treatment preferred, but hospital stay might be necessary 5
TST=tuberculin skin test. MDR=multidrug-resistant.*Armenia, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, 
Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine, and Uzbekistan. †Categories not 
mutually exclusive. 
Table: Number of countries with policies for detection, preventive treatment, and active treatment of 
children with tuberculosis
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No evidence exists on tuberculosis (TB) and latent TB infection (LTBI) management 
policies among refugees in European countries.
A questionnaire investigating screening and management practices among refugees 
was sent to 38 national TB programme representatives of low and intermediate TB 
incidence European countries/ territories of the WHO European Region.
Out of 36 responding countries, 31 (86.1%) reported screening for active TB, 19 for LTBI, 
and eight (22.2%) reporting outcomes of LTBI treatment. Screening for TB is based 
on algorithms including different combinations of symptom-based questionnaires, 
bacteriology and chest radiography and LTBI screening on different combinations of 
tuberculin skin test and interferon-γ release assays. In 22 (61.1%) countries, TB and 
LTBI screening are performed in refugee centres. In 22 (61.1%) countries, TB services 
are organised in collaboration with the private sector. 27 (75%) countries answered 
that screening for TB is performed as per national and international guidelines, while 
19 (52.7%) gave the same answer with regards to LTBI screening. Infection control 
measures are inadequate in several of the countries surveyed.
There is need for improved coordination of TB screening in Europe to implement the 
End TB Strategy and achieve TB elimination.
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Introduction 
According to the most recent World Health Organization (WHO) Global TB Report the 
estimated annual tuberculosis (TB) incidence decreased globally by an average of 1.5% 
per year since 2000 and the estimated TB prevalence in 2014 was 42% lower than in 1990 
[1]. However, an estimated 9.6 million people worldwide developed active TB in 2014, 
among them, 12% had HIV infection [1]. During the same year, TB caused 1.5 million 
deaths, making it one of the most common causes of death from an infectious disease 
alongside HIV.
In 2014, a total of 329 270 TB cases were reported from 51 countries in the WHO European 
Region (notification rate: 36.7 cases per 100000 population), with 33 000 estimated deaths 
[2]. The estimated incidence in Europe represents 3% of the global TB burden.
 
TB is considered a major public health challenge in many countries worldwide, particularly 
among vulnerable populations, such as individuals at higher risk of exposure to 
discrimination, hostility or economic adversity. These factors unfortunately afflict the lives 
of many migrants and refugees (here defined in agreement with the 1951 “Convention 
and Protocol relating to the status of Refugees”: www.unhcr.org/3b66c2aa10.html) [1–5].
Several factors have contributed to increase population mobility in the WHO European 
Region, such as the establishment of the European Union (EU) and free movement within 
the Newly Independent States (NIS), particularly for seasonal labour [5, 6], although 
refugees’ problems are specific. This increased population mobility poses challenges for 
TB control and requires effective and sustainable mechanisms to ensure quality TB and 
latent TB infection (LTBI) prevention, diagnosis and treatment [5, 7].
The need for coordinated intervention in these areas is justified from the perspective of 
individual human rights (independent of legal or residential status of the subject) as well 
as public health pre-requisites to control and ultimately eliminate TB, including multi- and 
-extensively drug resistant TB (MDR-TB and XDR-TB) [3, 8–10].
For refugees, full access to TB diagnosis and treatment (with guarantee of protection from 
deportation until the end of treatment) has been recommended by WHO; this is in the 
interest of both the individual and the wider hosting community in terms of TB control 
and elimination [11–15]. In 2015, more than one million migrants and refugees reached 
Europe by land and sea. In 2014 the estimated figure was significantly lower (219 000) [4, 
16]. According to official data, an estimated 181 673 new refugees and migrants arrived in 
Europe between January 1 and April 26, 2016, with 1261 reported deaths. 82% of arrivals 
via the Mediterranean sea originated from 10 countries only [16]. At the current time, the 
four countries from which most refugees originate are the Syrian Arab Republic (43% of 
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the overall flow), Afghanistan (23%), Iraq (14%), Pakistan (4%) and Iran (4%) (see also: 
https://ec.europa.eu/eurostat/statistics-explained/index.php/Asylum_statistics).
Despite the recent release of resolutions and statements by bodies such as WHO, the 
European Respiratory Society (ERS) and the EU [4, 17], not much is known about the 
policies in force in European countries with regards to TB and LTBI management among 
refugees upon arrival.
In light of the ongoing refugee situation in Europe, the aim of this ERS/WHO European 
Region study (performed through the ERS ad hoc Working Group on TB Advocacy) is 
to document the policies and practices of low and intermediate TB incidence European 
countries with regards to detection and management of TB and LTBI among refugees.
Methods
Survey questionnaire
In September–October 2015, experts from the ERS, WHO Regional Office for Europe 
and the WHO Collaborating Centre in Tradate, Italy, as members of the ERS ad 
hoc Working Group on TB Advocacy, (www.ersnet.org/index.php?option=com_
flexicontent&view=items&id=5200-tb-advocacy-working-group.html) developed a short 
questionnaire for a rapid survey containing multiple choice and open-ended questions on 
screening and management of TB and LTBI among refugees in Europe. The questionnaire 
was finalised after reviewing suggestions and comments received from the members 
of the ERS TB Advocacy ad hoc Working Group and reaching overall consensus among 
the members. In addition to basic demographic data of the respondents, the survey 
comprised questions on the following subject areas: screening for and management of 
TB/LTBI; guidelines, legislation and evidence for current practice; cross-border TB care; 
and organisational aspects of TB care and infection control measures.
The questionnaire was sent to the national TB programme representatives of all EU/
European Economic Area countries of the WHO European Region, Switzerland and six 
other countries who have hosted, or were deemed likely to host, or become a transient 
country for a significant number of refugees in the near future. The six additional countries 
were the current EU candidate countries (Albania, Bosnia and Herzegovina, the former 
Yugoslav Republic of Macedonia, Montenegro, Serbia and Turkey). The survey, along with 
a cover letter for additional information, was sent to each of the national TB programme 
representatives on October 23, 2015, with an initial deadline set for November 6, 2015. 
Furthermore, there was an offer for the TB programme representatives to conduct a 
telephone interview to complete the survey, should returning the document prove too 
difficult by the deadline provided. On November 9, 2015, a reminder email was sent to 
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programme representatives who had not responded. The survey was closed on February 
24, 2016.
Data analysis
The results of the survey were entered into a Microsoft Excel programme (Excel 2010; 
Microsoft Corporation, Albuquerque, NM, USA) and double-checked (L. D’Ambrosio; R. 
Centis) prior to analysis. Results produced a mixture of quantitative and qualitative data, 
with descriptive statistics being calculated where appropriate, and supplemented with 
qualitative information provided by responders to the survey.
Ethics
As a broad evaluation of current policies and practices within countries, ethical approval 
was not required because the study did not collect individualised information on subjects.
Results
36 (94.7%) out of 38 countries contacted responded to the questionnaire. The results 
from section 1 (Screening for TB and LTBI among refugees in the European Region) are 
summarised in table 1.
Refugees are routinely screened for active TB by the majority of the countries (31 (86.1%) 
out of 36), with the exception of Italy, Monaco and Portugal where a non-systematic 
screening is performed (only in symptomatic individuals); no screening is performed in 
Former Yugoslavia Republic of Macedonia (length of stay in holding centre is not long 
enough for screening to take place) and Serbia (insufficient governmental funding). 19 
(52.7%) countries (Belgium, Bulgaria, Croatia, Cyprus, Estonia, France, Greece, Iceland, 
Lithuania, Luxembourg, Malta, Montenegro, Norway, Romania, Slovakia, Spain, Sweden, 
Turkey and the UK) screen systematically for LTBI among refugees, eight (22.2%) countries 
(Denmark, Finland, Germany, Italy, Monaco, the Netherlands, Portugal and Slovenia (which 
reported low numbers)) do not perform it systematically and nine (25%) do not screen at 
all for LTBI (Albania, Austria, Czech Republic, Hungary, Ireland, Latvia, Former Yugoslav 
Republic of Macedonia, Serbia and Switzerland) (figure 1).
However, almost half of the countries (8 (47%) out of 17) that currently do not screen for 
TB and LTBI have plans to introduce it for TB and/or LTBI in the near future. There is a legal 
obligation to screen for TB and/or LTBI in 21 (58.3%) of the 36 countries responding to this 
survey.
Screening for TB is performed with algorithms using different combinations of symptom-
based questionnaires (21 (58.3%) out of 36, of which one not systematically collected), 
bacteriology (18 (50%) out of 36, sputum smear/culture collection of which nine for 
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symptomatic individuals only) and chest radiography (27 (75%) out of 36, of which two 
do not perform systematically, while in Germany, TB screening of adult immigrants (⩾15 
years old) is almost systematically performed by chest radiography (with exception of 
pregnant ladies as per legal act)); five countries (Denmark, Italy, Monaco, Portugal and 
Turkey) do not systematically perform any TB-specific examination. In two countries 
(Croatia and Hungary), routine bacteriology for TB (sputum smear and culture) is part of 
the screening procedure.
Similar to the findings described by a previous ERS/WHO Europe Region Study [10], LTBI 
screening is performed by using different combinations of tuberculin skin test (TST) and 
interferon-γ release assays (IGRAs) in 23 (63.8%) out of 36 different European countries 
(eight (22.2%) out of 36, TST only, 11 (30.5%) out of 36, TST plus IGRA, four (11.1%) out 
of 36, TST plus IGRA in selected cases (only in Bacillus Calmette–Guérin non-vaccinated 
children aged <12 years and after TB exposure in the Netherlands; and in case of recent 
exposure to TB in Portugal, Slovenia and Monaco).
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In 22 (61.1%) out of 36 countries, TB and LTBI screening are performed in refugee centres, 
using also other combinations of measures (See table 1 for details). The decision to 
perform TB/LTBI screening is determined by the TB incidence rate in the country of origin 
of refugees in 14 (38.8%) out of 36 of the surveyed countries. No single threshold was 
provided. In the majority of countries where any screening takes place, it is performed 
only once (28 (90.3%) out of 31). The results from section 2 (Management of TB and LTBI 
among refugees in Europe) are summarised in table 2.
Figure 1. Summary of the countries screening for tuberculosis (TB) and latent TB infection 
(LTBI).
In the majority of countries (24 (66.6%) out of 36) treatment after diagnosis of active TB in a 
refugee is required, whereas in Denmark, Monaco, the Netherlands and Portugal, TB treatment 
is voluntary; in six other countries (Belgium, Germany, Ireland, Sweden, Switzerland and the UK) 
individuals cannot be legally forced to take medications, but can usually be convinced to start 
anti-TB treatment; involuntary isolation is foreseen in case of refusal to comply with treatment, 
while in Serbia isolation is only considered for MDR-TB patients who refuse treatment and, in 
Macedonia, no TB treatment is proposed due to the short length of stay in the country. Overall, 
no EU country reported that TB detection was a reason for deportation.
Anti-TB treatment is proposed immediately after diagnosis in the majority of countries (26 
(72.2%) out of 36), where costs are covered by central governmental funds (26 (72.2%) out 
of 36). Almost three-quarters (23 (63.8%) out of 36) report that efforts are ongoing to adapt 
TB services to refugees’ specific needs through specific national/regional programmes and 
through specific national/regional programmes and improved cooperation with the non-governmental
sector. A similar number of countries (22 (61.1%) out of 36), directly or indirectly (through certified
non-governmental organisations (NGOs)) allow refugees access to TB services. Among countries with
general or specific regional/national programmes (or guidelines) for TB management in refugees (14 (38.8%)
out of 36), more than half (nine (64.2%) out of 14) report difficulties in fully complying with requirements of
their own guidelines, given the high number of refugees in the present situation. Further details on specific
national programmes are available in table 2.
The results from section 3 (Guidelines, Legislati n and Evidence on the results of screening and treatment
of TB and LTBI in Europe) are summarised in table 3. In particular, 27 (75%) 36 countries answered that
screening for TB is done as per national and international guidelines (offering the same services to
r fugees and nationals), while 19 (52.7%) out of 36 gave the same answer with regards to LTBI screening.
Similarly, while 22 (61.1%) out of 36 countries confirmed that they collect data on the yield of active TB
screening among refugees (with Estonia, Finland, Norway and the UK partially/not systematically
collecting data), only 11 (30.5%) out of 36 countries (Bulgaria, Finland, France, Iceland, Italy, Lithuania,
Norway, Slovakia, Slovenia, Turkey and the UK) are equipped to collect similar data for LTBI screening
(Finland, Norway and the UK providing data not systematically). Finally, detailed information on TB
treatment outcomes is available in 19 (52.7%) out of 36 countries, while tr atment completion rates for
LTBI therapy among refugees are available in only eight (22.2%) countries (Bulgaria, France, Iceland,
Netherlands, Portugal, Slovakia and Slovenia and Turkey).
The results from section 4 (Organisational aspects of TB care and infection control issues) are summarised
in table 4. Seven (19.4%) countries (Austria, Croatia, Germany, Greece, the Former Yugoslavia Republic of
Macedonia, Serbia and Turkey) reported to host >250000 refugees in the 6 months preceding the survey,
Hungary notified a range between 100001 and 250000, while Italy and Sweden reported hosting between
50001 and 100000 refugees. In the vast majority of the countries (30 (83.3%) out of 36), public sector
services are in charge of managing refugees for TB-related issues, complemented by international
Active TB and LTBI screening
Active TB and not systematic LTBI screening
Active TB screening only
Not systematic active TB and LTBI screening
No active TB and LTBI screening
Not included or not reported
FIGURE 1 Summary of the countries screening for tuberculosis (TB) and latent TB infection (LTBI).
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improved cooperation with the non-governmental sector. A similar number of countries (22 
(61.1%) out of 36), directly or indirectly (through certified non-governmental organisations 
(NGOs)) allow refugees access to TB services. Among countries with general or specific 
regional/national programmes (or guidelines) for TB management in refugees (14 (38.8%) 
out of 36), more than half (nine (64.2%) out of 14) report difficulties in fully complying with 
requirements of their own guidelines, given the high number of refugees in the present 
situation. Further details on specific national programmes are available in table 2.
The results from section 3 (Guidelines, Legislation and Evidence on the results of screening 
and treatment of TB and LTBI in Europe) are summarised in table 3. In particular, 27 (75%) 36 
countries answered that screening for TB is done as per national and international guidelines 
(offering the same services to refugees and nationals), while 19 (52.7%) out of 36 gave the 
same answer with regards to LTBI screening. Similarly, while 22 (61.1%) out of 36 countries 
confirmed that they collect data on the yield of active TB screening among refugees (with 
Estonia, Finland, Norway and the UK partially/not systematically collecting data), only 11 
(30.5%) out of 36 countries (Bulgaria, Finland, France, Iceland, Italy, Lithuania, Norway, Slovakia, 
Slovenia, Turkey and the UK) are equipped to collect similar data for LTBI screening (Finland, 
Norway and the UK providing data not systematically). Finally, detailed information on TB 
treatment outcomes is available in 19 (52.7%) out of 36 countries, while treatment completion 
rates for LTBI therapy among refugees are available in only eight (22.2%) countries (Bulgaria, 
France, Iceland, Netherlands, Portugal, Slovakia and Slovenia and Turkey).
The results from section 4 (Organisational aspects of TB care and infection control issues) 
are summarised in table 4. Seven (19.4%) countries (Austria, Croatia, Germany, Greece, the 
Former Yugoslavia Republic of Macedonia, Serbia and Turkey) reported to host >250000 
refugees in the 6 months preceding the survey, Hungary notified a range between 100 
001 and 250 000, while Italy and Sweden reported hosting between 50 001 and 100 000 
refugees. In the vast majority of the countries (30 (83.3%) out of 36), public sector services 
are in charge of managing refugees for TB-related issues, complemented by international 
organisations (e.g. Red Cross in Bulgaria, Denmark, the Former Yugoslavia Republic of 
Macedonia, Serbia and Spain; the International Organization for Migration in Romania 
and Medicine du Monde in the UK).
Several problems were reported among the different countries, including internal and 
external communication and coordination issues, cultural mediation/language differences 
and inadequate funding or human resources. The sheer volume of refugees was also cited 
as a challenge in eight (22.2%) countries (Austria, Belgium, Germany, Greece, Italy, the 
Netherlands, Norway, Serbia). Although respirators are generally available to protect staff 
and complement administrative infection control measures, a general lack of consistency 
with international guidelines emerged from the countries’ answers.
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Discussion
The aim of our study was to investigate which reported policies and practices exist for 
TB and LTBI screening and management among refugees in low and intermediate TB 
incidence countries of Europe. The survey had a very high response rate (36 (94.7%) out of 
38) which shows countries’ interest and prioritisation of this issue.
The results of our study confirm that screening for TB is considered as an important public 
health measure in Europe, although significant differences exist in screening practices 
among countries.
According to a survey conducted in 2012 on screening practices on infectious diseases 
among newly arrived migrants to Europe, all countries perform TB screening, with the 
second-most screened condition being Hepatitis B (30% of the countries) [18]. The results 
of our survey also indicate that there is a general lack of analysis of the yield of TB and 
LTBI screening among refugees. The huge workload is assumed as the main reason. 
Furthermore, much less information is available for LTBI than for active TB disease.
While our survey shows that 31 countries regularly screen refugees for TB, only 19 screen 
for LTBI, and even a fewer report outcomes of LTBI treatment [9]. In view of TB elimination, 
more and more emphasis will be given to the possibility of implementing LTBI registers in 
low TB incidence countries [19].
Although 11 out of 36 countries answered they were equipped to collect information 
on LTBI screening, only three (Finland, Norway and the UK) confirmed collection of data, 
although not systematically. LTBI management remains a component of the TB Elimination 
strategy which is challenging countries, particularly when a large number of patients 
is involved. In fact, the large number of arrivals in holding centres, particularly in some 
European countries, makes LTBI screening and subsequent management problematic. In 
addition, several countries reported difficulties in coordination between holding centres 
and TB services serving the native population.
Based on our survey, it appears that there are no systematic follow-up screening/check-
ups of refugees for TB sometime after their arrival. Given that refugees are often exposed 
to precarious, stressful travelling conditions during transit, which provide a risk of 
Mycobacterium tuberculosis transmission, there is a need to ensure people-centred care is 
available to them beyond arrival in their host country. Symptomatic screening of refugees 
and more intensive follow-up for those with LTBI may be justified. This is particularly 
important as many European countries are scaling-up their efforts to eliminate TB [10].
In an attempt to make screening as cost effective as possible, countries have applied 
different algorithms in-line with WHO recommendations [20]. According to our survey, 
Chapter 9174   |
they are based on different combinations of symptom-baseds and chest radiography, 
with addition of bacteriology in a few countries (table 2). Evaluation of the yield of these 
screening procedures was beyond the scope of this study; however, there is a real need for 
analysis of such data at national and regional level [5, 6].
Our study identified different models of screening for TB/LTBI in Europe. Some countries 
perform radiological screening of all refugees in a hub or holding centre, and carry out 
further investigations in decentralised centres only if radiological abnormalities are 
identified. Others implement different screening algorithms or organise provision of 
health services differently at the refugee centres. In this context, screening for LTBI, by use 
of IGRAs and/or TST, although considered an important intervention in the pursuit of TB 
Elimination [9, 10] is still difficult to implement in several countries.
Based on the unprecedented number of refugees, it is important to have a specific response 
plan and ensure its full funding both at the national and European level. Interestingly, in 
the majority of countries (22 (61.1%) out of 36), TB services are organised in collaboration 
with NGOs and other sectors. Among others benefits, this approach has the advantage of 
increasing cultural sensitivity of the TB services.
Infection-control measures are generally inadequate in a large proportion of the countries 
surveyed. Surgical masks are often used to “protect” healthcare workers when it is well 
known that they are ineffective against M. tuberculosis from active TB patients who are 
not on treatment; certified respirators are needed for this purpose. Furthermore, a lack of 
specific training on infection control measures has been reported. Similar problems have 
previously been described in European MDR-TB reference centres [21].
Although surveys of this kind are subject to several limitations (related to the instrument 
used, the missing information from non-responding countries, the possible erroneous 
responses from national programmes and the limitations of aggregated data), strengths 
of this study include: continuous dialogue with National TB representatives; the very high 
response rate (94.7%); and the consistency of the answers received with previous surveys 
carried out using similar methodology [10].
The results of the present study highlight the need for improved coordination of TB 
screening in Europe, with the ultimate goal of implementing the End TB Strategy, the TB 
Action Plan for the WHO European Region 2016–2020 [22] and the Health 2020 Policy 
Framework [23] to address inequity. The ultimate goal of these strategies is to achieve 
TB Elimination [9, 10, 24, 25]. This will require quality operational research evaluating 
surveillance (aimed at attaining better data for better planning), the efficacy of existing 
algorithms and the yield of screening activities [26]. Furthermore, within the limited 
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information available on LTBI in the European context, further clinical and operational 
research is also needed to inform clinicians and public health authorities on the correct 
approach to follow when LTBI is diagnosed in contacts of MDR-TB cases.
Finally, the new function of the ERS/WHO Europe TB Consilium (a free, internet-based 
instrument supporting clinicians to manage difficult-to-treat cases of tuberculosis) is now 
live and accessible under the TB Consilium website (www.tbconsilium.org). This electronic 
platform will allow better cross-border TB control by contributing to the provision of 
quality prevention, diagnostic and treatment services to migrants and refugees.
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This thesis covers several operational research studies on tuberculosis and drug resistance 
in the WHO European Region between 2010 and 2018. These studies can guide national 
health authorities and key stakeholders through evidence-informed decision making, focus 
on areas where there are still gaps in knowledge and utilise more effective interventions 
to end TB in the Region1 to attain the sustainable development goals. The findings of the 
studies in this thesis and their impact on policies and practices are summarized in table 1.
Epidemiology of TB and extrapulmonary TB in the WHO European Region 
and evolution of international recommendations from DOTS to the Stop TB 
Strategy
The focus of most studies on tuberculosis is on the pulmonary forms of the disease, 
as these are the forms of the disease that are considered to be the primary source of 
infection at the community level. However, the extrapulmonary forms of the disease are 
equally important due to the suffering people go through, as well as their link with HIV 
coinfection, mortality and their more frequent occurrence in certain population groups. 
In Chapter two, we discussed that the WHO European Region Member States in general 
have a good level of data completeness, with only handful of countries not reporting 
the localisation of the disease. We also found out that the rate of reported multi-drug 
resistant TB is lower among extrapulmonary forms of the disease than among pulmonary 
TB (2.3% versus 5.2%). This may have to do with the fact that extrapulmonary TB is more 
common among migrants coming from countries with lower rates of drug resistant TB or 
the difficulties in obtaining adequate samples for culture growth, which at the time was 
the gold standard for identifying drug resistance. Examining these trends, we also found 
that the treatment outcomes for all patients showed decreasing trends from 2005 to 2010. 
As reflected in consecutive studies, including those in this thesis, we observed that this 
negative trend was halted, and that treatment outcomes began to increase slowly from 
2010 onwards. As the international recommendations evolved from DOTS to the Stop TB 
strategy, we reviewed both strategies and argued that implementation of the wider Stop 
TB Strategy through people-centred integrated care, including all types of TB, calls for 
multidisciplinary approaches. Our study also identified gaps in surveillance and the need 
for more disaggregated data, including those on social determinants and HIV coinfection. 
Cost effective plans to prevent and control drug resistant TB
Despite having less than 3% of all TB cases in the world, the WHO European Region has the 
highest rates of drug resistant tuberculosis and one in every five people with MDR-TB are 
from this Region, the majority being in eastern Europe and central Asia. In order to address 
this situation, a Regional Action Plan to Prevent and Combat M/XDR-TB was developed. In 
1 ·The ‘End Tuberculosis Strategy’ is aiming for a 95% reduction by 2035 in the number of TB deaths 
compared with 2015, a 90% reduction by 2035 in TB incidence rate compared with 2015, and zero 
TB-affected families facing catastrophic costs due to TB by 2035.
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addition to early diagnosis and effective treatment of drug susceptible TB to prevent the 
acquisition of drug resistance, it is important to detect drug resistant TB in a timely fashion 
and provide adequate treatment to alleviate people’s suffering and cut the transmission 
cycle. Globally, only about half of all patients with MDR-TB are successfully cured.1 In order 
to assess the cost effectiveness of the proposed plan, using available data and resources, 
we developed a costing tool for the WHO European Region. In Chapter three, we used 
this costing tool and analysed the national and subnational data and found out that in 
high TB priority countries supported by the Global Fund to Fight AIDS, Tuberculosis and 
Malaria, 78% of M/XDR-TB patients were successfully treated compared to 20% in other 
settings. This provided powerful evidence suggesting that the mobilisation of adequate 
funding from the Global Fund, other international donors as well domestic resources 
can make the difference in achieving the goals of the Action Plan. A transmission model, 
using epidemiological data reported to WHO, was then developed to calculate expected 
achievements. The WHO-CHOICE database2 was used for the cost analysis. We calculated 
the cost of implementing the Action Plan at US$ 5.2 million for a period of five years. 
Implementation of the Plan, and in particular enhancing early TB detection and increasing 
treatment success while breaking the transmission cycle, would result in 263,000 M/
XDR-TB cases averted, with a short-term economic gain of US$ 6.9 million. The long 
term economic indirect gain has not been determined but will be far greater than that 
in the short-term because many future transmission events were not considered in our 
study. Based on our analysis, investing in the prevention, early diagnosis and effective 
treatment of multidrug resistant TB is highly cost effective. The plan is expected to prevent 
the emergence of 250,000 new MDR-TB and 13,000 XDR-TB patients, respectively, saving 
US$7 billion and 120,000 lives. At the time of the study, we found out that there was a 
considerable projected funding gap of over 60% in order to fully implement the Plan. This 
study highlighted the urgent need for countries and international partners to increase 
funding for TB and MDR-TB prevention, diagnosis and treatment to have the desired 
impact. Furthermore, there is an identified need to invest in health systems that place an 
emphasis on patient-centred models of care. This is in line with the Action Plan and the 
European Health 2020 policy framework. Since the target of 75% treatment success of 
MDR-TB was not achieved, the final achievements may be less than those foreseen and 
deserve further analysis. It is noteworthy that, at the time of publication, new medicines 
have not yet been approved and shorter treatment regimens for drug resistant TB are 
not recommended.3 This notwithstanding, the analysis provided useful information on 
the potential gains that supports the pillar of integrating patient-centred TB care and 
prevention within the TB action plan of the WHO Region and more broadly the need for 
more innovation and adapted models of care that can be guided by operational research. 
These findings support the need to increase the political commitment, provide further 
evidence for the investment case and underline the importance of increasing resources 
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and their efficient use in line with pillar two of the End TB strategy, as depicted in the 
conceptual framework of this thesis.
Using data at the national and subnational level to improve treatment 
outcomes and break the transmission cycle
Inadequate treatment of TB leads to unfavourable outcomes (death, treatment failure 
and loss to follow-up) and further transmission of disease. Unfavourable outcomes also 
negate the credibility of the TB programme in the eyes of health workers, patients and the 
community at large. In Chapter four, we analysed the reasons for unfavourable outcomes 
of more than 110,000 patients enrolled in treatment over a five-year period (2006-2010) in 
Uzbekistan, a high TB priority county. This is the largest study ever conducted in the Region. 
Our study showed that, 83% of patients were successfully treated, 6% died, 6% were lost 
to follow-up, 3% failed treatment and 2% were transferred out. Factors associated with 
death included being above 55 years of age, being HIV-positive, having a positive sputum 
smear result, having been previously treated, being jobless and living in certain provinces. 
Factors associated with loss to follow-up were being male, previously treated, jobless, 
living in an urban area and a resident of certain provinces. These findings highlight the 
need to have gender-specific and people-centred approaches to be able to reduce losses 
to follow-up. Having sputum smear positive pulmonary tuberculosis, being an adolescent, 
living in an urban population, being HIV-negative, previously treated, jobless and residing 
in particular provinces were associated with treatment failure. The considerable overlap 
of factors associated with the three specific adverse outcomes (death, treatment failure 
and loss to follow-up) suggests that similar social stratifiers are involved. These will need 
further in-depth research, but meanwhile being vigilant in following up and supporting 
individuals at risk would seem logical. Trends in unfavourable TB outcomes remained 
relatively stable over the five-year period, indicating that no additional measure is yet 
to play a significant role in reducing these proportions further. Some districts in the 
country revealed higher rates of unfavourable outcomes, particularly loss to follow-up. 
These findings calls for national programmes to continuously analyse both national as 
well as the subnational data, explore the reasons for unfavourable outcomes and address 
programmatic shortcomings, such as an overemphasis on centralised (hospital-based) 
models of care, insufficient staff and lack of psychosocial support. Our study also highlights 
the importance of analysing subnational data to identify actions that need to be taken 
at the national and district levels to adopt and implement people-centred policies and 
interventions that facilitate treatment adherence for patients and their families. These 
actions include expanding ambulatory services and mobile or home-based treatment, 
intensive management of adverse events, psychosocial support for patients and early 
detection of drug resistance and adaptation of treatment regimens accordingly. These 
efforts should lead to improved outcomes, alleviate suffering and break the transmission 
cycle. Moreover, our study shows that intersectoral collaboration and multidisciplinary 
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approaches are needed to address some of the determinants of unfavourable outcomes 
(e.g. imprisonment, unemployment and migration). The relatively high proportions 
of patients who were transferred out need to be addressed with improved recording 
and reporting measures and by implementing a case-based national register using 
digital health and real-time data management through which treatment outcomes are 
communicated, even if the patient is moved to another facility. Therefore, the importance 
of establishing and maintaining a robust online surveillance system across the country is 
a specific need that has been identified and could be bridged to fill gaps in surveillance 
and monitoring. 
In Chapter five, we analysed the situation of drug resistant TB in 11 countries of eastern 
Europe and central Asia and proposed a way forward. TB incidence has been decreasing 
at about 5% per year and consequently the number of drug resistant TB cases has been 
decreasing; however, the MDR-TB rates have been stable in the majority of those countries, 
increasing in two countries and decreasing in five countries (Armenia, Estonia, Georgia, 
Latvia and Lithuania). Since first-line DST coverage has been below 80% in Azerbaijan, 
Bulgaria, the Republic of Moldova and Ukraine, we could not conclude that the decrease in 
MDR-TB proportion was a true decrease. At the time of publication, none of the 11 eastern 
Europe and central Asian countries had achieved the 75% regional target of successful 
treatment of MDR-TB. Three countries (the Republic of Moldova with 18 per 100,000 and 
the Russian Federation and Ukraine with 13 per 100,000 had the highest TB mortality 
rates), while this rate in EU/EEA countries stands below 1 per 100,000. We also concluded 
that over half of all TB deaths occurred in the Russian Federation. On a positive note, with 
various national and international initiatives including those facilitated by WHO, such as 
technical guidance and capacity building through the Green Light Committee,3 treatment 
coverage of MDR-TB patients increased from 63% of estimated MDR-TB patients to 96% 
in 2013. Based on these data and country reports, we presented the main challenges 
as follows: a high level of resistance to fluoroquinolone and/or second line injectables 
as reported from various drug resistance surveys, very poor treatment success for drug 
resistant TB (as low as 28% in some settings) and unnecessary deaths and acquisition and/
or transmission of drug resistance. Inadequate ambulatory and people-centred models 
of care like home-based care and over-emphasis on hospitalisation have contributed to 
nosocomial transmission and inadequate follow-up of patients outside hospital settings. 
At the time of publication, new rapid molecular diagnostic tests were not yet available 
in several countries and/or were not widely available to facilitate early TB detection. 
Furthermore, only three countries had achieved nationwide universal coverage of 
second line DST. The needs of vulnerable populations such as migrants, children, people 
living with HIV and prisoners are yet to be fully addressed. We concluded that there is 
a need for full commitment, funding and implementation of the Regional Action Plan. 
Furthermore, new medicines including bedaquiline, linezolid and delamanid have not yet 
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been approved for use in M/XDR-TB patients.4 These measures, along with the possibility 
of full oral treatment regimens based on resistance patterns, need to be implemented 
fully across the Region to increase treatment success. We also highlighted that the 
spread of M/XDR-TB is driven by a complex interplay of factors, including inadequate 
treatment in terms of adherence and pharmacokinetics, a change in bacterial sensitivity 
towards resistance, as well as social and clinical determinants such as HIV, imprisonment, 
migration and socioeconomic factors. The concern is that, without further action, drug 
resistant strains of TB could become the dominant cause of TB in Europe.5 Referring to 
the successful example of New York in the early 1990s, and successful countries like Latvia 
and Estonia, there is a need to address vulnerable and key populations who lie outside the 
realms of the routine health care system. 
We concluded this chapter by discussing the need for integrating patient-centred TB 
care, bolder policies and support systems, as well as relevant operational research – these 
support all three pillars of the Tuberculosis Action Plan for the WHO European Region and 
provide equity in terms of ‘leaving no one behind’.
The role of BCG in the WHO European Region
In Chapter six, we reviewed the role of BCG vaccination. BCG is currently the only available 
vaccine to protect against severe forms of TB, including meningitis in children. With the 
decline of TB incidence, several countries in Europe discontinued BCG vaccination at the 
national level.6 With challenges in BCG procurement and supply, and after the interruption 
of production by Statens Serum Institute and changes to the BCG strain being administered, 
several countries observed increases in adverse events that were brought to media 
attention, risking breaching the population trust in immunisation. This prompted us to 
review the role of BCG by summarising current policies on vaccine administration and the 
management of adverse events of the BCG vaccine in the WHO European Region. Since its 
introduction in 1921, the BCG vaccine has been widely administered in the WHO European 
Region. However, with the decrease in the incidence of TB, many countries have moved 
to or are moving towards selective vaccination. In a few countries where the vaccination 
was suddenly stopped, an increase in severe forms of TB was noticed among children. 
We provided an overview of vaccination and revaccination policies in WHO European 
Region countries, which showed that policies at the country level varied widely. Most of 
the eastern European countries provide vaccination at birth, while many low incidence 
countries provide only selective vaccination.7 All 18 high priority countries of the WHO 
European Region administer BCG at birth, from day 0 in Georgia up to 2 months of age in 
Turkey. Six of those countries revaccinated children before the age of 14 years old. Among 
the non-high priority countries of the Region, Albania, Croatia, Greenland (of Denmark), 
Hungary, Ireland, Monaco, Montenegro, Poland, Portugal, Serbia and Slovenia continue 
with BCG vaccination at birth. The risk of stopping BCG vaccination in a low incidence 
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country will need to be carefully balanced against the risk of an increase in TB amongst 
children. There is no evidence of a threshold incidence; however, the International Union 
Against Tuberculosis and Lung Disease (IUATLD) expert opinion suggests a threshold of 
less than 5 in 100,000 new sputum smear positive pulmonary cases before stopping herd 
BCG vaccination.8 It is noteworthy that, even in low TB incidence countries, there may be a 
subset of the population, such as people who use injectable drugs, the Roma population 
and migrant populations, who have a higher risk of TB, and BCG vaccination should be 
made available to those groups. We also provided an overview of adverse events and 
using the existing data, and highlighted that there are currently no recommendations 
for the use of certain strains. This chapter provided evidence indicating the need for 
bolder policies and relevant operational research to use the BCG vaccine in settings with 
the highest expected impact, but also reiterate the underlying need for a new and more 
effective vaccine for TB.
TB in prisons and congregate settings
Prisons and congregate settings can be breeding grounds (‘hotspots’) for TB, particularly 
in eastern Europe and central Asia9, and yet they can create an important opportunity 
for intensified case finding and timely and effective treatment, which will contribute 
to ending TB. In Chapter seven, we conducted a review of published articles on TB in 
penitentiary services between 1990 and 2014. In addition, we reviewed the conference 
abstracts from the International Union Against Tuberculosis and Lung Disease and WHO 
publications during the same period. We analysed the programmatic challenges and gaps 
in the evidence on TB in prisons that need to be addressed through research. Among 
637 citations and 332 abstracts screened, 96 publications were used in our review. 21% 
of studies highlighted the lack of well-organised health systems and inadequate follow-
up of released prisoners. Although new molecular diagnostic tests often do not require 
complicated infrastructure, several recent studies referred to the unavailability of these 
new diagnostic tests. High sensitivity and specificity GeneXpert MTB/RIF and its rapid 
results make it an excellent tool for screening for TB and rifampicin resistance in congregate 
settings. Health policy makers and authorities need to provide adequate resources to 
ensure the use of GeneXpert in the prison or transport of samples to laboratories outside 
of prisons. In terms of treatment, four studies referred to the suboptimal quality of TB 
medicines, while 30% of studies mentioned that treatment is not observed (supervised 
therapy) in their settings. These may stem from prison services not having adequate staff 
or psychosocial or behavioural problems in prisons. Within most prison systems, follow-
up of released prisoners is limited or does not occur at all. 26% of studies reported that 
TB control in prisons is hampered by the prohibition to attend local clinics or hospitals 
for security reasons, and 31% of studies struggled with effective TB control due to 
prisoners being lost to follow-up and high turnover rates. Our review underlined the 
importance of facilitating data exchange and implementing interventions to reduce loss 
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to follow-up. In terms of HIV response, only seven studies mentioned the challenge of 
addressing TB/HIV coinfection. These studies highlighted key shortcomings such as a 
lack of awareness, increased stigma, weak counselling services, inadequate coordination 
of TB and HIV services, insufficient human resources and poor surveillance. In total, 18 
studies documented interventions for latent TB infection, with varying levels of treatment 
completion due to the high turnover rate or release of prisoners. One fourth of the studies 
highlighted the importance of high-level commitment to ensure adequate resources. This 
is particularly important in eastern Europe and central Asia where there are high rates of 
drug resistant TB. As part of building political commitment, it is essential to ensure that both 
legislation and national guidelines facilitate TB prevention and control in prisons. Given 
the differences in the transmission dynamics and characteristics of this population, an 
up-to-date guideline outlining research priorities needs to be developed for correctional 
institutions. All national TB strategic plans should include priority interventions for the 
prevention and control of TB, drug resistant TB and TB/HIV coinfection in prisons. Based 
on our review of the existing evidence and gaps, we outlined the research gaps and the 
areas in which further evidence is needed for introducing more effective and efficient 
TB prevention and control in prisons. Research conducted in prisons needs to have a 
specific approach in terms of obtaining ethical clearance.10 Our research in this chapter is 
in line with implementing people-centred care that is adapted to the needs of vulnerable 
and key populations who are often left outside the realms of the routine health system. 
Being able to reach these populations would help make a dent in missed TB cases and TB 
mortality as a whole.
New roadmap for childhood tuberculosis
Children represent a vulnerable population regarding TB, and this age group has not been 
adequately prioritised. In Chapter eight, we reviewed the TB situation in children and 
relevant policies in 18 high TB priority countries. In 2011, an estimated 23,000 children 
had tuberculosis, of whom nearly 5,000 were estimated to have had multidrug-resistant 
or extensively drug-resistant disease; however, only 1,000 children with TB had been 
reported.11 This reflects the difficulty in diagnosing TB among children and/or the fact that 
the estimates are not accurate. While all participating countries reported contact tracing 
of close household contacts, only eight countries had policies for contact tracing children 
with close non-household contacts. Four countries only treat children with bacteriologically 
confirmed MDR-TB, while it is evident that there are fundamental difficulties in obtaining 
bacteriological confirmation in young children. In terms of preventive therapy, several 
countries provide prophylactic TB treatment for all children irrespective of age or the 
tuberculin skin test result. Only eight countries provide prophylactic TB treatment for 
children with HIV. In this Chapter, we concluded that countries need to prioritise early 
detection, preventive treatment and full TB treatment and care of children. This evidence 
highlighted the gap in achieving all three pillars of the TB Action Plan in the European 
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Region. As research on drug resistant TB among children is rare, so too is evidence on the 
most effective management of drug resistant TB in children. The WHO Regional Office 
for Europe prepared an expert opinion paper to update readers on recent scientific 
evidence as well as region-specific clinical and public health recommendations on child 
and adolescent MDR-TB.12
Response to the migrant crisis and tuberculosis
Most EU/EEA countries have a low TB incidence (as defined by a notification rate below 
10 per 100,000 population); TB predominantly affects vulnerable populations, mainly 
migrants. In 2015 and 2016, the EU experienced an unprecedented influx of refugees and 
migrants. More than one million people arrived in the European Union, most of them 
fleeing from war and terror in Syria and other countries.13 Many of the migrants were from 
countries with a moderate to high incidence of tuberculosis. Although TB in pre-conflict 
Syria was reported to be as low as 20 per 100,000, with several years of conflict and 
consequent population movements, precarious living conditions and difficult travel along 
migrant routes, TB rates may be higher among these people. In order to document the 
policies and practices of TB diagnosis and care services for migrants, in collaboration with 
the European Respiratory Society, we designed and conducted a survey in 38 countries 
of the WHO European Region, including the EU/EEA and transit countries that migrants 
passed through. In Chapter nine, we reviewed and analysed the results of this survey. 
A total of 36 out of 38 countries provided responses, showing that various algorithms 
for active TB case finding exist, including different combinations of symptom-based 
questionnaires, bacteriology and chest radiography. LTBI screening was reported as being 
conducted with different combinations of tuberculin skin tests and interferon-gamma 
release assays. In more than half of these countries, TB and LTBI screening were performed 
in refugee centres. Three quarters of the countries reported that they are adapting services 
to refugee-specific needs. This is an important aspect, as refugees have various fears and 
face stigma as well as the cultural and language barriers that need to be overcome with 
the help of migrant communities. Two countries stated that they were not doing any 
screening, as in one country the duration of stay of migrants was too short and the other 
country mentioned a lack of funding as a reason for not performing TB screening. The 
survey revealed that, despite the high mobility of migrant populations, countries do not 
have coherent policies and practices and there is little or no coordination, in addition to 
a lack of data exchange across national borders. Furthermore, the results of our survey 
revealed that infection control measures are inadequate in several of these countries. We 
identified that only one third of countries have the possibility of collecting data for LTBI. The 
detection and treatment of LTBI are crucial to prevent further development of TB in these 
vulnerable populations. This is a gap that needs to be addressed to move faster towards TB 
elimination in the EU/EEA. Our survey also revealed that more efforts are needed to share 
good practice and ensure a continuum of care across national borders. In order to end TB, 
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efforts need to be scaled up in all countries in the region, irrespective of where they are 
classified in terms of TB burden (low, moderate or high). Several other studies have been 
conducted by national experts, including in the Netherlands, presenting their experience 
and the results of TB screening among migrants. The Dutch experience showed that active 
TB screening among Syrians led to very low TB yield.14 However, among Eritrean/Ethiopian 
asylum seekers, the prevalence and incidence in the first year in the Netherlands was high. 
This suggests that many of them had been recently infected, either in their country of 
origin or during the journey. Other interventions are required, such as screening for latent 
infection, to prevent tuberculosis among high-risk asylum seekers and further reduce the 
incidence of this disease in the Netherlands.15
It is likewise important that countries systematically review their screening practices for 
active and latent TB based on the methods used and their yield. Furthermore, there is 
a need to adapt policies and practices to improve the cross-border exchange of data in 
line with the Minimum Package of Cross Border TB Control and Care.16 Although TB is not 
readily transmissible and health systems of low incidence countries are strong enough 
to absorb the increase in TB among migrants, public health authorities and practitioners 
need to prioritise TB screening and the provision of quality and timely treatment.17 This is 
particularly important as TB is a rare disease in low incidence countries and its symptoms 
may go unnoticed for a while. Finally, this survey also highlights the need to reach out 
and adapt health systems in an innovative manner to reach vulnerable populations. This 
cannot be achieved without bold policies and supportive systems that cross national 
borders. 
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Samenvatting (summary of this thesis in Dutch)
Hoewel tuberculose (TBC) een oude ziekte is, zorgt het nog steeds voor een significante 
last op de mensheid. Naar schatting is één vierde van de wereldbevolking ermee 
geïnfecteerd. Jaarlijks ontwikkelen ongeveer 10 miljoen mensen de actieve ziekte en 
zijn er ongeveer 1,5 miljoen  sterfgevallen. In de Wereld Gezondheid Organisatie (WGO) 
Europese Regio wonen ongeveer 900 miljoen mensen, verspreid over 53 landen, welke erg 
divers zijn op het gebied van sociaaleconomische ontwikkeling en zorgsystemen. Deze 
diversiteit is ook terug te zien in de grote verschillen in TBC-incidentie en sterftecijfers 
tussen de landen van de Regio. Ondanks dat slechts 3% van de globale casussen in de 
Europese Regio voorkomt, huist het één vierde van alle patiënten met Multi-drug resistant 
TBC (MDR-TB) ter wereld. Sinds 2010 heeft de WGO, met bijdrage van haar lidstaten en 
partners, twee 5-jaar Actieplannen ontwikkeld om TBC en MDR-TB aan te pakken. Met 
behulp van de Wereldgezondheidsvergadering (World Health Assembly) en de resoluties 
van de WGO Regionale Commissie (WHO Regional Committee) voor Europa, hebben de 
overheden samen met donors en gemeenschappen zich toegewijd aan het elimineren 
van TBC. Ondanks de snelste daling in incidentie (ongeveer 5% per jaar) van TBC ooit, 
zijn de behandelingen nog niet succesvol genoeg. TBC blijft kwetsbare groepen 
disproportioneel aantasten. Het doel van de onderzoeken van dit proefschrift is bewijs te 
genereren voor het verbeteren van het TBC-beleid en behandeling in de WGO Europese 
Regio. De onderzoeken zijn opgebouwd op basis van de drie pijlers van de  ‘WHO End 
TB Strategy’ (Geïntegreerde Patiëntenzorg, Sterk Beleid en Onderzoek en Innovatie). De 
doelstellingen van dit proefschrift zijn: 1) Het evalueren van de epidemiologie van TBC 
in de WHO Europese Regio, de volksgezondheidsmaatregelen en de kosteneffectiviteit 
van MDR-TB preventie- en controleplan: Dit wordt beschreven in hoofdstuk twee en drie. 
2) Evalueren hoe de uitkomsten van TBC-behandelingen verbeterd kunnen worden in 
verschillende TBC categorieën: Dit wordt beschreven in hoofdstuk vier en vijf. In hoofdstuk 
vier kijken we naar nationale en sub-nationale data van een land met een hoge TBC-
incidentie en schetsen we een beeld van de ongunstige uitkomsten, welke kunnen leiden 
tot onnodige sterfte, ongeremde transmissie en de opkomst van medicatieresistentie. In 
hoofdstuk vijf analyseren we de situatie in Oost-Europa en Centraal-Azië. 3) Het evalueren 
van de rol van BCG-immunisatie in de preventie van TBC: In hoofdstuk zes bespreken we 
de gegevens van momenteel beschikbare vaccins bij kinderen en praktijken in de regio. 4) 
Het analyseren van de bestrijding van TBC in kwetsbare bevolkingsgroepen. In hoofdstuk 
zeven, acht en negen analyseren we deze aspecten met betrekking tot TBC-preventie 
en zorg in een gevangenissetting, in kinderen en in migranten.In onze operationele 
onderzoeken hebben we zowel jaarlijkse surveillancegegevens, die gerapporteerd 
zijn aan de WGO en de ECDC tussen 2005 en 2018 gebruikt,  als specifieke nationale 
ziekteregistratie en enquêtes van 2010 tot 2018. We bespreken onze bevindingen middels 
een grondige analyse van de data en bieden een toekomstbeeld.
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Doelstelling 1
In hoofdstuk twee evalueerden we de epidemiologie van tuberculose in de WHO 
Europese Regio en de evolutie van de volksgezondheidsmaatregelen van 2005 tot 2010. 
We hebben ook vastgesteld dat, ondanks de grote variaties in het aandeel extra-pulmonale 
TB onder alle TB-patiënten in alle landen (varieert van 4% tot 47%), het aandeel over 
de laatste vier jaar relatief stabiel is gebleven (17%). Onze studie stelde ook vast dat de 
werkzaamheid van de behandeling voor pulmonale tuberculose daalt (72,5% tot 68,7% 
voor nieuwe patiënten en 50% tot 47,6% voor herbehandelingen), terwijl het aandeel van 
MDR-TB onder alle TBC-patiënten stijgt van 4,3% naar 7,5%. We bespraken dat de Regio 
zich moet aanpassen en de uitgebreide ‘Stop TB Strategy’ moet implementeren om deze 
problemen te bestrijden.
In hoofdstuk drie presenteerden we met gebruik van een transmissiemodel de 
verwachte resultaten van het ‘Consolidated Action Plan to Prevent and Control Multidrug- 
and Extensively Drug-resistant Tuberculosis in the WHO Region 2011-2015’. Daarnaast 
creëerden we een model, waarin we de kosten van de opsporing en behandeling van M/
XDR-TB-patiënten en de besparing die het zou opleveren berekenden. We concludeerden 
dat de implementatie van het Actieplan zeer kosteneffectief is. Verwacht wordt dat het 
250.000 nieuwe MDR-TB en 13.000 XDR-TB casussen kan helpen voorkomen. Dit bespaart 
7 miljard Amerikaanse dollars en redt 120.000 levens.
In hoofdstuk vier evalueerden we de nationale en sub-nationale data van meer 
dan 107.000 nieuwe en opnieuw behandelde TBC-patiënten van 2006 tot 2010 in 
Oezbekistan. Hierbij keken we naar de relevante demografische factoren en de varianten 
die van invloed zijn op de behandelingsuitkomsten. Factoren geassocieerd met verlies 
van follow-up zijn: Het mannelijk geslacht, eerdere behandeling, werkeloosheid, wonen 
in een stedelijk gebied en wonen in bepaalde provincies. Factoren geassocieerd met het 
falen van de behandeling, zijn: Het hebben van een sputumkweek-positieve pulmonaire 
TB, jongvolwassenheid, wonen in een stedelijk gebied, HIV-negatieve status, eerdere 
behandeling, werkeloos en wonen in bepaalde provincies. Hoewel de nationale data 
van 83% succesvolle behandeling als een grote prestatie kan gezien worden, hebben 
de analyses van sub-nationale data een licht geworpen op de hoogste risicofactoren 
voor ongewenste uitkomsten. Deze analyses kunnen een richtlijn bieden voor nationale 
programma’s en lokale autoriteiten in de strijd tegen TBC.
In hoofdstuk vijf analyseerden we de trends en de proporties van MDR-TB onder alle 
TBC-casussen in 11 landen in Oost-Europa en Centraal-Azië. We evalueerden de ‘First-
line drug susceptibility testing’ (DST), succespercentage van behandeling, evenals de 
data van TB onder kwetsbare groepen (gedetineerden, mensen met HIV, kinderen en 
migranten). We stelden ook vast dat data over tweedelijnsmedicatie niet altijd verzameld 
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wordt en dat het succespercentage van behandeling bij XDR-TB  slechts 28% is. We 
keken naar de uitdagingen, met name het budgettaire deficit van 60% in 2011, welke 
de succesvolle preventie en controle van medicatie-resistente TBC in de weg staan 
en bieden een toekomstperspectief. We beschreven de noodzaak toegang tot snelle 
moleculaire diagnostiek te vergroten en om nieuwe medicatie zoals bedaquiline te 
introduceren en beschikbaar te maken. Ook moet er gewerkt worden aan het verkorten 
van de behandelduur, en het vergroten van de bewegingsvrijheid van patiënten met TB 
behandeling.
Doelstelling 2
In hoofdstuk zes presenteerden we, na het verstrekken van een overzicht van de 
geschiedenis, veiligheid en productie van BCG, de beschikbare beleidsopties en 
aanbevelingen. We presenteerden een overzicht van beleid van BCG-vaccinatie in de 
landen van de WGO Europese Regio in 2013. In alle 18 landen waar TBC een hoge prioriteit 
heeft, wordt BCG na de geboorte toegediend. Enkelen dezer landen dienen het vaccin een 
tweede maal toe aan 7 of 14-jarigen. In landen waar TBC minder prioriteit heeft (met name 
West-Europese landen met een lage TBC-incidentie) is BCG geen deel van het Nationaal 
Immunisatie Programma, hoewel het in sommige landen aan bepaalde groepen wordt 
gegeven. Naar mate meer landen in de lage TBC-incidentiecategorie vallen (minder dan 
vijf nieuwe casussen met sputumkweek-positieve per 100.000 inwoners per jaar), kan er 
vaker gekozen worden om BCG niet meer standaard toe te dienen. Landen kunnen er wel 
voor kiezen om BCG-vaccinaties beschikbaar te stellen aan kinderen die in hoog-risico 
gezinnen worden geboren.
Doelstelling 3
In hoofdstuk zeven, acht en negen evalueerden we de data en het beleid voor de 
bestrijding van TBC in kwetsbare groepen (gedetineerden, kinderen en migranten). 
Hoofdstuk zeven behandelt de data van gedetineerden in de Europese Regio. 
Gevangenschap verhoogt het risico op TBC aanzienlijk (22 keer hoger in gevangenissen 
dan in de rest van de bevolking). Het gemiddelde meldingspercentage in gevangenissen 
in de Regio was 749 per 100.000 inwoners in 2018. We presenteerden de obstakels voor 
TBC-preventie en zorg in gevangenissen in lijn met de ‘Stop TB Strategy’, en bespreken 
de gebreken in het beschikbare onderzoek en bewijs. Bekende uitdagingen zijn onder 
andere ontoereikende laboratoriumcapaciteit, diagnostische middelen en voorraad van 
medicatie, slechte integratie tussen het TBC-beleid in gevangenissen en daarbuiten, 
inadequate infectiepreventie en lage prioriteit voor gezondheidszorg in gevangenissen. 
In hoofdstuk acht presenteerden we de resultaten van een onderzoek naar de 
implementatie van door de WGO aanbevolen richtlijnen voor preventie, detectie en 
behandeling van TBC en medicatie-resistente TBC onder kinderen in 18 hoge-prioriteit-
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landen. Ons onderzoek laat zien dat veel landen in Oost-Europa en Centraal Azië deze 
richtlijnen, welke in lijn zijn met de ‘roadmap for childhood TB: towards zero deaths’, 
niet volledig implementeren. In 2011werden er naar schatting 23.000 kinderen met 
tuberculose getroffen, waarvan bijna 5.000 met MDR-TB of XDR-TB. Deze schattingen 
staan in sterk contrast met de gerapporteerde cijfers van minder dan 1.000 kinderen met 
TBC in deze landen.
In hoofdstuk negen herzien we TBC screening- en behandelingsbeleid bij vluchtelingen. 
In 2015 bereikten meer dan één miljoen migranten en vluchtelingen Europa over land 
of zee, veel hiervan kwamen uit een land met een hoge incidentie van TBC. In 2014 was 
dit getal naar schatting lager (219.000). Er was geen recente data bekend over het beleid 
voor actieve en latente TBC-screening en behandeling onder vluchtelingen. Om hier 
informatie over te verkrijgen, stuurden we een enquête naar vertegenwoordigers van 38 
nationale TBC-programma’s van landen met laag of laag-gemiddelde TBC-incidentie in 
de Europese Regio. Van de 36 respondenten, screenen 31 voor actieve TBC en 19 voor 
Latente TBC Infectie (LTBI) waarvan slechts acht de resultaten van LTBI-behandelingen 
rapporteerden. Infectiepreventie was niet adequaat in meerdere landen die onderzocht 
werden. Internationale TBC-preventie en zorg voor migranten en vluchtelingen is uiterst 
belangrijk. We toonden aan dat er significante verschillen zijn in het TBC-screening-en 
behandelbeleid, en de implementatie ervan. . Verbeterde coördinatie van TBC-screening 
en -behandeling in Europa is nodig om de ‘End TB Strategy’ succesvol te toe te passen en 
de ziekte uiteindelijk te elimineren.
Hoofdstuk tien biedt een overzicht gebaseerd op de bevindingen van de onderzoeken in 
dit proefschrift en de implicaties en invloed op het beleid.
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